




Title of Dissertation: STRUCTURE-GUIDED ENGINEERING OF A 
MULTIMERIC BACTERIOPHAGE- 
ENCODED ENDOLYSIN PLYC 
  
 Xiaoran Shang, Doctor of Philosophy, 2019 
  
Dissertation directed by: Associate Professor Daniel C. Nelson 
Institute for Bioscience and Biotechnology  
Research and Department of Veterinary Medicine 
 
 
Emerging antibiotic resistance has become a global health threat. One alternative 
to antibiotics is bacteriophage-encoded endolysins. Endolysins are peptidoglycan 
hydrolases produced at the end of the bacteriophage replication cycle resulting in 
bacterial cell lysis and progeny bacteriophage release. Endolysins are also capable of 
destroying the Gram-positive bacterial peptidoglycan when applied externally as 
recombinant proteins. These enzymes typically consist of an enzymatically active 
domain (EAD) and a separate cell wall binding domain (CBD). Studies have shown 
therapeutic efficacy of endolysins in vitro and in vivo, with no resistance developed to 
date. An endolysin from the streptococcal C1 phage, known as PlyC, has the highest 
activity of any endolysin reported. It also has a unique multimeric structure consisting 
of one activity subunit (PlyCA) harboring two synergistically acting catalytic 
domains, GyH and CHAP, and eight identical binding subunits (PlyCB) forming an 
  
octameric ring. Groups A, C, and E streptococci as well as Streptococcus uberis are 
sensitive to the lytic activities of PlyC. In order to harness the potent activity of PlyC 
for use against other bacteria, we sought to change/extend the host range of PlyC by 
engineering PlyCB and PlyCA, respectively. We first used a structure-guided 
mutagenesis method to obtain the single PlyCB monomer subunit, PlyCBK40A E43A 
(PlyCBm), aiming to study the binding mechanism of PlyCB. Via fluorescence 
microscopy and binding assays, we determined that PlyCBm retained the host range 
of the octamer with a much lower binding affinity, which suggests the PlyCB octamer 
binds concurrently to a specific epitope on the bacterial surface resulting in a tight, 
stable interaction. Thus, it is not feasible to change/extend the PlyC host range via 
engineering PlyCB. Next, we proposed a novel design to engineer PlyCA. We 
successfully created two chimeric endolysins, ClyX-1 and ClyX-2, possessing the 
synergistic activity of the GyH and CHAP catalytic domains, but extended the host 
range to include, Streptococcus pneumoniae, Group B streptococci, Streptococcus 
mutans, and Enterococcus faecalis, all strains previously insensitive to PlyC. Finally, 
we tested a novel hypothesis that a positively charged catalytic domain could display 
lytic activity in a CBD-independent manner resulting in a broad host range. Using the 
PlyC CHAP domain as a model, we converted the net surface charge of the CHAP 
domain from negative three to positive one through positive seven. Notwithstanding 
the range of charges, our mutant CHAP domains did not show lytic activity in a 
CBD-independent manner, suggesting that other factors, like surface charge 
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Chapter 1:  
Introduction and Literature Review 
 
1.1 Streptococcal Infectious Diseases 
The Streptococcus genus consists of a diverse collection of Gram-positive 
bacteria that is significant in human medicine and the animal industry. Various 
species of streptococci are important members of the commensal microflora on the 
mucosal surfaces of human and animals, although some can cause severe infectious 
diseases ranging from acute to chronic (Facklam, 2002; Mitchell, 2003; Patterson, 
1996). In humans, streptococcal infections cause diseases varying from dental caries 
and pharyngitis to life-threatening necrotizing fasciitis and meningitis. In animals, the 
infections cause equine strangles in horses, swine lymphadenitis in pigs, and bovine 
mastitis in dairy cows. Due to the resistance to conventional antibiotics and the lack 
of vaccines, infections of streptococci show an increased rate of morbidity, mortality, 
and treatment cost, leading to a tremendous burden in both public health and 
economy (Pfoh et al., 2008).  
 
Group A Streptococcus 
Streptococcus pyogenes, also known as group A streptococcus (GAS), is a 
human pathogen that infects over ~800 million people a year (Carapetis et al., 2005). 
It usually colonizes the epithelial surfaces of the throat and skin causing mild 
superficial diseases including pharyngitis, scarlet fever, and impetigo. Pharyngitis, 
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also known as “strep throat” or a sore throat,  is one of the most common childhood 
diseases, but it is able to infect people of all ages with over ~600 million cases per 
year (Carapetis et al., 2005). Scarlet fever can develop with GAS pharyngitis due to 
the pyrogenic exotoxin SpeA (Shulman & Tanz, 2010). GAS can also cause impetigo, 
a skin infection, affecting people living in a tropical and subtropical area with poor 
hygiene habits (Cole & Gazewood, 2007). These mild infections are not life-
threatening, but without the proper treatment, they may lead to autoimmune-related 
post-infection sequelae, such as rheumatic fever/heart disease, acute 
glomerulonephritis, and reactive arthritis. Acute rheumatic heart disease affects 2.4 
million children aged from 5 to 14 years old, and about 15.6 million of all one year-
olds, with 233,000 deaths each year, which is the greatest burden of GAS infections 
(Carapetis et al., 2005; Walker et al., 2014). Besides the local infections and post-
infectious diseases, GAS is capable of infecting soft tissues, joints, or the lower 
respiratory track, resulting in severe and potentially invasive fatal diseases such as 
necrotizing fasciitis and streptococcal toxic shock syndrome (STSS) (Cunningham, 
2000; Parks et al., 2015). The morbidity and mortality rates of invasive GAS 
infections are unexpectedly high, and 8-23% of patients die within a week of 
infection. On a global scale, GAS is related to 500, 000 deaths per year and, therefore, 
is rated as the ninth leading pathogen of human mortality (Carapetis et al., 2005).  
As a well-adapted human pathogen, GAS develops complex virulence 
mechanisms for different stages of infection. The initial attachment and invasion 
require a range of molecules on the surface of GAS including the hyaluronic acid 
capsule, lipoteichoic acid, fibronectin-binding proteins (FBP), and the M-protein 
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(Mitchell, 2003; Walker et al., 2014). To avoid the host defense, the M-protein is able 
to bind the innate immune complement–control proteins to change the complement 
pathway, while C5a peptidase displayed on the surface of GAS destroys the C5a 
thereby preventing neutrophil recruitment (Mitchell, 2003; Walker et al., 2014). In 
the meantime, GAS secretes toxins and tissue-degrading enzymes, such as 
hemolysins, streptokinase, hyaluronidase, and superantigens, to cause tissue damage 
and toxic-shock syndrome. Among these virulence factors, the M-protein has been 
studied comprehensively for its function and structure as a model for other bacterial 
surface proteins as well as a possible candidate for GAS vaccines development 
(Fischetti, 1991). To regulate the virulence factors in various niches, GAS exploits 
global regulatory circuits. One such pathway is controlled by the mga gene, which 
positively regulates itself and serves as a protein to bind to the promoter of the genes 
that it regulates, including M-protein (Ring et al., 2000), C5a peptidase (scpA), M-
like proteins (mrp, enn, and fcR), serum opacity factor (sof), and secreted inhibitor of 
complement (Cunningham, 2000). Further studies discovered the Mga pathway is 
related to carbohydrate uptake by GAS and the sugar acts as a signal for the 
phosphorylation of Mga (McIver et al., 1995). In summary, the various virulence 
factors of GAS enable it as the most “versatile” of the streptococcal pathogens.  
 
Group B streptococcus 
Streptococcus agalactiae, or group B streptococcus (GBS), colonizes the 
human gastrointestinal (GI) track where it co-exists as a commensal. However, it is 
an important causative agent of invasive infections in three populations: infants, 
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pregnant women, and non-pregnant immunocompromised adults. GBS is the main 
cause of neonatal sepsis, pneumonia, and meningitis in West Europe and the United 
State (Schuchat, 2001). Two types of GBS infections are found in early infancy. The 
early-onset disease occurs in the first week of life due to perinatal transmission during 
labor and delivery (Katz & Bowes, 1988). The late-onset disease occurs between 1 
week and 3 months of age, and the reason for that is less well understood. The acute 
GBS infections in newborns can lead to death, disability, and sometimes severe 
chronic sequelae, such as neurologic damage (Pearlman, 2003). GBS infections in 
pregnant women range from mild urinary tract infection to life-threatening sepsis and 
meningitis. In the US, about half of maternal GBS infections could cause fetal death, 
neonatal infection, neonatal death, or pregnancy loss (Phares et al., 2008). Besides the 
infants and pregnant women, the older adults, especially those with diabetes, 
malignancy, and other cause of immunodeficiency are in the danger of GBS invasive 
infections. Recently, the risk of infections in older people is increasing in nursing 
home residents, and in the US, over three-quarters of GBS infectious cases occur in 
the elderly and causes 90% of GBS death (Verani & Schrag, 2010).  
Like GAS, GBS expresses a variety of virulence factors to survive in the host. 
The polysaccharide capsule is important for protecting GBS from the innate 
complement pathway. A range of GBS surface proteins, such as laminin-binding 
proteins, fibrinogen-binding proteins, and fibronectin-binding proteins, enable the 
organisms to attach to human laminin and escape opsonophagocytosis (Li et al., 1997; 
Schubert et al., 2002; Spellerberg et al., 1999). The hemolysin, CylE, is the key factor 
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causing damage of lung epithelial and endothelial cells, brain epithelial cells, and 
macrophages (Ring et al., 2000).  
 
Streptococcus pneumoniae 
S. pneumoniae are usually considered normal flora when the colonize the 
mucosal surfaces of the human upper respiratory tract. Approximately 25-60% of 
children and <10% of adults are asymptomatic carriers of S. pneumoniae in the nose 
(Abdullahi et al., 2012; Nunes et al., 2005; Yahiaoui et al., 2016). However, 
pneumococci can cause mild to severe diseases, such as otitis media (middle-ear 
infection), pneumonia (lung infection), bacteremia (blood infection), and meningitis 
(brain infection), when they invade the sterile sites. According to Center for Disease 
Control, up to 1 million children below 5 years old die yearly due to pneumococcal 
infections, and about 5% of those that get pneumococcal infections die from the 
disease in the US. In 2017, the World Health Organization listed pneumococcus as 
the fourth leading pathogen of human mortality, only after HIV, Mycobacterium 
tuberculosis, and Plasmodium falciparum (Carapetis et al., 2005). 
  S. pneumoniae produce various virulence factors to survive in different host 
environments. Like other pathogens, the polysaccharide capsule is the main virulence 
factor mediating attachment and anti-phagocytosis properties. In addition to the 
capsule, pneumococci possess other virulence factors, including pneumolysin, 
phosphorylcholine, and choline-binding proteins. The pneumolysin is a type of pore-
forming protein involved in a range of activities. Pneumolysin actives the 
complement pathway to stimulate the productions of inflammatory mediators 
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(Cockeran et al., 2002). In addition, it causes damage to the ependymal cilia of the 
brain, inducing the program cell death of the brain cells (Braun et al., 2002; Hirst et 
al., 2000). Phosphorylcholine binds to the platelet-activating factor (PAF) receptor. 
PAF, by its name, can induce platelet aggregation, but several studies indicate that 
PAF is also a G-protein involved in signaling in a variety of cell types and tissues 
(Cundell et al., 1995; Ishii et al., 2002; Tuomanen et al., 1985). The choline-binding 
proteins (Cbp) include key proteins unique to S. pneumoniae. For example, the 
autolysin LytA is essential for cell division and surface protein A (PspA) is important 
for escape of the innate immune system (Hammerschmidt et al., 1997).  
 
Streptococcus mutans 
S. mutans belongs to the viridans streptococci and naturally colonizes the human 
oral cavity. Although the bacteria possess low virulence, it is the main factor of dental 
caries. With dissemination into the bloodstream, it may cause bacteremia and 
infective endocarditis (Parks et al., 2015). S. mutans with other oral bacteria, such as 
S. sanguis, S. mitis, and S. salivarius, attach to the surface of the teeth to form a 
biofilm known as “plaque”. When the sugar level increases in the oral cavity, S. 
mutans consumes the additional sugar generating an acid environment and, therefore 
leads to the decay of tooth enamel (Nomura et al., 2017). Dental caries is a prevalent 
chronic disease in the US with 3,000,000 cases per year. The annual cost in the US 
for dental infections is about 24 billion dollars, and 90% of these are related to the 
rebuilding of teeth. Not only dental caries, but also dental treatment and daily oral 
care practices may allow S. mutans to transmit into the bloodstream. Thus, bacteremia 
7 
 
may happen in people with vulnerable immune systems, such as patients following 
chemotherapy or transplant surgeries (Parks et al., 2015). Infective endocarditis is due 
to the adherence of bacteria to damage heart valves. In the US, about 15,000 new 
cases of infective endocarditis are reported each year with a 15% to 20% mortality 
rate (Nakano et al., 2007). 
To survive in the oral cavity, S. mutans expresses several adhesins, such as 
streptococcal protein antigen P (SpaP), on the bacterial surface. These adhesins bind 
to salivary agglutinin glycoprotein to start the initial attachment of a biofilm on the 
surface of the tooth. Genome analysis of S. mutans reveals numerous genes for 
transport and metabolism of various sugars. The fermentation of the sugars produces 
lactic acid, which creates an acid environment and causes tooth decay. The ATPase of 
S. mutans is capable of maintaining neutral intracellular pH and thus, allows S. 
mutans to become acid tolerant (Mitchell, 2003). These key virulence factors make S. 
mutans the leading pathogen in the oral cavity.  
 
Other streptococci 
Streptococci are not only human pathogens, but some of them also cause disease 
in animals. Group C streptococci, group E streptococci, S. uberis, and S. suis are 
related to essential diseases in cattle, pigs, horses, and sheep. The infections of the 
livestock usually lead to a significant economic loss in the US. Among these, S. suis 
is a zoonotic organism, which transmits from animal to human. This infection mostly 
occurs on pig farmers and abattoir workers due to exposure to the ill pigs or pig meat 
(Hardie & Whiley, 1997b).  
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To summarize, different groups of streptococci possess unique virulence factors 
that enable them to be versatile pathogens for humans and animals.  
 
1.2 Antibiotics and Resistance 
The discovery and application of antibiotics have transformed modern medicine 
and saved millions of lives. Since the 1940s to 1990s, the development of antibiotics 
from natural products and synthetic chemicals has propelled the battle with 
pathogenic bacteria, and the results have been revolutionary (Andersson & Hughes, 
2010). However, the overuse and misuse of antibiotics in recent years have increased 
the frequency of resistance gene transmission between both pathogens and 
commensal organisms (Kohanski et al., 2010). Compounding the situation, 
development of new antibiotics in the last few decades has slowed down due to rapid 
loss of efficacy and market failure due to limited profit motive. These circumstances 
created the “post-antibiotic” era and provoke the need for new, novel antibacterial 
approaches.  
 
Antibiotics Discovery and Resistance Development  
One day in 1928, a scientist had been cultivating Staphylococcus spp. in a petri 
dish when he left for a two-week vacation. After the vacation, he found the petri dish 
was contaminated by a Penicillium mold, and interestingly, no bacteria grew close to 
the mold. This scientist was Alexander Fleming and he eventually discovered 
penicillin from the Penicillium mold, thereby founding the field of classical 
antibiotics. He devoted his life trying to cultivate penicillin from the mold and use as 
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an antimicrobial agent. With many attempts and failures, the chemists Howard Florey 
and Ernest Chain from Oxford University, fulfilled the goal of the large-scale 
production of penicillin in 1940. The first use of penicillin was in 1942. John Fulton, 
a friend of Howard Florey, used 5.5 grams of crude penicillin saved the life of Anne 
Miller from septicemia. In 1943, streptomycin, the first aminoglycoside antibiotic, 
was discovered by Albert Schatz and Selman Waksman. Streptomycin was used in 
many cases with Gram-negative bacterial infections and was an active drug against 
Mycobacterium tuberculosis. 
The use of penicillin and streptomycin in controlling bacterial infections during 
World War II propelled the golden era of antibiotic development. Numerous 
antibiotics containing different chemical groups/classes were discovered between the 
1950s and 1970s including tetracycline (1950), chloramphenicol (1951), 
erythromycin (1953), vancomycin (1972), and carbapenems (1976). After the 1980s, 
pharmaceutical companies started to investigate synthetic antibiotic compounds based 
on previously discovered classes. In the last 30 years, only three antibiotics with a 
novel mode of action were introduced to the market (Linezolid, Daptomycin, and 
Ceftaroline).  
The race between the development of antibiotic resistance and new antibiotics 
has never stopped. The first clinical resistance to penicillin was observed in 1945, 
only 3 years after its first, although resistance in the laboratory had been noted as 
early as 1940. Similarly, resistance to tetracycline was detected in the laboratory even 
before it reached the market. In general, resistance to new antibiotics was 
continuously noted within several years after the drugs reached the market (Table 1-
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1). Moreover, emerging bacterial pathogens have evolved the ability of multi-
resistance, such as multidrug-resistant Acinetobacter, multidrug-resistant 
Pseudomonas aeruginosa, and so on (Davies & Di Girolamo, 2010). Although low in 
frequency, clinical resistance now has been documented for every “last-resort” 




Table 1-1. Antibiotic resistance development: A timeline of key events. 
Adapted from (Ventola, 2015). 
Antibiotic Introduced Resistance Observed Organism 
Penicillin 1942 1945 Staphylococcus 
  1965 Pneumococcus 
Streptomycin 1943 1958 Gonococcus 
Tetracycline 1950 1959 Shigella 
Erythromycin 1953 1968 Streptococcus 
Methicillin 1960 1962 Staphylococcus 
Gentamicin 1967 1979 Enterococcus 
Vancomycin 1972 1988 Enterococcus 
  2002 Staphylococcus 
Imipenem 1985 1998 Enterobacteriaceae 
Ceftazidime 1985 1987 Enterobacteriaceae 
Levofloxacin 1996 1996 Pneumococcus 
Linezolid 2000 2001 Staphylococcus 
Daptomycin 2003 2005 Staphylococcus 










Antibiotic Mechanisms of Action 
Antibiotics are classified into five categories based on the mechanism of action. 
Most current used antibiotics are bactericidal resulting in bacterial death. These 
antibiotics target essential processes or structures of bacteria, such as cell wall 
synthesis, protein synthesis, or nucleic acid synthesis (Kapoor et al., 2017; Kohanski 
et al., 2010).  
The largest class of antibiotics inhibit cell wall synthesis leading to improper cell 
division, autolysin activity, and SOS response (Kapoor et al., 2017). These antibiotics 
can function in two ways. In one mechanism, they act as analogs which bind to the 
proteins necessary for cell wall synthesis. The most famous antibiotic, penicillin, 
belongs to this mechanism as the β-lactam moiety binds to penicillin-binding proteins 
inhibiting the normal function of these proteins in the bacterial cell wall. The second 
mechanism hinders cell wall synthesis by binding to the precursor peptidoglycan 
subunit. Vancomycin, a large drug molecule vancomycin, uses this mechanism by 
binding a D-alanyl subunit in the cell wall and preventing transpeptidation.  
The second large class of antibiotics includes inhibitors of protein biosynthesis. 
Aminoglycosides (e.g., tetracycline, gentamicin, streptomycin, and kanamycin) 
interact with the 16S rRNA of the 30S subunit resulting misreading and premature 
termination of the translation of mRNA. Chloramphenicol (e.g., erythromycin, 
azithromycin) interacts with the 23S rRNA of the 50S subunit resulting in the 
inhibition of binding t-RNA. Antibiotics in this class must pass the cytoplasmic 
membrane and, in this process, they need energy generated from oxygen and active 
proton motive force. Thus, this group of antibiotics works poorly for anaerobic 
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bacteria. However, they may be used together with the cell wall targeting drugs to 
facilitate the entry, displaying synergism.   
The third group of antibiotics inhibits the synthesis of DNA or RNA. 
Fluoroquinolones and trimethoprim-sulfamethoxazole are drugs that block DNA 
synthesis via interfering with DNA gyrase/topoisomerase IV (e.g., ciprofloxacin, 
levofloxacin). Rifampicins block RNA synthesis via binding the DNA-dependent 
RNA polymerase.  
The fourth antibiotic class disturbs cell membrane permeability, preventing the 
growth of bacterial cells. Examples include colistin, daptomycin, and ionophores. The 
last category includes drugs that interfere with bacterial metabolism. Isoniazid and 
sulfonamides inhibit the normal function of certain essential energy pathways.  
It is notable that antibiotics can be more effective in a combination treatment due 
to either an additive effect or a synergistic effect (Kohanski et al., 2010). As 
mentioned above, the protein synthesis inhibitors display synergism with cell wall 
synthesis inhibitors. However, the combination can also be antagonistic, meaning the 
effect of the two drugs is less than the effect of the single-drug treatment. This effect 
can be observed from the combination of a DNA synthesis inhibitor and a protein 
synthesis inhibitor due to the non-structured RNA from DNA synthesis inhibitor 
slowing the function of protein synthesis inhibitor. Further studies of the synergy or 
antagonism effect will provide more insight into the cell death mechanism and could 




Mechanisms of Antibiotics Resistance 
Although there are five categories of antibiotics focusing on different 
mechanisms of action, bacteria have adopted many ways to develop resistance. Some 
bacteria are naturally resistant to certain antibiotics. Others can survive via genetic 
mutations through antibiotic selection, and these advantageous mutations can be 
passed through different generations and even transferred to other organisms via 
horizontal gene transfer (Blair et al., 2015; Munita & Arias, 2016).  
The intrinsic resistance of a bacterial species is the ability to prevent the entry or 
function of specific antibiotic due to inherent structural or functional properties. One 
simple example is the aminoglycoside group. The aminoglycosides need to pass the 
bacterial membrane and enter the cytosol with the help of the energy-dependent 
bacterial transport system facilitated by oxygen and proton force. Thus, this group of 
drug works better on aerobic bacteria than anaerobic bacteria. The other example is 
the biocide triclosan. This drug displays broad efficacy against Gram-positive and 
most Gram-negative bacteria, but it cannot prevent the growth of Pseudomonas due 
to an insensitive allele of the target of the drug. Some drugs are only effective against 
Gram-positive but not Gram-negative organisms, such as the lipopeptide daptomycin 
or the glycopeptide vancomycin. These restrictions are due to the primary difference 
between the Gram-positive and Gram-negative cell wall compositions (Blair et al., 
2015). 
In addition to intrinsic resistance, bacteria also develop mutational resistance in 
four aspects: (i) target modification, (ii) antibiotic inactivation, (iii) activation of 
efflux pumps, (iv) changes in the metabolic pathway (Munita & Arias, 2016). In the 
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first group, bacteria modify the antibiotic target site resulting in the improper binding. 
One example is the penicillin-binding protein 2a (PBP2a) transpeptidase of 
methicillin-resistant Staphylococcus aureus. The mecA gene encodes the PBP2a 
instead of PBP, inhibiting the binding of β-lactams. To cooperate with the change of 
PBP2a, the peptidoglycan of S. aureus changes in composition and structure, which 
involved several additional genes (Tenover, 2006). The second primary resistance 
mechanism requires the production of enzymes that degrade the drug, such as 
hydrolysis, group transfer, or a redox mechanism (Bonnet, 2004; Bush et al., 1995; 
Kotra & Mobashery, 1999; Poole, 2004). The most well-known enzyme is the β-
lactamase family, which can cleave the ring of β-lactams. Other hydrolytic enzymes 
include esterases in macrolide resistance, transferases in aminoglycosides, and 
virginiamycin M in streptogramin. The efflux pumps can be found in both Gram-
positive and Gram-negative organisms and are used to pump the antibiotics out of the 
cytoplasm. This mechanism is well known for the multidrug-resistance (MDR) efflux 
pumps (Blair et al., 2015). The resistance nodulation division (RND) pump is found 
in Gram-negative bacteria and is one of the best-characterized efflux transporter. One 
example of the RND pump is the AcrB in E. coli. Once E. coli infects, the acrB genes 
encounter the small molecules, such as indole and bile, to overexpress the AcrB 
pump. The structure of AcrB pump consists of two distinct pockets that can 
accommodate different substrates (Eicher et al., 2012; Hung et al., 2013; Vargiu & 
Nikaido, 2012). The last mechanism is due to global cell adaptations, which change 
important metabolic pathways via modulation of the network during infection.  
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The gain of foreign DNA material via horizontal gene transfer (HGT) is another 
vital factor of bacterial evolution and resistance.  The simplest type of HGT is via 
transformation by incorporation of DNA in the environment by naturally competent 
bacteria. However, this method is not responsible for clinically relevant antibiotic 
resistance. In contrast, conjugation is the most relevant form of HGT clinically. In 
conjugations, many bacterial surface components, like pili, can make cell-to-cell 
contact allowing exchange of DNA, and this contact occurs at high rates in the 
gastrointestinal tract (GI) of a human. In another method, lysogenic bacteriophages 
can also be carriers of resistant genes and spread these genes via transduction (Munita 
& Arias, 2016). 
 
Antibiotics Resistant Streptococci 
Antibiotics are still an effective treatment for streptococcal infectious diseases 
due to the fact that streptococci remain susceptible to common antibiotics (Cattoir, 
2016). However, in the past 15 years, the rate of streptococcal antibiotic failure has 
increased to 40% in some regions of the world (Brook, 2013). S. pneumoniae are 
associated with a rising rate of resistance to penicillin and are possibly resistant to 
other new antibiotics. One remarkable capability of S. pneumoniae is the ability to 
uptake and incorporate exogenous DNA (natural competence) from other 
pneumococci. Group A streptococci, group B streptococci, and viridans group 
members are also pathogens with a high rate of resistance development as genes 
related to resistance have been noted in these species via meta-gene analysis (Cattoir, 
17 
 
2016). In 2013, antibiotic-resistant S. pneumoniae infections were reported as one of 



















































1.3 Alternative Antimicrobial: Bacteriophage-Derived Endolysins 
Widespread distribution of antibiotic-resistance genes in bacteria has led us to 
enter the post-antibiotic era. Bacterial infectious diseases that were once treatable 
through the use of antibiotics are becoming deadly again (Brown & Wright, 2016). 
Moreover, the overuse of broad-spectrum antibiotics accelerates the dispersal of 
resistance genes not only to pathogens, but also to commensal organisms (Nelson et 
al., 2012). Thus, the development of alternative antimicrobial agents is one of the 
highest global priorities in biological, pharmaceutical, and medical investigations 
(Veiga-Crespo et al., 2007). One alternative to antibiotics is the use of endolysins, 
which are bacteriophage-derived peptidoglycan hydrolases, and alternately termed 
phage lysins or enzybiotics.  
 
History 
Bacteriophage (phage) are viruses that infect bacteria. They were discovered 
independently by Frederick Twort and Félix d’Hérelle in 1915 and 1917, 
respectively, and are considered as the most abundant microbial agents on the earth 
(Summers, 2011). Not long after d’Hérelle’s discovery, phage were studied as a 
treatment of bacterial infectious diseases due to their potent bactericidal capacity. The 
first reported case of phage application was in 1921 from Richard Bruynoghe and 
Joseph Maisin, who used phage to treat a staphylococcal skin infection (Hermoso et 
al., 2007). Several companies started the commercialization of phage in the 1930s in 
the US, France, and the region of the former Soviet Union now known as Georgia. 
With the discoveries and industrial manufacturing of antibiotics in the 1940s, the use 
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of phage as antimicrobial treatments was abandoned in the US and western Europe, 
leaving the former Soviet Union and eastern Europe to continue actively studying and 
using phage (Sulakvelidze et al., 2001). However, over 60 years later, there is 
renewed interest in phage as potential therapies for the management of bacterial 
pathogens that have emerged resistance to clinically approved antibiotics. A few 
human phage therapy studies have been performed in Poland, Georgia, and Russia, 
including studies on Shigella phage against bacterial dysentery in 1968, 
Staphylococcus phage against lung and pleural infections in 1982, E. coli phage 
against recurrent subphrenic abscess in 1994, and a phage cocktail therapy against 
various infections in 1987 (Sulakvelidze et al., 2001). In the meantime, the 
application of phage has grown to more areas, such as agriculture, aquaculture, and 
wastewater treatment (Goodridge, 2004; Withey et al., 2005). Moreover, in August 
2006, the US Food and Drug Administration (FDA) approved the use of a cocktail 
phage therapy containing six individual, purified phage against Listeria 
monocytogenes for decontamination of ready-to-eat meat and poultry products. This 
action indicates that the FDA is open to consideration of using phage as an 
antimicrobial for bacterial infectious diseases in humans.  
However, there are still several concerns using the whole phage for therapeutic 
application. First, phage usually have a relatively narrow host range. Phage often 
show strain specificity, thus necessitating various phage just to cover all strains 
within a single bacterial species. Second, the lifestyles of phage are unpredictable 
under different physiological conditions. Phage have two distinct life cycles, lytic and 
lysogenic. When phage therapy is considered, it is important to select strictly lytic 
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phage to assure bacterial killing. Third, bacteria can evolve resistance towards phage 
that targets every stage of the phage infection process. The surface proteins of 
bacteria may be mutated to prevent phage attachment. The injected phage DNA may 
either be degraded via a variety of restriction-modification systems or the CRISPR-
Cas system. Alternately, the infected bacterium may commit cell death through the 
abortive infection system to limit the viral propagation and spread through the clonal 
bacterial population (Dy et al., 2014). Fourth, the administration of phage is more 
complicated than that of chemical drugs. Due to the self-replication, the 
pharmacokinetics is of phage therapy is hard to measure which, results in additoinal 
problems associated with the regulation of phage therapies. Thus, the use of phage-
produced molecules or enzymes that are capable of direclty killing bacteria would 
have inherent advantages over whole phage therapy.   
One of the most promising phage molecules is a class of cell wall hydrolases 
termed as endolysins. Endolysins are produced at the end of the phage replication 
cycle resulting in cell lysis and progeny phage release. During this cycle, phage also 
produce another protein called holin, which accumulates until it reaches a critical 
mass and forms pores in the cytoplasmic membrane, allowing the endolysins to gain 
access to the cell wall (Fischetti et al., 2006). However, endolysins are also capable of 
destroying the Gram-positive bacterial peptidoglycan when applied exogenously, 
resulting in “lysis from without” (Figure 1-2). Several phage endolysins had been 
purified and used as a laboratory tool for cell wall extractions before the 1990s. 
However, when antibiotic resistance became a serious problem, scientists proposed 





Figure 1-2. Comparison of phage therapy and endolysin therapy. Phage therapy 
(on the left) applies lytic phage (in red) to lyse the bacteria, which usually occurs over 
30 min. The electron microscope picture shows the phage particles adhering to the 
debris of a lysed streptococcal cell. In comparison, endolysin therapy includes the use 
of recombination endolysins (in blue) applied outside the bacteria, resulting in 
osmotic lysis within a few minutes. The electron microscope picture shows a cross-
section of Bacillus anthracis treated with the purified PlyG displaying an externalized 




Through the past 20 years of study, the efficacy of endolysins has been validated 
both in vitro and in vivo against a variety of Gram-positive pathogens, and few 
endolysins have entered human clinical trials. 
 
Domain Architecture of Endolysins 
Endolysins usually consist of two components: the conserved enzymatically 
catalytic domains (ECD)/enzymatically active domains (EAD) and a cell wall binding 
domain (CBD). Depending on the different origins of endolysins, they can adopt 
different modular structures (Figure 1-3). 
Endolysins derived from phage that infect Gram-positive bacteria have a very 
similar modular structure with one or more N-terminal EADs and a C-terminal CBD 
(Fischetti, 2010; Loessner, 2005; Oliveira et al., 2012; Schmelcher et al., 2012). The 
EADs possess the hydrolytic activity of the enzyme, and the CBDs possess the 
binding activity to carbohydrates on the surface of the peptidoglycan (PG). In some 
cases, the endolysins contain two EADs connecting to each other at the N-termini. 
However, the presence of more than one EAD in endolysins does not ensure higher 
activity since the EAD(s) in the middle are usually silence (Becker et al., 2009). 
Whereas many EADs require the presence of the CBD for binding and subsequent 
activity, some EADs can bind the bacterial surface independently of the CBD such as 
T4 lysozyme (Matthews & Remington, 1974). One unique example of endolysins 
derived from phage infecting Gram-positive bacteria is the streptococcal C1 phage 
endolysin, PlyC. This endolysin is composed of nine subunits in a 114 kDa 





Figure 1-3. Modular Architectures of Gram-positive and Gram-negative 
endolysins. The endolysins derived from phage that infect Gram-positive bacteria 
display five possible structures: (A) Single globular enzymatically catalytic domain 
(ECD)/enzymatically active domain (EAD). (B) On N-terminal ECD/EAD and one 
C-terminal CBD. (C) Two N-terminal ECDs/EADs and one C-terminal CBD. (D) 
Three ECDs/EADs. (E) Multimeric structure with one ECD/EAD and eight CBDs. 
The endolysins derived from phage that infect Gram-negative bacteria display three 
possible structures: (F) Single globular ECD/EAD. (G) One N-terminal CBD and one 
C-terminal ECD/EAD. (H) Two N-terminal CBDs and one N-terminal ECD/EAD. 





Endolysins derived from phage that infect Gram-negative bacteria are simple in 
structure comprising of a single globular EAD, since the peptidoglycan of Gram-
negative bacteria, contained between the inner and outer membranes, is thin and lacks 
carbohydrates or other surface moieties associated with the Gram-positive 
peptidoglycan (Oliveira et al., 2013). Notwithstanding, some exceptions exist. For 
example, some of these endolysins may possess a modular structure with an N-
terminal CBD and C-terminal EAD, such as KZ144 of phage phiKZ (Briers et al., 
2007). However, the CBDs of endolysins targeting Gram-negative bacteria directly 
bind to PG, not to the surface carbohydrates (Briers et al., 2007). 
 
Bacteriolytic Mechanism 
The PG layers of Gram-positive and Gram-negative organisms are different in 
both thickness and composition. The PG of Gram-positive bacteria is about 20-80 nm 
thick and is the core element of the bacterial surface. In contrast, the PG of Gram-
negative bacteria is 5 to 10 nm and the PG is shielded from the external environment 
by the protective outer membrane, which contains teichoic acids and surface proteins 
(Schleifer & Kandler, 1972). The sugar backbone of PG is conserved in all bacteria 
and consists of N-acetylmuramic acid (MurNAc) and N-acetylglucosamine (GlcNAc) 
connected by β-1,4 glycosidic bonds. The differences between organisms is in the 
composition of the short stem tetrapeptide and the crossbridge (Meroueh et al., 2006). 
An L-lysine type (Lys-type) PG is typical for most Gram-positive organisms, while a 
meso-2,6-diaminopimelic acid type (mDAP-type) is observed in all Gram-negative 
organisms, as well as the Gram-positive Bacillus and Listeria spp.  The mDAP-type 
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PG consists of simple peptide stems directly linked to each other via an amide bond. 
However, in the Lys-type PG, the peptide stems are connected by crossbridges 
consisting of different amino acids in different species, such as a pentaglycine 
crossbridge in staphylococci or a dialanine crossbridge in streptococci (Figure1-4) 
(Schleifer & Kandler, 1972).  
Although the types of PG are different, the covalent bonds in the PG are 
conserved. Thus, because endolysins are PG hydrolases, their EADs target a limited 
number of chemical bonds and can, therefore, be classified into five enzymatic groups: 
N-acetylmuramidases, lytic transglycosylases, N-acetyl-β-D-glucosaminidases, N-
acetylmuramoyl-L-alanine amidases, and endopeptidases (Borysowski et al., 2006). 
Among the five groups, N-acetylmuramidases and lytic transglycosylases cleave the 
N-acetylmuramoyl-β-1,4-N-acetylglucosamine bond (Figure 1-4, label 2,3). N-acetyl-
β-D-glucosaminidases cleave the sugar backbones at the N-acetylglucosaminyl-β-1,4-
N-acetylmuramic acid bond (Figure 1-4, label 1). N-acetylmuramoyl-L-alanine 
amidases release the peptide stem from sugar backbone via cleaving between 
MurNAc and L-alanine (Figure 1-4, label 4). Endopeptidases cleave the bond 
between two amino acids that occur either in the peptide stems or in the crossbridges 
(Figure 1-4, label 5,6,7,8). The cysteine, histidine-dependent 
amidohydrolase/peptidase (CHAP) domain is the most common EAD observed in 
endolysins. CHAP domains can either be an L-alanine amidase or an endopeptidase. 
The first reported CHAP displaying both amidase and endopeptidase activity is as the 








































































































































































































Cell Wall Binding Domains 
The cell wall binding domains (CBDs) possess no enzymatic activity but rather 
function to bind a specific substrate, usually a carbohydrate or teichoic acid, attached 
to the host PG (Fischetti, 2008). Thus, the specificity of the endolysin is often 
dictated by the specificity of the CBD. Unlike the EADs, the CBDs are divergent 
since they have been evolving over millions of years to recognize many different 
ligands on the cell wall. Researchers are interested in studying the binding affinity 
and binding ligands for CBDs. Unfortunately, few ligands for CBDs have been 
precisely identified, and without the known ligands, the study of affinity is 
complicated.  
Although the CBDs are diverse, some common domain motifs have been 
identified: (i) The LysM (Lysin Motif) is considered to bind the broadest range of 
receptors and may bind specifically to GlcNAc residues in the sugar backbone of the 
PG (Buist et al., 2008; Garvey & Santi, 1986; Ohnuma et al., 2008; Visweswaran et 
al., 2011). One notable LysM domain is the CBD of the endolysin from phage Lb338-
1 infecting Lactobacillus (Oliveira et al., 2013). (ii) Another common motif is the PG 
binding domain (Peptidoglycan Binding Domain), which targets the D-Asn residue in 
PG crossbridges in both Gram-positive and Gram-negative organisms. Examples 
include the LcLys and LyLys2 of Lactobacillus casei phage, PVP-SE1 of Salmonella 
phage, and KZ144 and EL188 of Pseudomonas phage (Briers et al., 2007; Regulski et 
al., 2013; Walmagh et al., 2012). (iii) Less common CBD motifs include FOG (Friend 
of GATA-zinc finger protein), SLAP (SRC-like Adapter Protein), and SPOR 
(Sporulation Related Domain) (Oliveira et al., 2013). (iv) The Choline-Binding 
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Modules are CBDs that specifically target and bind choline-containing teichoic acids 
in the cell wall of S. pneumoniae (Hermoso et al., 2007). The CBDs in this group 
usually consist of different repeats of choline-binding modules that display various 
binding affinities (Garcia et al., 1987). (v) CWH (Clostridial Hydrophobic with 
Conserved Tryptophan W) is the family of CBDs that  target the cell wall of 
Clostridium acetibutylicum (Sullivan et al., 2007). (vi) Lastly, SH3 (SRC Homology 
3- domain) binds to proline-rich ligands and is the family most associated with 
staphylococcal endolysins (Buist et al., 2008; Grundling et al., 2006; Mayer et al., 
1988). 
 
Antimicrobial Potential (Bacterial resistance, Safety, Immunogenicity, Synergy, 
Biofilm) 
One advantage of endolysins over traditional antibiotics is the near-species 
specificity displayed by these enzymes. The overuse and misuse of broad-range 
antibiotics usually disturb the normal flora resulting in the growth of opportunistic 
pathogens, such as Clostridium difficile in the GI tract. Moreover, these practices 
accelerate the horizontal gene transfer of resistance within the bacterial community 
consisting of both pathogens and commensal organisms (Nelson et al., 2012). To 
date, there are not any reports of strains developing resistance to endolysins. One 
likely explanation is the coevolution of bacteriophage and bacteria has led to the 
endolysins binding to and cleaving essential and highly conserved targets in the PG 
(Fischetti, 2005). The other explanation is the highly lytic efficacy of endolysins 
applied from without, killing bacteria within seconds or minutes, thereby not allowing 
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time for selective pressure to generate resistance mechanisms. Several studies have 
attempted to address the lack of resistance to endolysins. In one study, S. pneumoniae 
cells were continuously treated with increasing concentrations of the Pal endolysin, 
but no resistant strains were detected (Loeffler et al., 2001). In the other studies, the 
PlyG endolysin and chemical mutagens were added to Bacillus anthracis culture in 
order to accelerate evolution of PlyG-resistant strains. However, these organisms 
remained fully sensitive to PlyG while they generated 1,000-10,000-fold increases in 
streptomycin resistance under the same conditions (Schuch et al., 2002). Another 
study using an engineered endolysin, ClyS, against MRSA found that the MIC was 
unchanged after repeated treatment of the endolysin (Pastagia et al., 2011). Despite 
these encouraging results, it is important to note that there are reports of resistance to 
non-endolysin PG hydrolases, specifically lysozyme and bacteriocins. Resistance 
against human lysozyme has been linked to secondary changes of the cell wall, such 
as O-acetylation and N-deacetylation of the PG (DeHart et al., 1995; Grundling et al., 
2006; Sugai et al., 1997). Notably, endolysins that utilize the EADs with lysozyme-
like activity are quite rare. In a second example, S. aureus generates resistance to 
lysostaphin, a bacteriocin, by changing the constituents of the crossbridge, the target 
of this enzyme (DeHart et al., 1995).  
Preclinical safety and toxicity profiles on mammalian cells and tissues are 
critically necessary for future translational development of endolysins. According to 
clinicaltrails.gov, there are at least three endolysin-based therapies in Phase 2 clinical 
trials. SAL200, a pharmaceutical composition containing the SAL-1 endolysin 
specific for S. aureus, displayed no signs of toxicity in the central nervous and 
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respiratory system of rodents and dogs (Jun et al., 2014). Similarly, there were no 
signs of abnormalities or adverse events in monkeys (Jun et al., 2016). In a Phase 1 
human trial, again, no adverse events were detected using SAL200 (Jun et al., 2017). 
Another safety trial was recently completed by the Dabrowska group in Poland 
(Harhala et al., 2018). In this study, the authors were able to show that two 
pneumococcal endolysins, Cpl-1 and Pal, are overall safe in terms of immune 
responses, microbiome changes, and inflammatory response. Although more studies 
are anticipated to emphasize the safety of endolysins, the proteinaceous nature of 
these enzymes implies a noncorrosive and biodegradable nature, which is another 
advantage compared to chemical antimicrobials (Nelson et al., 2012). 
The immune response is a considerable part of the safety issue, but in this 
section, we only focus on the antibodies that are generated against the endolysins. 
Specific serum antibodies against PlyG, PlyC, and Pal were raised and mixed in vitro 
with these endolysins and it was found that the killing of bacterial targets was slowed, 
but not terminated (Fischetti, 2005; Loeffler & Fischetti, 2003). In another study, 
mice were injected with Cpl-1 three times a week for four weeks resulting in positive 
IgG production against Cpl-1. However, when S. pneumoniae was given 
intravenously to immunized and naïve mice followed by Cpl-1 treatment, there was 
no significant difference between the two groups regarding the reduction of bacteria 
(Loeffler & Fischetti, 2003). Similarly, multiple enzymes have been shown to display 
the same efficacy in the presence or absence of high titer antibodies (Fischetti, 2010; 
Jado et al., 2003; Rashel et al., 2007). Taken together, the data suggest that specific 
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antibodies are developed to endolysins in vivo but they do not neutralize their 
hydrolytic activity.  
Like antibiotics, the synergy effect has been noted for multiple PG hydrolases in 
combination with other PG hydrolases or antibiotics. The pneumococcal endolysin 
Cpl-1 displayed synergy with either the Pal pneumococcal endolysin or traditional 
antibiotics like penicillin (Djurkovic et al., 2005; Jado et al., 2003; Loeffler & 
Fischetti, 2003). The S. aureus endolysin, LysK, displayed synergy with the 
bacteriocin lysostaphin in a checkerboard assay (Becker et al., 2008), even on strains 
normally resistant to lysostaphin. To conclude, most synergy effects were observed 
between the endolysins targeting different bonds in PG and the combined use of 
endolysins with antibiotics may slow down the development of resistance.  
A biofilm is a growth phenotype of a bacterial community that grows as a thick 
mat on a solid or liquid surface in order to protect the community from environmental 
stress, such as antimicrobials or limited nutritional sources. Several studies have 
described the effectiveness of endolysins at dispersing the biofilm and killing the 
bacteria (Kokai-Kun et al., 2009; O'Flaherty et al., 2005; Sass & Bierbaum, 2007; 
Shen et al., 2013; Son et al., 2010; Walencka et al., 2005; Wu et al., 2003; Yang et al., 
2016).  The endolysins Φ11, SAL-2, PlyGRCS, LysK, and lysostaphin have all been 
shown to eliminate static staphylococcal biofilms. PlyC can eliminate both static and 
dynamic S. pyogenes biofilms. An engineered endolysin, ClyR, can eliminate a S. 
mutans biofilm under both physiological and cariogenic conditions. These results 




Endolysins-Related Applications (Medicine, Food Safety, Disinfectant) 
Although phage therapy was used to treat bacterial infections in the 1920s before 
the discovery of antibiotics and the phage endolysins have been studied, purified, and 
used a laboratory tools for cell wall extraction since the 1970s, it was not until the 
2000s when researchers started to investigate the use of endolysins as antimicrobials. 
The first study supporting this role and showing in vivo efficacy was done at 
Rockefeller University by Nelson et al. (Nelson et al., 2001). It was discovered that 
oral administration of a streptococcal phage endolysin, later named PlyC, could 
prevent and treat upper respiratory colonization in mice by S. pyogenes. Later, more 
endolysins were tested in vivo to validate these enzymes as candidate therapeutics for 
the treatment of bacterial infections. Nasopharyngeal colonization of mice by S. 
pneumoniae could be eliminated by a single dose of the specific enzyme Pal within 5 
h (Loeffler et al., 2001). In another study, a different S. pneumoniae endolysin, Cpl-1, 
was proven to be effective both in a mucosal colonization model and in a systemic 
bacteremia model (Loeffler et al., 2003). One endolysin targeting group B 
streptococci, PlyGBS, could significantly reduce bacteria in a vaginal and 
oropharyngeal colonization model (Cheng et al., 2005).   
The use of endolysins was expanded to include bacterial infection caused by 
bacteria other than streptococci. PlyG, an endolysin from γ-phage of Bacillus 
anthracis, displayed the ability to protect 70-80% of infected mice when injected with 
B. anthracis spores (Schuch et al., 2002). By 2000, methicillin-resistant S. aureus 
(MRSA) had become an emerging public health threat and several studies focused on 
endolysins targeting both planktonic cell and biofilms of S. aureus. The first anti-
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MRSA study was done with MV-L, endolysin from the ΦMR11 phage (Rashel et al., 
2007). In vivo, this enzyme was shown to reduce MRSA nasal colonization by 3 logs 
and protect 100% of mice in an intraperitoneal model. More staphylococcal 
endolysins, such as LysK and LysGH15, were then shown to be effective against 
MRSA in vivo (Fenton et al., 2010; Gu et al., 2011). Recently, two drugs 
compositions containing endolysins are in Phase 2 clinical trials against 
staphylococcal infections (SAL200 and CF-301).  
In addition to directly killing bacteria as antimicrobials, the CBDs of endolysins 
can be fused to the Fc region of human IgG to create a targeted immunotherapeutic. 
One study by Raz et al. created a “lysibody” by fusing the CBDs of endolysins 
targeting MRSA to the Fc region of human IgG. These lysibodies induced the fixation 
of complement on the surface of the staphylococci and promoted phagocytosis by 
macrophages and neutrophils (Raz et al., 2017). This was the first published study to 
exploit the high binding affinity of CBDs to eliminate bacterial infections. This 
approach provides another possibility of using endolysins as anti-infection 
therapeutics.  
Endolysins can also be used for detection and control of foodborne pathogens. 
As stated above, the CBDs of endolysins are specific for their targets with high 
affinity. These advantages have made CBDs good candidates for detection tools. One 
example is the use of Listeria phage endolysin CBDs. Kretzer et al. took advantage of 
these features designing a CBD-based magnetic separation tool for detection of 
Listeria (Kretzer et al., 2007). This method was better than the conventional plating 
method in both accuracy and efficacy. Purified endolysins can also be used as 
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biopreservatives. Obeso et al. showed an endolysin (LysH5) effectively killed S. 
aureus in cow milk with a reduction of 8 log units compared to the control (Obeso et 
al., 2008). Additional endolysins and engineered endolysins, such as B30, Ply700, 
λSA2E-Lyso-SH3b, have likewise shown antimicrobial activity in milk or milk 
products (Celia et al., 2008; Mayer et al., 2011; Schmelcher et al., 2015). Moreover, 
the Listeria phage endolysins Ply118, Ply511, and PlyP35 are promising agents to 
decrease the number of bacteria on solid surface of food products (Zhang et al., 
2012). An alternative approach to control foodborne pathogens is the production of 
endolysins by recombinant starter organisms. Engineered probiotics can harbor 
endolysin genes on interest, and under certain circumstances the probiotics can be 
triggered to produce endolysins targeting pathogens. This application has been used 
in the food fermentation process (Rodriguez-Rubio et al., 2012). Although there are 
still limitations of endolysin applications in food safety due to the complex matrix of 
food products and limited accessibility, these studies are still valuable for further 
endolysins development.  
Another use of endolysins is for the decontamination of environmental 
pathogens. The chemical disinfectants have drawbacks of being toxic and/or 
corrosive due to reactive chemical groups. Endolysins do not depend upon the 
chemically toxic reactive groups, and as proteins, they are biodegradable and non-
corrosive. Research done by Hoopes et al. demonstrated the potential of a 
streptococcal endolysin, PlyC, to be used as a disinfectant against Streptococcus equi, 
which is transmitted through the shedding of live bacteria by horses and drainage 
onto surfaces in stalls or barns. PlyC was found more active than commercial 
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disinfectants with 1 μg of PlyC able to sterile 108 CFU/ml S. equi within 30 min 
(Hoopes et al., 2009). Because an endolysin disinfectant is considered a “green” 
disinfectant, it could have applications in nursing homes, surgical suites, meat-
packing facilities, and child care settings.  
 
1.4 PlyC, A Unique Multimeric Streptococcal Endolysin 
PlyC, an endolysin derived from streptococcal C1 phage, is an evolutionary 
outlier of all discovered endolysins due to its unique molecular structure and 
noteworthy lytic activity (Nelson et al., 2003). First discovered in 1957, lysates of the 
C1 phage containing PlyC were capable of lysis of Group A, Group C, and Group E 
streptococci (Krause, 1957). During the past 50 years, the studies of the genomics, 
methods of purification, protein structure, in vivo and in vitro anti-streptococcal 
efficacy have demonstrated PlyC as one of the most potent endolysins (Fischetti et 
al., 1985; Nelson et al., 2001; Wheeler et al., 1980).  
 
Unique High Bactericidal Activity  
Since the discovery of PlyC, it has been used as a laboratory tool for isolating 
peptidoglycan-associated proteins and extracting DNA from GAS (Fischetti, 2018). 
The first study of PlyC, then called the C1 lysin, focusing on anti-streptococcal 
activity was published in 2001 by Nelson et al. In this study, both in vitro and in vivo 
activity were assessed (Nelson et al., 2001). For the in vitro study, PlyC was diluted 
to from 1,000 U to 10 U and challenged with 106 CFU/ml of GAS. 1,000 U of PlyC 
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completely sterilized cultures in 5s, whereas 100 U of PlyC could reduce the bacterial 
viability by 3 logs in 5 s, 4 logs in 1 min, and 6 logs in 10 min (Figure 1-5 B). The 
killing mechanism of PlyC is via the disruption of PG resulting in the osmotic lysis of 
the bacterial cells (Figure 1-5 A).   
The lytic profile of PlyC was also analyzed in vitro. Representative streptococcal 
strains were exposed to 250 U of the purified PlyC. As expected, PlyC displayed lytic 
activity against all GAS strains tested, consisting of the serological grouping strain, 
an M protein-negative strain, 8 unique M protein types, and an A-variant strain. Also, 
PlyC was also effective against GCS, and GES (Nelson et al., 2001).  
For the in vivo study, a murine model was used. In the first experiment, 1,000 U 
of PlyC or buffer was premixed with GAS in vitro and then orally and nasally 
administered to 5 mice. None of the PlyC-treated mice were colonized after 24 h. In 
the second experiment, 21 mice were pretreated orally with 250 U PlyC before 
challenge with 107 GAS to confirm the prevention ability of PlyC. In these two 
experiments, PlyC showed a protective effect against bacterial infection. In the third 
experiment, 9 mice were heavily colonized by GAS for 4 days. With 500 U of PlyC, 












Figure 1-5. In vitro and in vivo efficacy of PlyC against GAS. (A) Thin-section 
electron micrograph of PlyC-treated GAS for 15 s. (B) In vitro analysis of PlyC 
against GAS. (C) In vivo analysis of PlyC elimination of GAS. Taken from 
(Nelson et al., 2001). 
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Unique Multimeric Structure 
In 2001, PlyC was shown to be a potential antimicrobial agent based on the in 
vitro and in vivo studies, but little was known about the enzyme itself. In 2006, 
Nelson et al. dissected the catalytic domain and cell binding domain of PlyC, and first 
proposed a multimeric structural model (Nelson et al., 2006). Unlike other endolysins 
derived from phage infecting Gram-positive bacteria, PlyC was shown to be encoded 
by two genes, plyCB and plyCA. The gene of plyCB encodes a 72 aa protein product 
with the molecular mass of ~8 kDa, and the gene of plyCA encodes a 465 aa protein 
product with a molecular mass of ~50 kDa. Interestingly, a simple 1:1 heterodimer 
model of PlyCA and PlyCB does not rationalize the ~114 kDa mass of the native 
PlyC as determined by dynamic light scattering. In contrast, 8 PlyCB/1 PlyCA or 2 
PlyCB/2 PlyCA stoichiometric models would fit the observed mass of PlyC. The 
polypeptide-extinction coefficient was then calculated to further validate the model, 
and confirmed a stoichiometric assumption of the 8:1 holoenzyme model.  
Pfam database analysis revealed a putative C-terminal CHAP domain of PlyCA, 
indicating that PlyCA would contain the potential catalytic domain. Alignment of 
PlyCA against known members of the CHAP family suggested that Cys-333 and His-
420 were the putative active-site residues. Thus, site-directed mutagenesis of cysteine 
to serine (C333S) and histidine to alanine (H420A) were made and the mutants PlyC 
(PlyCA) C333S and PlyC (PlyCA) H420A were shown to have significantly reduced 
lytic activity, about 1% activity compared to wide-type PlyC (PlyCA) (Figure 1-6A). 
As controls, the mutations of other cysteine residues did not affect the activity. 
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Therefore, these results confirmed that Cys-333 and His-420 are the active sites and 
the CHAP domain in PlyCA serves the role as the EAD in the native PlyC.  
PlyCA alone cannot lyse the bacteria cell (<1% WT activity), so PlyCB was 
hypothesized to act as the CBD of the native PlyC that brings PlyCA to the cell 
surface. To validate this, PlyC (PlyCA) C333S and PlyCB were purified and 
fluorescently labeled, added to bacteria, and observed for cell binding via 
fluorescence microscopy. Purified PlyCB self-assembled into an octamer with a mass 
of 64 kDa based on analytical gel fitration. The microscope pictures confirmed the 
hypothesis that PlyCB is the CBD. Both PlyC (PlyCA) C333S and PlyCB could 
decorate the surface of S. pyogenes cell walls (Figure 1-6 B and C), but no other 
bacteria were sensitive to PlyC (Figure 1-6 D).   
The crystal structure of PlyC was solved by McGowan in 2012 (McGowan et al., 
2012). This structure confirmed the hypothesis that PlyC contains nine subunits, eight 
PlyCB monomers for each PlyCA (Figure 1-7 A). In addition to a previously known 
CHAP domain, a glycoside hydrolase domain (GyH) was revealed as a second 
catalytic domain in PlyCA, and furthermore, it is shown to work 
synergistically/cooperatively with the CHAP domain to achieve the unusually high 
activity noted for PlyC. A docking domain of PlyCA between the two EADs (yellow 
in Figure 1-7A) forms an antiparallel bundle of three α-helices, which interacts with 
the N-terminus of the eight PlyCB subunits to form the PlyC holoenzyme. Eight 
PlyCB monomers arrange into an octameric ring with a diameter of 80 Å and a height 












Figure 1-6. PlyCA contains the catalytic domain and PlyCB contains the cell wall 
binding domain. (A) PlyCA mutants C333S and H420A displayed no activity. (B) 
PlyC (PlyCA) C333S conjugated to AlexaFluor-568 specifically labels S. pyogenes. 
(C) PlyCB conjugated to AlexaFluor-488 specifically labels S. pyogenes. (D) 





Each PlyCB monomer contains a four-stranded β-sheet in the middle of a short 
α-helix at each side (Figure 1-8 A). It displays no significant sequence similarity to 
any other protein and, thus, presents a rare example of a CBD. The oligomerization of 
PlyCB is mediated through strand/helix hydrogen bonding interactions at each surface 
(Figure 1-8 C). Mutational data reveals that each PlyCB monomer contains potential 
binding sites for cell wall components (Figure 1-8 A and B). Modulation of the 
PlyCB CBD may lead to enhancement of binding properties and subsequent activity. 
Specifically, it is unknown whether all eight PlyCB monomers participate in binding 
or whether the presence of all eight merely increased the avidity of the interaction. 
Importantly, point mutagenesis has shown that the key residues involved in binding 
are on the monomer surface rather than at the monomer/monomer junction, which 






Figure 1-7 Structure of PlyC. (A) The 3.3Å X-ray crystal structure of PlyC consists 
of eight PlyCB subunits for each PlyCA. The PlyCB monomers are colored 
alternately and labeled as monomers A-H. The PlyCA subunit is colored by domains 
as indicated. (B) PlyCB alone colored alternately by monomers. (PlyCB PDB: 4F87, 




Figure 1-8. PlyCB dissection. (A) PlyCB has eight cell-wall binding grooves. The 
cell-wall-binding surface of PlyCB alone shows the residues involved in cell wall 
binding in yellow. Cartoon depiction of PlyCB monomer A shows cell wall binding 
residues in yellow sticks as indicated. (B) The electrostatic surface potential of 
PlyCB. Lys and Arg residues were assigned a single positive charge, and Asp and Glu 
residues were assigned a single negative charge. Blue color indicates positive 
potential charge, and red color indicates negative potential charge. The binding 
grooves are positively charged. (C) The 1.4Å X-ray crystal structure of PlyCB 
monomer/monomer interface. The interaction is mediated by 12 H-bonds. (PlyCB 




1.5 Engineering of Bacteriophage Endolysins 
Bacteriophage optimize endolysins for lytic activity through coevolution with 
bacterial hosts to ensure phage survival. When applied as recombinant proteins 
exogenously, endolysins are being used for a different purpose, and therefore, lose 
this evolutionary pressure. Thus, there exists an engineering potential for endolysins 
to modify their function to increase activity, alter host range, or overcome complex 
extracellular environments (Sao-Jose, 2018). As a growing amount of research 
focuses on the modular designs and crystal structures of endolysins, structure-based 
rational engineering, such as domain swapping, structure-guided mutagenesis, and 
chimeragenesis, has produced endolysins with desirable properties for specific 
applications.  
 
Increasing the Lytic Spectrum and Activity 
Chimeragenesis is a potential engineering approach that has been successfully 
exploited by nature, such as the pneumococcal endolysin Pal, whose two domains 
indicate homology to different phage species (Sheehan et al., 1997). Chimeragenesis 
by scientists via domain swapping, later, proved the capability to create engineered 
endolysins possessing higher activity or an expanded lytic spectrum. Several 
examples of endolysin engineering are noted below. 
Two Listeria monocytogenes phage endolysins, Ply118 and PlyPSA, were used 
for domain shifting to generate fusions with improved capacity (Schmelcher et al., 
2011). One of the fusions (EAD118_III_CBDPSA) displayed a 3-fold increase in 
activity against Listeria serovars that were naturally targeted by the parental PlyPSA. 
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The other chimeric endolysin, PL3, combined the EAD of Pal, a pneumococcal 
endolysin, and the CBD of LytA, a pneumococcal autolysin, exhibited higher activity 
and stability than the parental enzymes (Blazquez et al., 2016). Another example is 
the chimeric pneumococcal endolysin Cpl-711, which is the combination of the EAD 
from Cpl-7 and the CBD from Cpl-1 (Diez-Martinez et al., 2015). Although both 
parental enzymes are specific for pneumococci, Cpl-711 showed significant 
improvement in killing and antibiofilm activity in vitro and in a mouse model 
compared to the parental enzymes.  
In some cases, chimeric endolysins may keep the parental activity, but with an 
expansion of the lytic spectrum. For example, domain swapping between an EAD of 
the streptococcal prophage λSA2 and the SH3b-type CBD of either LysK or 
lysostaphin created two new chimeras. LysK and lysostaphin both target 
staphylococci whereas λSA2 targets streptococci. Both new chimeras (λSA2-E-Lyso-
SH3b and λSA2-E-LysK-SH3b) showed 5-fold increased anti-staphylococcal activity 
when compared to the parental λSA2 endolysin while retaining impressive anti-
streptococcal activity (Becker et al., 2009). In another example, the CBD of PlySs2 is 
recognized as having a broad host spectrum binding domain. Yang et al. fused the 
CHAP domain of PlyC to the CBD from PlySs2, creating a chimeric enzyme ClyR. 
This enzyme displayed antibacterial efficacy towards streptococcal, enterococcal, and 
staphylococcal species similar to PlySs2, but also had activity against species that 
PlySs2 does not work on, such as S. mutans (Yang et al., 2015). 
Many EADs require the presence of the CBD for binding and subsequent 
activity. For example, PlyCA displays no activity without PlyCB, however, some 
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EADs can bind the bacterial surface independently of CBD. One example is 
staphylococcal endolysin LysK. The LysK EAD, a cysteine-histidine 
amidohydrolase/peptidase domain (CHAP), displays higher lytic activity against live 
clinical staphylococcal isolates than the full-length LysK (Horgan et al., 2009). The 
other example is the clostridial endolysin CD27L, where deletion of the CBD not 
only increases lytic activity against Clostridium difficile stains compared to full-
length CD27L, but the host range is extended to include listerial strains that are not 
sensitive to CD27L (Mayer et al., 2011). These cases indicate that the modular design 
of endolysins active against Gram-positive organisms are similar but are not 
necessarily limited to one model and domain deletions are a method to increase lytic 
spectrum and activity. As mentioned above, not all EADs display activity in the 
absence of the CBDs, thus, there remains a good bit to be learned about the molecular 
interaction between EADs and CBDs. A study by Low et al. showed that a net 
positive charge of an EAD enables it to function independently of its CBD, 
presumably through ionic interactions with the bacterial surface, which typically has a 
net negative charge due to surface carbohydrates (Low et al., 2011). This conceptual 
understanding was then applied to endolysin engineering studies for increasing EAD 
activity and expansion of host range. For example, the EAD of the B. subtilis phage 
endolysin, XlyA, has a net charge of Z=-3 at neutral pH. Site-directed mutagenesis of 
five non-cationic residues to lysine (K) produced a shift in net charge from Z=-3 to 
Z=+3, and the mutated XlyA EAD was able to lyse B. subtilis cells at a rate nearly 
identical to that of full-length XlyA. Currently, it is unknown if this principle applies 
to all EADs with a net negative charge. However, using this principle to delete a CBD 
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to make a smaller enzyme may also serve to increase the efficacy where size may be a 
limiting factor. For example, the S-layer of B. anthracis acts as a molecular sieve, and 
the positively charged EAD from PlyL was shown to display higher lytic activity than 
the full-length PlyL. Additionally, change of the net charge of the CBD could also 
enhance the lytic activity of the enzyme. Cpl-7 is a pneumococcal endolysin but 
presents much lower bacteriolytic activity when compared to other pneumococcal 
enzymes, such as Cpl-1 and Pal (Diez-Martinez et al., 2013). After Low et al. ’s 
study, Díez-Martínez et al. found that the CBD of Cpl-7 possesses a negative charge 
at neutral pH. Moreover, they changed the net charge of the CBD from -14.93 to +3 
via site-directed mutagenesis of 13 non-structural amino acids. The new mutant was 
called Cpl-7S, and it displayed improved bactericidal activity against pneumococcal 
and non-pneumococcal species when compared to its parental enzyme (Diez-
Martinez et al., 2013).  
 
Improving the Stability 
A crucial property for development of endolysins as therapeutic agents is the 
shelf-life relating to its intrinsic thermal stability. Many naturally thermostable 
endolysins have been discovered, such as the Ph2119 endolysin, which retains 87% of 
its activity after 6 h of incubation at 95°C (Plotka et al., 2014), a Salmonella phage 
endolysin, Lys68, which is not completely inactivated until it is exposed to 100°C for 
39 min (Oliveira et al., 2014), a Clostridium endolysin, LysCPS2, which retains 30% 
of its lytic activity after 10 min of incubation at 95°C (Ha et al., 2018), and a Bacillus 
endolysin, PlyG, which retains 50% of lytic activity after being heated to 80°C 
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(Heselpoth et al., 2015). However, most endolysins are easily denatured at mesophilic 
temperatures. One way to engineer stability to an endolysin is via chimeragenesis to 
increase thermostability.  For example, the chimera containing the EAD of the 
thermostable endolysin PlyGVE2 and the CBD of PlyCP26F not only retains the host 
range of PlyCP26F towards to C. perfringens, but also preserved more than 57% of 
its lytic activity after incubation for 30 min at 55°C, comparing to the total loss of 
activity for the parental endolysin PlyCP26F under the same conditions (Swift et al., 
2015).  
In addition to chimeragenesis, random mutagenesis with selective pressure is 
another method used by bioengineers to integrate thermostability into endolysins. 
One example is the multimeric domain endolysin, PlyC. A heating experiment 
ranging from 37°C-100°C demonstrated that PlyC irreversibly denatured at 42°C. 
Interestingly, the TG of PlyCB is 75°C, whereas the TG of one of the catalytic domains, 
CHAP, in PlyCA is around 39.1°C, suggesting that this domain is the most heat-
susceptible structural element. A study done by Heselpoth et al. used a random 
mutagenesis method based on the error-prone PCR, followed by a selective screening 
for the mutants with enhanced thermostability. The 29C3 mutant displayed more than 
a 2-fold increase in stability at 45°C (Heselpoth & Nelson, 2012). In a parallel study, 
the Heselpoth took advantage of bioinformatic tools to predict the mutation and one 
of the mutants, PlyC (PlyCA)T406R, illustrated a 16-fold increase in stability and an 
increased denaturation temperature by 2.2°C compared to the WT PlyC (Heselpoth et 
al., 2015).  
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Another important consideration for therapeutic development of endolysins is 
their half-life in the bloodstream. Research done by Resch et al. aimed to increase the 
half-life of the endolysin, Cpl-1 (Resch et al., 2011). They discovered that the 
dimerization of a Cpl-1 mutant (Cpl-1C45S, D324C) via the disulfide bonding displayed a 
10-fold decrease in plasma clearance in mice compared to native Cpl-1, while 
doubling the lytic activity of Cpl-1 at the same time. This method worked because the 
size of the dimeric endolysin is 74kDa, while proteins below 45-50kDa tend to be 
cleared from plasma by renal filtration. The same result can be achieved via the 
addition of non-immunogenic polymers to the endolysins. One example is the 
addition of conjugated poly-L-lysine polycationic polymers to lysostaphin, which 
resulted in reductions of immunogenicity, proteolysis, and instability (Veronese & 
Mero, 2008; Walsh et al., 2003). 
 
Reducing the Resistance Possibility 
In the previous section, bacterial resistance to endolysins has been thoroughly 
discussed. Endolysins specifically cleave the essential bonds in the PG within seconds, 
and several studies support that repeated exposure of bacteria to endolysins does not 
affect the MIC. These facts support that emergence of resistance to endolysins should 
be rare. Moreover, a great number of phage endolysins possess dual lytic domains, 
which are predicted to be more difficult to develop resistance (Fischetti, 2005). With 
the inspiration of the dual lytic domains, the Donovan laboratory has taken a more 
advanced step to create three lytic domains in one endolysin, aiming to further reduce 
the resistance possibility (Becker et al., 2009). In this study, they engineered triple-
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lytic-domain constructs using the enzymes LysK and lysostaphin; two PG hydrolases 
well-known to be active against several MRSA strains. The authors created fusions of 
the two lytic domains of LysK and the lytic domain of lysostaphin, in two 
combinations that were capable of cleaving three different. LysK-Lyso, two lytic 
domains of LysK to the N-terminal of lysostaphin, and Lyso-LysK, two lytic domains 
of LysK in the middle of lysostaphin, were created. In an assay to evaluate the 
resistant development in vitro against S. aureus strain Newman, the parental 
enzyme’s MIC increased 42-fold and 585-fold, respectively. In contrast, LysK-lyso 
and lyso-LysK yielded only 8-fold and 2-fold increases in MIC, respectively.  
  
Enhancing the Activity against Gram-Negative Bacteria 
Due to the protection of the outer membrane of Gram-negative bacteria, native 
endolysins cannot cleave the peptidoglycan “from without” unless there is a 
disruption and/or translocation of the outer membrane. Concerning protein 
engineering strategies, two principal methods have been applied to improve outer 
membrane penetration by endolysins.  
One engineering method is to provide the enzyme with a binding capacity for the 
receptor on the outer membrane. The first successful engineering effort to create an 
endolysin active against a Gram-negative organism was done by Lukacik et al., who 
creating an engineered T4 lysozyme that killed E. coli via fusion of the N-terminal 
binding domain of pesticin (Lukacik et al., 2012). Pesticin is a bacteriocin produced 
by Yersinia pestis that specifically binds to the outer membrane transporter FyuA. 
FyuA is a major virulence factor in some pathogenic E. coli strains. The engineered 
52 
 
T4 lysozyme with an N-terminal FyuA binding domain could bind to FyuA, was 
transported across the outer membrane to the periplasmic space, and resulted in 
cleaves of the PG by the T4 lysozyme.   
An alternative method is to arm the endolysin with membrane-penetrating 
peptides that can disrupt the lipopolysaccharides (LPS) and some phospholipids. 
These studies were done extensively by Briers and Lavigne, and the engineered 
endolysins were called “Artilysin®”, for artificial lysin (Briers & Lavigne, 2015).  
The most successful examples have fused the endolysin from Pseudomonas 
fluoresens and Salmonella enterica, OBPgp279 and PVP-SE1gp146, with a 
polycationic nonapeptides to the N-terminus (Briers et al., 2014). Both artilysins 
displayed improved antibacterial effects against P. aeruginosa and expanded efficacy 
against A. baumanni. Further refinements to adjust the flexibility of the artilysins via 
increasing linker length between the peptide and enzyme resulted in even higher 
activity. Remarkably, several follow-on studies suggested that artilysins also 
displayed potent bactericidal activity against multidrug-resistant strains and bacterial 
persisters (Gerstmans et al., 2016).  
 
1.6 Purpose of Research 
Given the unique structure and high activity of PlyC, there is much interest in 
understanding the mechanism that governs this enzyme as well as approaches that can 
be used to modify its properties and activity. With a long-term goal of exploiting the 
specialties of PlyC on more bacterial species as a new antimicrobial agent, custom 
engineering methods based on its structure should be developed. This dissertation 
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focuses on engineering methods for PlyC as well as the outcomes that can then be 
further applied. A structure-guided, site-directed mutagenesis method is applied to 
create monomeric PlyCB in order to understand the binding mechanism and creating 
a specific CBD for chimeragenesis (Chapter II). A novel design strategy to apply the 
synergy of the PlyCA dual lytic domains led to several potent engineered endolysins 
active against other streptococci (Chapter III). Finally, a hypothesis of the role of 
protein net charge has been tested using the negatively charged PlyCA CHAP domain 
as a model (Chapter IV). Taken together, the bioengineering strategies contained in 
this dissertation provide a better understanding of the PlyC mechanism of action 
while at the same time suggests several strategies for improving or expanding the 
lytic properties of PlyC. 
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Chapter 2: Structure-Guided Mutagenesis of PlyCB – 
Dissecting the Binding Mechanism 
 
2.1 Abstract 
Bacteriophage endolysins are murein hydrolases produced at the end of the 
phage replication cycle and have been studied as novel antibacterial therapeutic 
agents. PlyC, an endolysin from the C1 streptococcal bacteriophage, possesses the 
most potent activity towards specific streptococcal hosts. Structural and biochemical 
studies reveal the molecular basis behind this potency: PlyC is a holoenzyme 
consisting of one enzymatically active domain (PlyCA) and eight identical cell 
binding domains (PlyCB) that self-assemble into an octamer, which represents a 
unique structural arrangement not seen in any other endolysin. Despite detailed 
structural information, there remain questions on the binding mechanism of the 
PlyCB octamer and how it affects the lytic activity. Here, we demonstrate that the 
native PlyCB octamer can be engineered to a PlyCB monomer (PlyCBm) through 
structure-guided mutagenesis that breaks hydrogen bonds between PlyCB octamer 
subunits. Tandem duplication of the PlyCB monomer (PlyCB2m) is then created to 
further analyze the binding. Gel-filtration and protein cross-linking confirm the mass 
of PlyCBm and PlyCB2m, and fluorescence microscopy validates that they retain the 
same binding capability to streptococci as the PlyCB octamer. In addition, the 
comparison of EC50 among PlyCBm, PlyCB2m, and PlyCB octamer suggests a 
concurrent binding model for the PlyCB octamer. The PlyCBm/PlyCB2m-derived 
chimeras provide a rationale to further study the relations between binding affinities 
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and lytic activities. Finally, the observations that PlyCBm translocates epithelial 
membranes and, with an enzymatically active domain, kills intracellular S. pyogenes 




The development of alternative antimicrobial agents is one of the highest 
global priorities in biological, pharmaceutical, and medical investigations due to the 
ever-growing concern of antibiotic resistance (Brown & Wright, 2016). One class of 
alternative antimicrobial agents that has attracted increasing attention is endolysins, 
also termed phage lysins or enzybiotics, which are bacteriophage-encoded 
peptidoglycan hydrolases (Fischetti, 2008). They are produced at the end of the phage 
replication cycle resulting in bacterial cell lysis and new phage release. In addition, 
these enzymes are also capable of destroying the Gram-positive bacterial 
peptidoglycan (PG) when applied extrinsically as recombinant proteins (Fischetti et 
al., 2006). As antimicrobial agents, endolysins feature a defined host spectrum and 
kill bacteria regardless of their antibiotic sensitivity (Fischetti, 2008).  
The structure of endolysins that act on Gram-positive organisms mostly 
features a similar modular design with an enzymatically active domain (EAD) at the 
N-terminus fused via a short linker to a cell-binding domain (CBD) at the C-terminus 
(Fischetti, 2005; Loessner, 2005). The CBD binds to distinct epitopes on the bacterial 
cell wall, faciliating hydrolysis of the PG bonds by the EAD.  
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The streptococcal phage C1 endolysin, known as PlyC, possesses the highest 
activity of any endolysin reported to date and it is a rare example of a multimeric 
endolysin (McGowan et al., 2012; Nelson et al., 2001; Nelson et al., 2006). 
Biochemical and biophysical characterization of PlyC reveal that it is a holoenzyme 
composed of nine proteins: eight 8 kDa PlyC cell binding domain subunits (PlyCB) 
and one 50 kDa enzymatically active subunit (PlyCA) (Nelson et al., 2006). PlyCB 
and PlyCA are encoded by two separate genes, plycB and plycA, respectively, which 
is a distinctive feature that separates PlyC from all other endolysins. Furthermore, 
PlyCA contains two catalytic domains, CHAP and GyH, which work synergistically 
to achieve the noted high rate of bacteriolytic activity. The eight PlyCB subunits self-
assemble in an octameric ring-shaped structure that interacts with PlyCA via unique 
protein-protein interaction (McGowan et al., 2012). Like CBDs of other endolysins, 
the PlyCB octamer defines the host range of PlyC to groups A, C, E streptococci and 
Streptococcus uberis, which cause diseases in both human and animals (Nelson et al., 
2006). In addition to binding the surface of streptococcal cells, PlyCB is also capable 
of binding to phosphatidylserine on the plasma membrane of eukaryotic cells and 
mediates PlyC internalization, allowing activity of the holoenzyme against 
intracellular streptococci (Shen et al., 2016). These features make PlyCB an 
exceptional example of an endolysin CBD. 
Despite substantial study on PlyC, many questions remain on the binding 
mechanism and binding epitopes of PlyCB. The streptococcal binding site of PlyCB 
is found on each subunit, and there are thus eight binding sites on the PlyCB octamer. 
Point mutagenesis has shown that the key residues involved in binding are on the 
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monomer surface rather than at the monomer/monomer junction, which interacts 
through inter-subunit hydrogen bonds. However, it is unknown whether all eight 
PlyCB monomers participate in binding. Concurrent binding may lead to 
enhancement of binding properties and subsequent activities, whereas a consecutive 
interaction may result in a more fleeting binding (McGowan et al., 2012).  
Here, the PlyCB monomer (PlyCBm) and a duplication of the PlyCB 
monomer (PlyCB2m) were created via structure-guided mutagenesis to study the 
binding mechanism of the PlyCB octamer. In addition, these two new CBDs were 
engineered with an N-terminal EAD to evaluate lytic activity on extracellular and 
intracellular bacteria in vitro. The different properties observed for the 
PlyCBm/PlyCB2m derived chimeras suggested a rationale for optimizing the 
endolysin activity.  
 
2.3 Materials and Methods 
Bacterial Strains and Growth Conditions 
Bacterial strains used in this study are listed in Appendix B. Streptococcus 
pyogenes strain D471 was the primary strain for the cell wall binding assay and the 
turbidity reduction assay, although additional strains were tested as indicated. All 
strains were stored at -80°C and grown at 37°C. Streptococci were grown in liquid 
THY medium (Todd-Hewitt broth, supplemented with 1% (wt/vol) yeast extract); 
staphylococci were grown in TSB medium (trypticase soy broth); and bacilli were 
grown in BHI medium (brain heart infusion). Escherichia coli strains DH5ɑ and 
BL21 (DE3), containing the constructs, were grown in LB medium (Luria broth) with 
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kanamycin (50 µg/ml) or carbenicillin (50 µg/ml) in a shaking incubator unless 
otherwise stated. All chemicals and culture media were acquired from Sigma unless 
otherwise stated. 
 
PlyCB Octamer Interactions 
PyMOL was used to perform the PlyCB structural representations including 
the H-bonds and the suggested mutations (The PyMOL Molecular Graphics System, 
Version 2.0 Schrödinger, and LLC). The residues involved in H-bond formation at 
the interfaces of the PlyCB octameric ring were identified through PDBePISA 
(Protein Interfaces, Surfaces, and Assemblies) (Krissinel & Henrick, 2007). The 1.4-
Å resolution crystal structure of PlyCB (Protein Data Bank ID 4F87) was used for 
both the PyMOL offline package and the PDBePISA online server.  
 
Cloning and Site-Directed Mutagenesis 
The plasmids and primers used in this work are listed in Appendix A. The 
constructs for pBAD24::plyCB, pBAD24::plyC, and pBAD24::plyC∆GyH were 
previously described (McGowan et al., 2012; Nelson et al., 2012). An N-terminal 
His-tag was added to plyCB following standard DNA manipulation and cloning 
procedures (Sambrook, 1989). Plasmids harboring the plyCB mutants were 
constructed by mutagenesis using the QuikChange II Site-Directed Mutagenesis Kit 
(Agilent Technologies) with phosphorylated primers. The double CBD (PlyCB2m) 
construct was made via insertion an additional CBD gene downstream of the 
pBAD24::plyCBm-N-6His via XbaI/SalI sites. The quadruple CBD (PlyCB4m) 
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construct was made via insertion an additional double CBD gene downstream of the 
pBAD24::plyCB2m-N-6His via SalI/PstI sites.  
To create a series of PlyCBm/PlyCB2m chimeric proteins, the DNA 
sequences of the GyH domain (PlyCA1-205), CHAP domain (PlyCA309-465), and PlyCA 
subunit were amplified by PCR from pBAD24::plyC (McGowan et al., 2012). 
Likewise, the CHAPLysK domain with linker sequence (1-197aa) and CHAPPlySs2 
domain with linker sequence (1-161aa) were amplified by PCR from pBAD24::lysK 
and pBAD24::plySs2, respectively, which in turn had been chemically synthesized by 
GenArt ThermoFisher. The AmidasePlyG domain with linker sequence (1-172aa) was 
amplified by PCR from pBAD24::plyG and the Amidasepal domain with linker 
sequence (1-149aa) was amplified by PCR from pBAD24::pal. All of the amplified 
DNA sequences of the EADs contained first 20 nucleotides of plyCBm/PlyCB2m at 
their 3’ends. Similarly, the DNA sequences of plyCBm/plyCB2m were amplified with 
the last 20 nucleotides of each EAD at the 5’ ends. The resulting PCR fragments were 
joined and amplified by PCR-based Gene Splicing by Overlap Extension PCR (SOE 
PCR) (Horton et al., 1990; Pease, 1990) before insertion into NdeI/BamHI sites of a 
pET28a vector. All plasmids encoding recombinant proteins were verified by DNA 
sequencing before being transformed into the expression strain E. coli BL21 (DE3).  
 
Protein Expression and Purification 
For overproduction of different constructs, E. coli BL21 (DE3) cells were 
grown in baffled Erlenmeyer flasks at 37°C until the OD600 reached 0.6-0.8. Protein 
expression was induced at 18°C for 20 h with 0.25% L-arabinose for pBAD24 
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constructs or 0.1 mM isopropyl β-D-thiogalactoside (IPTG) for pET28a (+) 
constructs. The cells were harvested at 5,000 rpm for 15 min at 4°C and resuspended 
in PBS, pH 7.4, supplemented with 1 mM phenylmethanesulfonyl fluoride (PMSF) 
and 10 mM imidazole. The bacteria were sonicated on ice for 15 min, with the 
insoluble cellular debris subsequently pelleted at 12,000 rpm for 1 h at 4°C. The 
soluble lysate was applied to a nickel-nitrilotriacetic acid (Ni-NTA) column (Qiagen). 
Protein samples were eluted from the column using a step gradient consisting of 
imidazole concentrations ranging from 20 mM to 500 mM in PBS, pH 7.4. The 
elution fractions were subjected to 7.5% SDS-PAGE before being dialyzed against 
PBS, pH 7.4, overnight at 4°C.  The protein concentrations were determined 
spectrophotometrically (NanoDrop 2000c) using the theoretical molar absorption 
coefficient at 280 nm. Purified proteins were stored at 4°C in PBS.  
 
Protein Mass Analysis 
PlyCB WT and mutants were characterized for proper folding and mass 
estimation by analytical gel filtration as previously described (Nelson, D. et al., 
2006). Briefly, 500 µl of 2 mg/ml of each sample was subjected to analytical gel 
filtration on a Superose 12 column (GE Healthcare) calibrated with gel filtration 
standards (Bio-Rad). The cross-linking experiment was performed using 
bis(sulfosuccinimidyl) (BS3) (ThermoFisher) per the manufacturer’s instructions. A 
fresh stock of BS3 was made in 20 mM sodium phosphate buffer, pH 7.4, then added 
to 100 µg of purified protein to reach a final concentration of 5 mM/10 mM. The 
reaction was allowed to react for 1 hour at room temperature and quenched by the 
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addition of Tris buffer (final concentration of 50mM) for 15 min at room temperature. 
The crosslinked protein samples were analyzed by 7.5% SDS-PAGE in reduced 
sample buffer. 
 
Fluorescent Labeling of Proteins 
Purified PlyCB, PlyCBm, PlyCB2m, or PlyCB R66E were reacted with the 
carboxylic acid, succinimidyl ester of AlexaFluor® 555 (Molecular Probes) 
according to the manufacturer’s instructions. Briefly, 1 mg of proteins was mixed 
with 10 µl of AlexaFluor® 555 dye (2.0 mg/ml in DMSO), then incubated at room 
temperature for 1 hour with constant stirring. Unreacted dye was removed from the 
labeled protein by application to a 5 ml HiTrap desalting column (GE Healthcare) 
equilibrated with PBS.  
 
Cell Wall Binding Assays and Fluorescence Microscopy 
Overnight cultures of bacteria were pelleted (5,000 rpm, 10 min, 4°C), 
washed, and resuspended with PBS, pH 7.4. 100 µl of each bacterial culture was 
incubated at room temperature with either 10 µg of AlexaFluor® labeled PlyCB or 
PlyCBm/PlyCB2m containing the 6xHis tag for 10 min. The samples containing 
PlyCBm/PlyCB2m were washed with PBS and incubated for another 10 min at room 
temperature with 1 µl of AlexaFluor® 488 conjugated His-tag monoclonal antibody 
(Invitrogen). Both samples were rewashed with PBS before being visualized via 
fluorescence and bright field microscopy. Negative controls, bacteria only, and 
bacteria with unlabeled proteins, were applied. An Eclipse 80i epifluorescent 
62 
 
microscope workstation (Nikon) with X-Cite 120 illuminator (EXFO) and Retiga 
2000R CCD camera was used. NIS-Elements software (Nikon) was used for image 
analysis. 
 
Effective Concentration (EC50) of PlyCB, PlyCBm, PlyCB2m 
The EC50 was quantified using a whole bacterial ELISA as previously 
described (Elder et al.), with minor modifications. An overnight S. pyogenes D471 
culture was treated with 0.4% formalin (ʋ/ʋ) for 4 hours at room temperature. Then, 
the bacterial cells were washed three times and resuspended with PBS, pH 7.4, 
containing 0.05% (ʋ/ʋ) Tween 20 (PBST) to reach a final OD600=1. 100 µl of the 
bacterial suspension was added to a black 96-well plate with clear bottom coated with 
poly-D-lysine (Corning Incorporated) and incubated overnight at 4°C. Next morning, 
plates were centrifuged (4,000 rpm, 10 min, 4°C), and washed three times with 
PBST. Bacterial adherence was confirmed by scanning with an inverted light 
microscope, and nearly confluent coverage of all wells was considered satisfactory. 
The bacteria-coated wells were received 100 µl of serial diluted AlexaFluor® 555 
labeled PlyCB WT, PlyCBm, or PlyCB2m, and incubated for 1 h at room temperature 
covering by aluminum foil. The plate was then washed three times with PBST. 
Controls included the flowing: (i) wells with PBST only, (ii) wells with serial diluted 
unlabeled proteins, (iii) wells with bacteria only, (iv) wells with serial diluted 
AlexaFluor® labeled proteins and (v) wells with bacteria and AlexaFluor® labeled 
PlyCB R66E, a mutant known to lack the ability to bind the streptococcal surface. 
The binding was quantified through fluorescence reading at excitation wavelength 
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555 and emission wavelength 580 via a SpectraMax M5 Multi-Mode Microplate 
Reader (Molecular Devices). The fraction bound was calculated using the 
fluorescence reading of protein-bacteria complexes over the saturated binding signal. 
EC50 was the concentration achieving 50% of binding (fraction bound=0.5). All tests 
were performed in triplicate. 
 
Turbidity Reduction Assay 
Turbidity reduction assays were performed as previously described (Nelson, 
D. C. et al., 2012). Briefly, overnight bacterial cells (stationary phase) were 
centrifuged (4,000 rpm, 5 min, 4°C), washed and resuspended in PBS, pH 7.4, and 
mixed 1:1 (ʋ/ʋ) with endolysin to a final OD600=1 in a standard 96-well titration plate 
(ThermoFisher). OD600 readings were taken every 15 sec for 20 min at 37°C on a 
SpectraMax 190 spectrophotometer (Molecular Devices). The OD600 reduction curve 
and Vmax, the slope of the linear portion, was used to represent the endolysins activity. 
All tests were performed in triplicate.  
 
Epithelial Cell Culture and Confocal Microscopy 
Human alveolar epithelial A549 cells (Human Lung Carcinoma cell line, 
CCL-185) were cultured in F-12K medium supplemented with 10% fetal bovine 
serum (FBS) at 37ºC, 5% CO2, and 95% relative humidity. The second or third 
generation of cells was seeded onto 12 mm2 coverslips in 24-well tissue culture 
plates. When reaching 80% confluence, cells were washed twice with PBS before 
incubation with 20 µg/ml AlexaFluor® labeled PlyCB or PlyCBm in serum-free 
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medium for 30 min. The cells were again washed three times with PBS, fixed by 4% 
paraformaldehyde, and mounted with ProLong® Gold Antifade Reagent with 4',6-
diamidino-2-phenylindole (DAPI) on glass slides for microscopic examination using 
an inverted scanning confocal microscope with Argon laser excitation (Carl Zeiss 
LSM 710). Images and Z-stacks were obtained with a Plan Apochromat 100×/1.4 
objective lens and analyzed with the Zen 2010 digital imaging software (Carl Zeiss).  
 
Streptococci/Epithelial Cell Co-culture Assay 
The co-culture assay was conducted as previously described (Shen et al., 
2016). Briefly, lung epithelial cells A549 were grown to 80% confluent monolayers 
in 24-well tissue culture plates. An overnight culture of S.pyogenes D471 was washed 
in sterile PBS, pH 7.4, and then, resuspended in serum-free media and incubated with 
epithelial cells at a multiplicity of infection of 100 bacterial cells per one epithelial 
cell for 2 h. 10 μg/ml penicillin and 200 μg/ml gentamicin were added to the co-
culture for 1 hour to kill non-adherent and adherent bacteria. Different amounts of 
endolysins were added to the post-antibiotic treated co-culture and incubated for two 
hours. Epithelial cells were detached by 100 μl of a 0.25% trypsin/0.02% EDTA 
solution before being lysed by 400 μl of a 0.025% Triton X-100 solution in PBS. The 
lysed cells in solution were serially diluted in PBS and plated on blood agar plates for 





Prediction of Monomeric Mutations via PlyCB Octamer Interactions 
PlyCB, the cell wall binding domain of PlyC, consists of eight identical 
subunits forming a self-assembling octameric ring. The binding site of each PlyCB 
subunit is lined by residues Tyr28, Lys59, and Arg66 (Fig 2-1 A) (McGowan et al., 
2012). The interactions between any two PlyCB octamers are mediated by 15 
hydrogen bonds (H-bonds) and 3 van der Waals forces in the strand/helix interfaces 
(Fig 2-1 B) (McGowan et al., 2012). In this study, Protein Interfaces, Surfaces and 
Assemblies (PDEePISA) was applied to the 1.4-Å resolution structure of PlyCB 
(Protein Data Bank ID 4F87) for the identification of the residues involved in the H-
bonds (Krissinel & Henrick, 2007) (Table 2-1). Two H-bonds are formed between the 
backbone of Val10 and Ser11 in the chain A with Gly15 in the chain B at both N-
termini. The other 13 H-bonds are formed between the side chains of residues 40-44 
in chain A with residues 20-21 and 56-61 in chain B (Fig. 2-1 B, 2-1 C, Table 2-1). 
Among the residues in this section, five are polar amino acids with charged side 
chains and participate in up to 11 H-bonds (Table 2-1).  
To create a PlyCB monomer, we hypothesized that mutation of the polar 
amino acids to a non-polar amino acid (i.e. alanine) would prevent the formation of 
H-bonds, and as such, formation of the octamer. Therefore, three residues (Lys40, 
Asp41, and Glu43) that were not involved in the bacterial binding sites and did not 
otherwise play an evident structural role, were selected for site-directed mutagenesis 




Figure 2-1. Cartoon models of PlyCB monomer and PlyCB octamer interactions. 
(A) The 1.4 Å X-ray crystal structure of the PlyCB monomer, containing four β-
sheets and two -helicies. The residues involved in the binding site of each PlyCB 
monomer to the bacterial surface are indicated in yellow. (B) The 1.4 Å X-ray crystal 
structure of PlyCB interactions between chain A (magenta) and chain B (cyan). The 
interactions are mediated through 15 H-bonds indicated as black dash lines. (C) 
Altered orientation of PlyCB chain A and chain B interactions. Thirteen H-bonds 
(black dash lines) are formed between the side chains of residues 40-44 in chain A 
with residues 20-21/56-61 in chain B. The residues that are collectively involved in 
11 H-bonds are labeled in green. (D) Mutagenesis of residues K40 and E41 (grey) to 





PlyCBK40A:E43A is a Monomer 
A total of seven PlyCB mutants, K40A, D41A, E43A, K40A:D41A, 
K40A:E43A, D41A:E43A, and K40A:D41A:E43A were made. All expressed as 
soluble proteins indicating them to be ~8 kDa PlyCB monomers on SDS-PAGE 
analysis (Fig. 2-2 A). Mutants were then applied to analytical gel filtration using a 
Superose 12 column with a broad fractionation range between 1,000 Da and 300,000 
Da for proper folding and size prediction. The triple mutation, K40A:D41A:E43A, 
was eluted from the void volume suggesting that the protein was either aggregated or 
in a non-globular shape (data not shown). Five of the other six mutants were eluted in 
the same fraction, between the 158 kDa and 44 kDa molecular mass standards, which 
is the same elution profile noted for the WT PlyCB octamer. In contrast, the double 
mutation, K40A:E43A, was eluted in a late fraction, smaller than the 17kDa 
molecular mass standard, indicating that PlyCBK40A:E43A is a potential monomeric cell 
binding domain at ~8 kDa (Fig. 2-2 B). The computational model via PyMOL 
implied these two mutations dramatically diminished the formation of H-bonds in this 
region of the structure (Fig 2-1 D). To further authenticate the mass of 
PlyCBK40A:E43A, we used a non-cleavable cross-linker, bis(sulfosuccinimidyl) (BS3), 
which reacts with primary amines and the  amine of lysine. SDS-PAGE analysis of 
the cross-linked PlyCB WT with 5 mM BS3 showed different oligomeric PlyCB 
monomers, and an increasing amount of 10 mM BS3 produced octameric PlyCB as 
well as oligomers of PlyCB octamers (Fig. 2-2 C). Compared to PlyCB WT, 
PlyCBK40A:E43A remained steady at the mass of ~8 kDa in the presence of 10 mM BS3, 
confirming that it is a PlyCB monomer. Hence, it was named PlyCBm (Fig. 2-2 C).  
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In order to understand the binding mechanism of PlyCB, the tandem duplicate 
of PlyCBm, called PlyCB2m, and quadruple PlyCBm, called PlyCB4m, were 
constructed aiming to compare the binding affinity of different PlyCB oligomers. No 
protein expression was observed for PlyCB4m and, therefore, it was excluded from 
further study (data not shown). Analytical gel filtration of purified PlyCB2m showed 
the expected double monomer mass of ~16 kDa (Fig. 2-2 D).  
 
PlyCBm and PlyCB2m Retain the PlyCB Octamer’s Binding Ranges 
After the mass of PlyCBm and PlyCB2m was confirmed, we sought to know 
whether they retained the ability to bind the streptococcal surface, which would 
indicate both proper folding and that a single site is sufficient for binding. Both 
PlyCBm and PlyCB2m bound the surface of S. pyogenes D471 in the same manner as 
the WT PlyCB octamer as viewed by fluorescent microscopy (Fig. 2-3 A-C). 
Moreover, both PlyCBm and PlyCB2m bound to other streptococcal strains sensitive 
to PlyC, including group C streptococci (S. dysagalactiae subs. equisimilis, S. equi, S.  
equi subs. zooepidemicus), group E streptococci, and S. uberis, but not non-host 





Figure 2-2. Elucidation of the mass of PlyCBm and PlyCB2m. (A) 7.5% SDS-
PAGE indicates ~8 kDa bands for PlyCB WT and various PlyCB mutants. The lanes 
correspond to: (M) BioRad protein marker, (1) PlyCB WT, (2) PlyCB K40A, (3) 
PlyCB D41A, (4) PlyCB E43A, (5) PlyCB K40A:D41A, (6) PlyCB K40A:E43A, (7) 
PlyCB D41A:K43A, (8) PlyCB K40A:D41A:K43A. (B) Analytical gel filtration of 
PlyCB WT and PlyCB K40A:E43A (PlyCBm) using a Superose 12 column. BioRad 
standard indicated as the blue curve; PlyCB WT octamer is indicated as the red curve; 
PlyCBm is indicated as the green curve. (C) Cross-linking of PlyCB WT and 
PlyCBm. 7.5% SDS-PAGE shows both PlyCB WT and PlyCBm at ~8 kDa without 
bis(sulfosuccinimidyl) (BS3) crosslinker. At the presence of 5 mM/10 mM of BS3, 
PlyCB WT forms oligomers, while PlyCBm is still a monomer. The lanes correspond 
to: (M) BioRad protein marker, (1) PlyCB WT, (2) PlyCB WT with 5 mM of BS3, (3) 
PlyCB WT with 10 mM of BS3, (4) PlyCBm, (5) PlyCBm with 10 mM of BS3  (D) 
Analytical gel filtration of PlyCBm and PlyCB2m using a Superose 12 column. 
BioRad standards indicated as the blue curve; PlyCB K40A:E43A (PlyCBm) is 




Figure 2-3. Binding of PlyCB octamer, PlyCBm, and PlyCB2m to the surface of 
S. pyogenes D471. Images represent the bright field (top panel) and fluorescent field 
(bottom panel). (A) AlexaFluor® 555-labeled PlyCB octamer. (B) PlyCBm with 
AlexaFluor® 488 conjugated His-tag monoclonal antibody. (C) PlyCB2m with 
AlexaFluor® 488 conjugated His-tag monoclonal antibody.  
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Table 2-2. Binding of CBDs to different Gram-positive bacteria. 
   
  Binding of CBD2 
Bacteria Strain1 PlyCB octamer PlyCBm PlyCB2m 
S. pyogenes D471 + + + 
S. agalactiae A909 - - - 
S. dysagalactiae subs.equisimilis ATCC 21597 + + + 
S. equi ATCC 9528 + + + 
S. equi subs.zooepidemicus ATCC 700400 + + + 
Group E streptococci K131 + + + 
S. uberis BAA-854 + + + 
S. pneumoniae TIGR4 - - - 
S. mitis ATCC J22 - - - 
S. mutans ATCC 25175 - - - 
S. oralis ATCC PK34 - - - 
S. rattus BHT - - - 
S. sobrinus ATCC 6715 - - - 
B. cereus ATCC 4342 - - - 
S. aureus NRS385 - - - 
1See Appendix B for the source of species and strains. 
2 +, binding; -, no binding. 
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EC50 Suggests PlyCB Octamer Binds Concurrently 
It is unknown whether all eight subunits of PlyCB bind to the bacterial surface 
at the same time (i.e. concurrent model) or one after another in a rolling manner (i.e. 
consecutive model) (McGowan et al., 2012). Because a single PlyCBm containing 
one binding site was capable of binding, we assessed the binding pattern of the 
PlyCBm versus the PlyCB octamer. A whole cell bacterial ELISA was conducted and 
the effective concentration of the CBD that gives half-maximal binding (EC50) was 
used to represent the binding avidity. The EC50 values for PlyCBm, PlyCB2m, and 
PlyCB were 120, 570, and 900 nM, respectively (Fig. 2-4). In contrast, PlyCB R66E, 
a known PlyCB mutant that abolishes binding, acted as a negative control, and 
showed no detectable binding. The data, taken together, supports a concurrent model 
and suggests all eight PlyCB subunits simultaneously participate in binding the 




Figure 2-4. EC50 of PlyCB WT, PlyCBm and PlyCB2m.  Various amounts of 
AlexaFluor® 555 labeled proteins were incubated with S. pyogenes D471 at room 
temperature for 1 hour to make a saturation binding curve using a nonlinear fit 
analysis. The fraction bound represents the percentage of binding. EC50 is the 
effective concentration of each CBD at 50% maximal binding. Error bars represent 
the standard deviation, and all tests were conducted in triplicate.  
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Binding Affinity Affects Lytic Activity 
We next sought to determine whether the differences in binding affinity 
affected the lytic activity of PlyC. The EC50 data indicated that the PlyCB octamer 
displayed a very tight, stable interaction between the PlyC holoenzyme and cell wall. 
However, strong binding does not necessarily correlate with an increase of lytic 
activity as tight binding may decrease the turnover rate of the endolysin. Notably, 
Schmelcher et al. demonstrated that the increased binding affinity of Ply500 CBD 
tandem repeats targeting Listeria reduces the lytic activity of Ply500 in physiological 
condition (Schmelcher et al., 2011). To test this hypothesis, PlyCBm-derived 
chimeras were made with the parental EADs: CHAP_CBm (i.e. the PlyCA CHAP 
domain fused to the PlyCBm), GyH_CBm (i.e. the PlyCA GyH domain fused to 
PlyCBm), and PlyCA_CBm (full-length PlyCA fused to PlyCBm). Lytic activity of 
all chimeras was then determined against S. pyogenes D471 via the turbidity 
reduction assay. No protein expression was observed for PlyCA_CBm, hence it was 
excluded from further testing. 10 µM of CHAP_CBm displayed moderate activity 
corresponded to a 50% decreases in OD600 in 20 min, whereas GyH_CBm only 
caused ~15% decreases in OD600 and was not considered further (Fig. 2-5 A). The 
endolysin PlyC∆GyH, containing the PlyCA CHAP domain in contaxt of the full 
PlyCB octamer (McGowan et al., 2012) was used here to demonstrate the effect of 
the binding affinity on activity. When tested at equimolar concentrations and under 
physiological condition (PBS, pH 7.4), CHAP_CBm displayed ~40% of the 
PlyC∆GyH activity (Fig. 2-5 B), indicating that the tighter binding provided by the 
PlyCB octamer promoted the lytic activity. To validate the observation, we reasoned 
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that a chimera of the PlyCA CHAP domain with PlyCB2m (i.e. CHAP_CB2m) 
should exhibit stronger activity than CHAP_CBm. As shown in Fig. 2-5 B, the two 
cell wall binding sites of CHAP_CB2m helped the increase of activity to ~60% of 
PlyC∆GyH. The data suggests that increasing the binding affinity by increasing the 
number of PlyCB subunits increases the lytic activity of chimeras containing the 
PlyCA CHAP domain as an EAD. 
 
Different Enzymatically Active Domains Affect Lytic Activity 
We next sought to evaluate different EADs with PlyCBm since catalytic 
efficiency of the EAD may also play a role in the lytic activity. Notably, such 
chimeragenesis approaches have demonstrated a range of activities, with some greater 
than that displayed by the parental enzymes (Blazquez et al., 2016; Diez-Martinez et 
al., 2015; Schmelcher et al., 2011; Vazquez et al., 2017; Yang et al., 2016; Yang et 
al., 2015). Thus, other two CHAP domain EADs, CHAPLysK from LysK and 
CHAPPlySs2 from PlySs2, and two amidase EADs from PlyG and Pal, were selected to 
make CHAPLysK_CBm, CHAPPlySs2_CBm, AmidasePlyG_CBm, and AmidasePal_CBm. 
All chimeras were expressed as soluble proteins, purified to homogeneity, and the 
lytic activities were assessed by turbidity reduction. When tested at equal 
concentrations using stationary phase S. pyogenes D471, CHAPPlySs2_CBm, 
AmidasePlyG_CBm, and AmidasePal_CBm only displayed ~20%, ~50%, and ~25% of 
the CHAP_CBm activity, respectively (Fig. 2-6 A). However, CHAPLysK_CBm with 
the EAD from a staphylococcal endolysin, LysK, displayed nearly twice the lytic 
activity of CHAP_CBm (Fig. 2-6 A). Furthermore, the activity of CHAPLysK_CBm 
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was comparable to the activity of PlyC∆GyH (Fig. 2-6 B), which contained the 
PlyCA CHAP in context of the full PlyCB octamer. Taken together, the data suggests 
the catalytic efficiency of the EAD is just as important in determining overall activity 
as binding affinity of the CBD for a given endolysin. It should, therefore, be possible 
to “tune” a chimeric endolysin to produce optimal activity by proper selection of the 





Figure 2-5. Lytic activity of PlyCBm/PlyCB2m-derived chimeras against 
stationary phase S. pyogenes D471. 10 µM of each enzyme was added to bacteria 
and the decrease of OD600 was followed for 20 min to allow for calculation of Vmax as 
described in Methods. (A) OD600 curves of PBS (triangles), CHAP_CBm (circles), 
and GyH_CBm (squares). (B) Effect of binding affinity on lytic activity. The lytic 
activities, based on Vmax of each enzyme, were normalized to 100% Vmax of 
PlyC∆GyH. Error bars represent the standard deviation, and all tests were conducted 





Figure 2-6. Effect of EADs on lytic activity. 10 µM of each enzyme was added to 
stationary phase S. pyogenes D471. The OD600 was followed for 20 min and the Vmax 
was calculated as described in Methods. (A) The % lytic activities of each enzyme 
were normalized to 100% Vmax of CHAP_CBm.  (B) OD600 curves of PBS (triangles), 
CHAP_CBm (circles), CHAPLysK_CBm (squares), and PlyC∆GyH (diamonds). Error 




PlyCBm Mediates Epithelial Cell Internalization, and CHAP_CBm Can Kill 
Internalized S. pyogenes D471 
In addition to the streptococcal binding properties of PlyCB, our laboratory 
has recently shown that the key residues R29, K59, and R66 on PlyCB subunits form 
a pocket that binds phosphatidylserine on the eukaryotic membrane, which mediates 
internalization of PlyC and subsequent eliminating intracellular streptococci (Shen et 
al., 2016). As R29, K59, and R66 were not affected by mutations to create PlyCBm, 
we hypothesized that PlyCBm should retain the membrane translocation 
characteristics of the PlyCB octamer. At a concentration of 5 g/ml, fluorescently 
labeled PlyCB octamers and PlyCBm were internalized by human A549 epithelial 
cells within 30 min (Fig. 2-7 A). Both the internalized PlyCB octamer and PlyCBm 
were found in vesicle-like structures and diffused in the cells indicating they 
internalized via a similar mechanism.  
Next, we determined whether a chimera of PlyCBm with an EAD could kill 
the intracellular S. pyogenes D471. A co-culture model of human epithelial cells and 
S. pyogenes D471 was conducted to address the killing by CHAP_CBm. Treatment 
with 2 mg/ml CHAP_CBm reduced intracellular colonization by 50% within 2 hours, 
and lower concentrations resulted in a dose-response (Fig. 2-7 B). These data 
indicated that PlyCBm was able to cross the plasma membrane and eliminate the 





Figure 2-7. Internalization of PlyCBm. (A) Confocal microscopy of internalized 
PlyCB octamers and PlyCBm at 100x. DAPI stains A549 epithelial cells nucleus; 
PlyCB octamer and PlyCBm are labeled with AlexaFluor® 555. (B) CHAP_CBm 
eliminates intracellular S. pyogenes D471 in a dose-dependent manner. The tests were 
conducted in triplicate, with means and standard deviations displayed. Statistical 




The PlyC cell binding domain (PlyCB) displays high specificity against 
groups A, C, and E streptococci in addition to S. uberis, yet it also mediates the 
internalization of PlyC to eliminate intracellular streptococci. These features endorse 
the use of PlyC as a novel antibacterial therapeutic agent. Moreover, the molecular 
basis for PlyCB is interesting from the perspective of understanding the binding 
mechanism and for the development of PlyCB-derived chimeras. Here we show 
computational analysis of the inter-subunit interactions of the PlyCB octamer 
following by site-directed mutagenesis that a PlyCB monomer (PlyCBm) can be 
created, as well as the tandem duplication of PlyCB monomer (PlyCB2m). With the 
essential binding residues intact on each PlyCB subunit, PlyCBm and PlyCB2m 
retain the same binding ability and host range as the PlyCB octamer. In addition, the 
chimeras created with PlyCBm/PlyCB2m hint at the relationship between binding 
affinity and activity, as well as prove that PlyCBm can contribute to further 
chimeragenesis that is specific for both streptococci and intracellular delivery.   
As a cell binding domain, PlyCB shares no sequence similarity to any other 
proteins and thus represents a rare example of CBD (McGowan et al., 2012). While 
some multimeric endolysins have recently been described, they contain a second 
CBD as the result of an alternate start codon within the endolysin gene rather than 
being product of a second gene. Furthermore, no described endolysin contains an 
octameric CBD. Whether all eight PlyCB monomers participate in binding or whether 
the presence of all eight merely increases the avidity for the bacterial surface has 
never been addressed. The EC50 data show that PlyCBm and PlyCB2m bind less 
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tightly than the PlyCB octamer, implying that more than two binding sites, and 
possibly all eight, are concurrently involved in epitope binding on bacterial cell wall. 
Although the EC50 of PlyCBm and PlyCB2m is relatively high, they are still within 
the nanomolar range, which is comparable to the affinity of an antibody-antigen 
complex (Lopez & Garcia, 2004; Schmelcher et al., 2010). It is worthy to note that 
CBDs with such high specificities and binding affinities have been applied as 
biosensor tools to detect Listeria cells, Bacillus cereus cells, and Staphylococcus 
aureus cells (Kong et al., 2017; Kong et al., 2015; Tolba et al., 2010; Walcher et al., 
2010; Yu et al., 2016). In comparison with the PlyCB octamer, the monomeric 
structure of PlyCBm is easier to engineer as a biosensor tool to diagnosis 
streptococci.  
The goal of endolysin engineering is to be able to fine tune the interplay 
between on and off rates for both the EAD and CBD. If the on rate or off rate is too 
slow, the catalytic efficiency decreases. Until recently, chimeragenesis has been the 
only method employed for endolysin engineering. While this approach does allow 
selection of different EAD and CBD combinations to optimize activity, it does not 
inherently provide the ability to modulate the binding ability of either domain. For the 
first time, the creation of monomeric PlyCB as well as the ability to add tandem 
PlyCB monomer repeats allows for a method to “tune” the binding, and subsequently 
the activity, of an engineered endolysin.  
The tuning concept is further supported through the change of EADs. When 
CHAPLysK replaced the PlyC CHAP domain in the chimera, the activity doubled. 
CHAPLysK is an EAD of LysK endolysin targeting staphylococcal pathogens. 
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Although the endopeptidase cleavage site for CHAPLysK is reported between D-
alanine and the first glycine in the pentaglycine cross-bridge of staphylococci, a bond 
not present in the streptococcal PG, CHAPLysK can nonetheless lyse streptococci in a 
moderate to weak manner without the CBD (Becker et al., 2009; Fenton et al., 2010; 
O'Mahony & Coffey, 2011). CHAP from PlyC and CHAPLysK belong to the same 
cysteine, histidine-dependent amidohydrolases/peptidases family (CHAP). One 
theory for the doubling of activity with CHAPLysK compared to the PlyC CHAP may 
be the positive charged carried by CHAPLysK (pI=9.08) in contrast to the negative 
surface charge for the CHAP from PlyC (pI=4.03), as a number of studies have 
reported (Low et al., 2011 Osterman, & Liddington, 2011; Mayer et al., 2011 Narbad, 
& Meijers, 2011). The difference in enzymatic activity between CHAP_CBm and 
CHAPLysK_CBm hints that a more catalytically active EAD can facilitate a CBD with 
a lower binding affinity to improve total activity. On the other hand, the observation 
that PlyC∆GyH shows similar activity as CHAPLysK_CBm suggested that a less active 
EAD can be facilitated by a CBD with high binding affinity to improve bactericidal 
efficacy. Accordingly, we infer that the efficiency of the endolysins depend on the 
balance between binding affinities of CBDs and enzymatic activities of EADs. 
Furthermore, these observations provide a way to optimize the endolysin through 
chimeragenesis: a less active EAD needs a tighter binding CBD to ensure hydrolysis 
thoroughly; a more active EAD needs a less tight binding CBD to increase the 
turnover rates.  
It is anticipated that PlyCBm inherits the capability of internalization via the 
interaction of a cationic binding groove with plasma membranes. We speculate that 
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the lower killing efficiency of CHAP_CBm compared to PlyC in the mammalian cells 
is because PlyC is the most active endolysin described to date. However, the instance 
that CHAP_CBm kills the internalized S.pyogenes D471 proves the possibility that 
PlyCBm can work as an intracellular cargo for delivery into mammalian cells.  
This study, through a monomerized CBD to confirm the binding mechanism of the 
PlyCB octamer, suggests a rationale to optimize the activities of endolysin. Finally, 
the creation of PlyCBm as the dual functional CBD, streptococci recognition and cell 




Chapter 3: A Novel Design to Exploit the Synergy of the 
PlyC Catalytic Domains 
 
3.1 Abstract 
Bacteriophage-derived endolysins have great potential as alternative 
antimicrobial agents for Gram-positive bacterial infectious diseases as they are 
peptidoglycan hydrolases that can destroy susceptible bacteria when applied 
exogenously. Due to the modular structure of endolysins, engineering methods can be 
used to improve their properties or change their host range via manipulation of the 
functional domains. The multimeric endolysin, PlyC, has potent activity on groups A, 
C, and E streptococci, as well as Streptococcus uberis, but is devoid of activity on 
other streptococci such as S. agalactiae (i.e., group B strep), S. mutans, or S. 
pneumoniae. PlyCA, the enzymatically active domain of PlyC, consists of two 
catalytic domains, GyH, a glycosyl hydrolase, and CHAP, a cysteine, histidine-
dependent amidohydrolase/peptidase. Notably, GyH and CHAP have been shown to 
work synergistically to achieve lytic rates ~100 fold higher than comparable single 
catalytic domain endolysins. In this work, we provide a new design of chimeric 
endolysins to take advantage of the synergistic effects of PlyCA. ClyX-1 was created 
via fusing the pneumococcal Cpl-1 cell binding domain (CBD) in between the GyH 
and CHAP catalytic domains of PlyCA. This chimera displayed ~100 fold increase in 
activity in vitro against S. pneumoniae and dramatically improved activity in vivo 
compared to the parental Cpl-1 enzyme. ClyX-2 was then created using a similar 
strategy by fusing the broad host range PlySs2 CBD between GyH and CHAP 
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catalytic domains. ClyX-2 not only demonstrated wild-type PlyC activities on groups 
A, C and E streptococci but now included high levels of activity against S. mutans 
and S. agalactiae. Moreover, this design format (i.e., CBD in the middle of two 
catalytic domains) can also be applied to other enzymes in order to achieve improved 
activity. CHAP or GH25 catalytic domains were added to the C-terminus of full-
length Cpl-1 and PlySs2, respectively, and displayed synergistic effects. To date, with 
the exception of PlyC, two catalytic domains in one endolysin have not shown 
synergism, even in enzymes that naturally contained two catalytic domains. Our work 
suggests a novel design for adopting the synergy of two catalytic domains for 
increased lytic activity. 
 
3.2 Introduction 
The Streptococcus is a genus of Gram-positive bacteria consisting of diverse 
species widely distributed across the normal flora of human and animals (Pouliot et 
al., 2015). Although some streptococci cause no harm or are carried 
asymptomatically, most species are highly virulent and known to cause significant 
diseases. Streptococcus mutans, Streptococcus pyogenes (GAS), Streptococcus 
agalactiae (GBS),  and Streptococcus pneumoniae are particularly notable as 
causative agents of serious acute infections in human, ranging from dental caries and 
pharyngitis to life-threatening conditions such as necrotizing fasciitis and meningitis 
(Mitchell, 2003). As animal pathogens, group C streptococci (GCS), group E 
streptococci (Oliveira, L. M. et al.), Streptococcus uberis, and Streptococcus suis 
infect major livestock (i.e., cattle, pigs, and horses) leading to considerable economic 
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loss to farmers (Hardie & Whiley, 1997a). Due to the widespread distribution of 
antibiotic-resistance genes and the overuse of broad-spectrum antibiotics, streptococci 
that used to sensitive to conventional antibiotics have started developing resistant 
phenotypes (Brown & Wright, 2016; Macris et al., 1998). In a report published by the 
Centers for Disease Control (CDC 2013), drug-resistant Streptococcus pneumoniae 
has been labeled as a “serious” public health threat and  erythromycin-resistant GAS 
and clindamycin-resistant GBS as “concerning” public health threats. The emergence 
of resistant streptococci calls for the need to source alternative antimicrobial agents.  
Bacteriophage-encoded endolysins, one of the alternative treatments, have 
gained attention and been extensively studied (Fischetti, 2005; Loessner, 2005). 
Endolysins, also known as phage lysins or enzybiotics, are peptidoglycan (PG) 
hydrolases produced at the end of the phage replication cycle resulting in cell lysis 
and new phage release. When applied exogenously, these enzymes are capable of 
destroying the Gram-positive bacterial PG rapidly and specifically (Loeffler et al., 
2003; Royet & Dziarski, 2007; Schuch et al., 2002). Endolysins derived from phage 
that infect Gram-positive hosts have modular structures with the enzymatically-active 
domain(s) (EADs) at the N-terminus and a cell-binding domain (CBD) at the C-
terminus. The EADs are capable of cleaving specific covalent bonds in the PG 
network to damage the intrinsic structural integrity. The CBDs possess no enzymatic 
activity but rather function to bind a specific substrate, usually a carbohydrate or 
teichoic acid, attached to the host PG (Fischetti, 2005). 
Several streptococcal endolysins have been discovered and investigated for 
enzymatic activity, structure-related characteristics, and in vivo safety and efficiency. 
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PlyC, an endolysin from streptococcal C1 phage, displays the most remarkable 
activity, ~100 fold that of the other endolysins. Unlike other endolysins, PlyC is the 
only multimeric structured endolysin consisting of nine subunits — eight CBDs 
(PlyCB) to one EAD (PlyCA) encoding from two genes. Previous research has shown 
that PlyCB is specific for GAS, GCS, GES, and Streptococcus uberis, limiting the 
PlyC activity against these species. Moreover, the high activity of PlyC is due to 
synergistic activity of two catalytic domains, an N-terminal glycoside hydrolase 
(GyH) and a C-terminal cysteine, histidine-dependent amidohydrolase/peptidase 
(CHAP), that are positioned such that their catalytic active sites face each other 
forming a central binding grove (McGowan et al., 2012; Nelson et al., 2001; Nelson 
et al., 2006). Cpl-1, derived from the streptococcal Cp-1 phage, is another well-
studied streptococcal endolysin whose CBD contains six repeated choline binding 
domains that specifically binds to the choline on the teichoic acid of pneumococci 
(Garcia et al., 1987). This enzyme has been validated to efficiently protect rats from 
pneumococcal-induced endocarditis and meningitis (Entenza et al., 2005; Grandgirard 
et al., 2008; Loeffler et al., 2001). Another streptococcal endolysin possessing broad 
host range is known as PlySs2, derived from Streptococcus suis phage. It displays 
lytic activity against multiple species of different bacterial pathogens, including 
methicillin-resistant Staphylococcus aureus (MRSA) (Gilmer et al., 2013 & Fischetti, 
2013). Due to the potent efficacy against MRSA, PlySs2 (CF-301) is being developed 
by the ContraFect Corporation and has shown improved results in S. aureus 
bacteremia compared to antibiotics alone (Schuch et al., 2014). 
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As a growing amount of research focuses on the modular design and crystal 
structures of endolysins, structure-based rational engineering has produced endolysins 
with desirable properties for specific applications (Broendum et al., 2018; Sao-Jose, 
2018). Chimeragenesis is a potential engineering approach that has been successfully 
exploited by nature, such as pneumococcal endolysin Pal, whose EAD and CBD 
indicate homology to different phage species (Sheehan et al., 1997; Garcia, 1997). 
Engineering chimeras through domains shuffling have also been shown to be useful 
for extending specificity and increasing activity. For example, one streptococcal 
chimera, ClyR, is the combination of the PlyCA CHAP as and EAD and the PlySs2 
CBD, retains the host range of PlySs2 with extension to Streptococcus mutans (Yang 
et al., 2015). The other example is the pneumococcal chimera, Cpl-711, the 
combination of the Cpl-7 EAD and Cpl-1 CBD, displays much higher activity and 
stability than the parental enzymes (Diez-Martinez et al., 2015).    
Given the unique structure and high activity of PlyC, there is much interest in 
creating PlyCA chimeras with different CBDs to take advantage of the synergistic 
effects of the EADs and to expand its host range. Here, we provide modular designs 
that use both EAD domains of PlyCA with either a choline specific CBD from Cpl-1 
or a broad host CBD from PlySs2. By doing so, we were able to create ClyX-1 and 
ClyX-2 with a design that contains the two PlyCA EADs on each side of the Cpl-1 
CBD or PlySs2 CBD, respectively, to preserve the distance/positioning of the EADs 
and maintain synergy. We then applied this design rule (i.e. EAD-CBD-EAD) to 
other EADs and assessed whether the chimeras possessed additive or synergistic 




3.3 Materials and Methods 
Bacterial Strains and Growth Conditions 
The bacterial strains in this study were stored at -80°C as frozen stock in 20% 
glycerol, and are described in Appendix B. Streptococcal strains were cultivated in 
Todd Hewitt broth supplemented with 1% (wt/vol) yeast extract without shaking. 
Bacillus strains were grown in brain heart infusion broth. All other bacterial strains 
including staphylococci and enterococci were cultured in tryptic soy broth (TSB). E. 
coli strains DH5α and BL21(DE3) were cultured in Luria-Bertani (LB) broth 
supplemented with 50 µg/mL carbenicillin or kanamycin as needed. All media were 
purchased from Fisher Scientific, Hampton, NH. Unless otherwise stated, bacterial 
strains were propagated at 37°C and shaken at 200 rpm.  
 
Cloning of Chimeric Proteins 
The plasmids and primers used in this study are listed in Appendix A. The plasmid 
constructs for pBAD24::plyC, pBAD24::plyCA, pBAD24::plyC∆GyH, and 
pBAD24::plyC∆CHAP were cloned as previously described (McGowan et al., 2012; 
Nelson et al., 2006). The sequence of endolysins Cpl-1 and PlySs2 were previoulsy 
published (Garcia et al., 1987; Gilmer et al., 2013). Cpl-1 was cloned into pBAD24, 
and PlySs2 were codon-optimized for expression in E. coli and chemically 
synthesized by Thermo Fisher (Waltham, MA). Primers were designed with 20 amino 
acid overlap at each end of the connected pieces. First, each part of the chimera was 
individually amplified through PCR to equip with the overlapping sequences. Then, 
the resulting PCR fragments were fused and amplified again by PCR-based Gene 
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Splicing by Overlap Extension PCR (SOE PCR) (Horton et al., 1990; Pease, 1990). 
For constructions contain three gene pieces (clyX-1, clyX-1 Linkers, clyX-2), another 
round of SOE PCR was performed. Final recombinant gene products were inserted 
via NdeI/BamHI sites into pET28a vector and cultured on LB plates supplemented 
with 50 µg/mL kanamycin. The resistant colonies were again picked and verified by 
DNA sequencing before being transformed into the expression strain BL21 (DE3).  
 
Expression and Purification of Chimeric Proteins 
E. coli BL21 (DE3) cells containing the recombinant genes were grown 
overnight in LB broth with carbenicillin or kanamycin (50µg/mL). The next day, the 
culture was 1:100 diluted into a 1.5 L of fresh sterile LB broth supplemented with 
carbenicillin or kanamycin (50µg/mL). The culture was shaken at 200 rpm at 37°C 
for 3.5 h to reach OD600=0.8. Proteins were induced using 0.25% (wt/vol) of L-
arabinose for pBAD24 constructs or 0.1 mM isopropyl β-D-thiogalactoside (IPTG) 
for pET28a (+) constructs at 18°C for another 20 h. The next morning, the cells were 
pelleted at 5000 rpm for 15 min at 4°C and stored at -80°C overnight before 
sonication. The frozen pellets were thawed in lysis buffer (PBS, pH 7.4, 
supplemented with 1 mM phenylmethanesulfonyl fluoride (PMSF) and 10 mM 
imidazole) with shaking until dissolved completely. Sonication was then applied to 
lyse cells on ice for 15 min. The cell debris was removed via centrifugation at 12,000 
rpm for 1 h at 4°C. The soluble portion containing recombinant proteins was passed 
through a nickel-nitrilotriacetic acid (Ni-NTA) column (Qiagen) and fractions were 
collected from eluted buffers (PBS, pH 7.4, supplemented with 20, 50, 100, 250, and 
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500 mM imidazole). Purified proteins were verified by SDS-PAGE analysis with 
Coomassie stain and the fractions containing recombinant proteins were dialyzed 
against PBS, pH 7.4, overnight at 4°C. The proteins were concentrated to the desired 
concentration and sterilized through the 0.2 µm filter before being stored at -80°C for 
further analysis. For the in vivo murine model, the endotoxin was removed via 




The bacteriolytic assay was adapted from a turbidity reduction assay as 
previously described (Nelson et al., 2012). An overnight bacterial culture (stationary 
phase) was harvested at 5,000 for 10 min at 4°C, washed twice and resuspended in 
PBS buffer, pH 7.4. In a standard 96-well titration plate (Thermo Fisher), the 
resuspended bacterial solution was mixed 1:1 (ʋ/ʋ) with endolysin to a final OD600 
between 0. 8 to 1.0. In each run, PBS was included as a negative control. 
Spectrophotometric readings (OD600) were taken every 15 s over 10 min on a 
SpectraMax 190 spectrophotometer (Molecular Devices). Vmax was calculated as the 
slope of the linear portion and represented the endolysins activity. All experiments 
were conducted in triplicate to obtain the standard deviation.  
 
In Vitro Characterization of ClyX-1 
The optimal biochemical conditions for ClyX-1 against stationary phase S. 
pneumoniae TIGR 4 were determined using the turbidity reduction assay described 
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above. For temperature stability, ClyX-1 was incubated at indicated temperatures 
(4°C, 16°C, 25°C, 37°C, 45°C, 55°C, or 65°C) for 30 min, recovered on ice for 5 
min, and subjected to the spectrophotometric analysis. For optimal pH condition, 
pneumococci (TIGR 4) were suspended in 40 mM boric acid/phosphoric acid (BP) 
buffer, pH 3-10, and were challenged against ClyX-1. 
 
Bactericidal Assay 
Overnight bacterial cells were diluted 2x in rich media to generate a final 
concentration of 5.0 x 106 CFU/ml. 100 µl of the diluted bacterial culture was added 
into a standard 96-well titration plate (Thermo Fisher) in triplicate and mixed with 
100 µl of sterile-filtered enzymes. Plates were sealed and incubated at 37°C for 5-60 
min. After incubation, bacterial cells were serially diluted in 10-fold increments into 
sterile PBS and plated on THY/TSB agar. Log killing was calculated as follows: -log 
[(CFU under enzyme treatment)/ (CFU under PBS treatment)]. 
 
Dimerization of ClyX-1 
The dimerization of ClyX-1 was based on the size change in the presence of 
choline monitored by the analytical gel filtration on a Superose 12 column (GE 
Healthcare). Briefly, 500 µl of 1 mg/ml ClyX-1 was injected in the sample loop. PBS 
and PBS with 50 mM choline were used as the elution buffer separately to determine 
the change of protein mass. The standard protein mass curve was obtained through 





The minimal inhibitory concentrations (MICs) of enzymes and antibiotics 
were determined in a standard 96-well titration plate (Thermo Fisher) in triplicate as 
described previously (Wiegand et al., 2008). Briefly, overnight pneumococcal 
cultures were diluted with 2x THY to obtain a final concentration of 1 x 107 CFU/ml, 
and other bacterial species were diluted 2-fold in medium to 1 x 105 CFU/ml. 100 µl 
of the diluted bacterial culture was placed into each well, mixing with the serial 2-
fold diluted 100 µl of enzymes/antibiotics. PBS buffer was used as a negative control.  
The plates were sealed with parafilm and statically incubated at 37°C for 24 h. The 
MIC was defined as the lowest concentration of treatment that inhibited visible 
growth of the bacterium. 
 
Peptidoglycan Purification and Digestion by PlyC 
The purification of the S. pyogenes D471 peptidoglycan was carried based on 
a previously described protocol with minor modifications (Pritchard et al., 2004). 
Briefly, an overnight bacterial culture was pelleted at 5,000 rpm for 15 min in a 
centrifuge and resuspended in 25 ml of PBS per liter of cells. French Press using a 
cellular pressure of 15,000 p.s.i was applied twice to lyse the cells. The unbroken 
cells were removed at 5,000 rpm for 5 min. The supernatant was again subjected to 
centrifugation at 20,000 rpm for 45 min at 4°C to pellet cell walls. The pelleted cell 
walls were rinsed and resuspended in PBS buffer supplemented with 0.2% (wt/vol) 
benzonase and proteinase K for 7 h. After incubation, the samples were boiled at 
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100°C in 4% (wt/vol) SDS for 30 min, washed at least 3 times and resuspended in 
MiliQ water.  
50 µg of PlyC in PBS buffer, pH 7.4, was added to S. pyogenes D471 cell wall 
suspensions (OD600=1.0, PBS buffer, pH 7.4) in a final volume of 500 µl. After 
digestion at 37°C for 16 h, the reaction mixture was clarified by centrifugation 
(13,000 rpm, 5 min), and the supernatant was ultrafiltered using a 5000-MW cutoff 
Vivaspin. The flow-through was aliquoted and prepared for mass spectrometry 
analysis.  
 
In Vivo Mouse Infection Models 
All mouse infection experiments were carried out in an ABSL-2 lab, and all 
experimental methods were carried out following the regulations and guidelines set 
forth by the Animal Experiments Committee of Wuhan Institute of Virology, Chinese 
Academy of Sciences. All experimental protocols were approved by the Animal 
Experiments Committee of Wuhan Institute of Virology, Chinese Academy of 
Sciences (WIVA17201602). Animals were randomized and cared in individually 
ventilated cages following a set of animal welfare and ethical criteria during the 
experiment and euthanized at the end of observation.  
In the mouse systemic infection model, female BALB/c mice (6-8 weeks old) 
were injected intraperitoneally with S. pneumoniae NS26 at a single dose of 2.95×107 
CFU/mouse and divided randomly into multiple groups. Bacterial burden in blood 
and organs in mice 1 h post-infected were confirmed by plating on THY agar as 
described previously. One hour post-infection, these groups intraperitoneally received 
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a single dose of 20, 40, or 80 μg/mouse of PlyCpl-1 (n=10); 20, 40, or 80 μg/mouse 
of Cpl-1 (n=10); 100 μg/mouse of penicillin G (n=10); or an equal volume of PBS 
buffer (n=10). The survival data for all groups were recorded for 10 days. 
 
3.4 Results 
Design and Engineer Specific Host Chimeras Containing PlyCA 
With the aim of creating endolysins that possess highly active PlyCA but 
work against non-PlyC sensitive species, we chose to incorporate a specific-binding 
CBD. Thus, the Cpl-1 CBD, which is strictly dependent on the presence of choline 
residues in the teichoic acid of pneumococci strains, was chosen as the bacterial 
recognition domain. Figure 3-1 displays a schematic representation of the three 
engineered chimeric proteins (PlyCA_Cpl-1 CBD, ClyX-1, ClyX-1 linkers) and their 
parental proteins (PlyCA and Cpl-1).  
PlyCA_Cpl-1 CBD contains full-length PlyCA at the N-termini and the full 
length of Cpl-1 CBD at the C-termini. The structure follows the typical native 
endolysins and the chimeric endolysins module, which is N-terminal EADs and C-
terminal CBDs. ClyX-1 contains the Cpl-1 CBD in the middle of PlyCA, substituting 
for the docking domain, which does not affect activity (McGowan et al., 2012), and 
ClyX-1-linkers is similar to ClyX-1 but with two extra native linkers in the PlyCA.  
ClyX-1 and ClyX-1 linkers expressed as soluble enzymes and were purified to 
homogeneity based on SDS-PAGE analysis. No protein expression was observed for 




Figure 3-1. Schematic of the constructs. Cpl-1 and PlySs2 are the full length 
endolysins derived from phage Cp-1 and S. suis phage respectively. The GH25 and 
CHAP domains are the EADs; the cyan rectangles indicate the choline binding 
repeats in Cpl-1 and the SH3-5 domain is the CBD of PlySs2. The PlyCA is the EAD 
of PlyC composing N’ terminal GyH domain and C’ terminal CHAP domain. The 
PlyCA_Cpl-1 CBD, ClyX-1 linkers, ClyX-1, ClyX-2, ClyX-3, and ClyX-4 are 
chimeric endolysins by shuffling the different EADs and CBDs from Cpl-1, PlySs2, 
and PlyCA.   
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In Vitro Characterization of ClyX-1 
The bacteriolytic capacity of ClyX-1 and ClyX-1 with linkers were analyzed 
via the turbidity reduction assay against an overnight culture of S. pneumoniae ATCC 
TIGR 4. Both enzymes-induced lysis of the bacterial peptidoglycan caused a decrease 
in OD from 1.0 to 0.2 (80%) within the first 2 min of the turbidity assay at 5 µg/ml 
(Figure 3-2 a). The result was not surprising since the linkers were the only difference 
between these two enzymes, and it is plausible that the unstructured regions of the 
PlyCA GyH, PlyCA CHAP, and Cpl-1 CBD provide sufficient flexibility for 
enzymatical activity without the additional linkers. Therefore, we only focused on 
ClyX-1 for the remainder of the experiments. The high lytic activity noted by 
turbidity reduction correlated well with the data for bacterial survival treatment. 
ClyX-1 nearly sterilized the culture after just 5 min, causing a decrease in TIGR 4 
viability of ~6 logs at as low as 0.5 µg/ml (Figure 3-2 b). Next, the stability of ClyX-
1 at different temperatures and pH was surveyed to determine the optimal conditions. 
ClyX-1 was stable at lower temperatures and displayed highest activity at 37°C, 
however, the activity rapidly dropped above 45°C (Figure 3-2 c). These observations 
were consistent with the known Tm values of Cpl-1 (42.9°C) and PlyCA (46.2°C) 
(Heselpoth et al., 2015 & Nelson, 2015; Sanz et al., 1993 Usobiaga, & Menendez, 
1993). The optimal pH is and ClyX-1 completely lost activity at pH values above 8 
and below 4 due to protein precipitation (Figure 3-2 d). These observations were 
compatible with previous studies of Cpl-1 (Garcia et al., 1987; Loeffler et al., 2003).  
The antimicrobial spectrum of ClyX-1 was tested in vitro via turbidity reduction 
assay on a variety of S. pneumoniae strains and other streptococci. All tested strains 
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of pneumococci were susceptible to ClyX-1 including the 14 most frequent serotypes, 
mutants that have a non-functional LytA autolysin (Lyt 4.4), and strains that lack 
capsule (R36A and R6) (Figure 3-2 e). The variations in activity on these different 
serotypes may be due to accessibility of the peptidoglycan. The killing spectrum of 
ClyX-1 was specific for pneumococci, as no other streptococcal strains tested were 
lysed. Collectively, our data suggests the Cpl-1 CBD provides the specificity of 
ClyX-1 and it retains a host range limited to pneumococci.  
The Cpl-1 CBD is known to dimerize in the presence of choline and Cpl-1 is 
suspected to dimerize on the pneumococcal surface upon binding choline containing 
teichoic acids. We, therefore, wondered if ClyX-1 was able to form dimers in the 
presence of choline, especially since ClyX-1 contains the Cpl-1 CBD in the middle of 
the polypeptide rather than on the C-terminus, as it is located in Cpl-1. We analyzed 
ClyX-1 by analytical gel filtration in the absence or presence of 50 mM choline 
(Figure 3-2 f). In PBS, ClyX-1 eluted ~57 kDa based on protein standards, whereas 
the presence of choline shifted the elution curve to ~114 kDa, indicating that ClyX-1 







Figure 3-2. Characterization of ClyX-1. (a) Bacteriolytic effects of 5 µl/ml ClyX-1 
and ClyX-1 with linkers against stationary phase S. pneumoniae TIGR 4. (b) 
Bactericidal effects of ClyX-1 against stationary phase S. pneumoniae R6. Different 
concentrations of ClyX-1 were mixed with 106 colony forming units for 5 min. Log 
killing was determined through the comparisons of PBS treatment and ClyX-1 
treatment. (c)-(d) Biochemical characterization of ClyX-1. The effects of temperature 
stability (c) and pH (d) were evaluated. 5 µl/ml of ClyX-1 was assayed for lytic 
activity via turbidity reduction assay against stationary phase S. pneumoniae TIGR 4 
cells for 10 min. Values were presented as a percentage of lytic activity in relation to 
activity observed for pH 7 and 37ºC. (e) The host range of ClyX-1. Multiple strains of 
streptococci were tested for susceptibility. The bacterial cells were washed twice and 
resuspended in PBS to a final OD600 of 0.9-1.0. The changes of OD600 were presented 
after treating with 5 µg/ml of ClyX-1 for 10 min. All experiments were done in 
triplicate, and the error bars represent the standard deviations. (f) Gel filtration shows 
dimerization of ClyX-1 in the presence of choline.  
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ClyX-1 is More Active than Parental Enzymes in vitro and in vivo 
After demonstrating the extremely high activity of ClyX-1, we compared its 
efficacy with Cpl-1 both in vitro and in vivo. Bactericidal assays were repeated using 
ClyX-1, Cpl-1, and PlyCA at different concentrations (0.5 µg/ml to 50 µg/ml) on S. 
pneumoniae D39 (Figure 3-3 a). ClyX-1 sterilized the bacteria within 5 min at even 
the lowest concentration (0.5 µg/ml), while Cpl-1 also sterilized the culture, required 
a concentration of 50 µg/ml and only reduced < 1 log at 0.5 µg/ml. PlyCA displayed 
no bactericidal activity against pneumococci, which supports previous reports that 
that PlyCA has negligible inherent lytic activity in the absence of the PlyC CBD 
(PlyCB) (McGowan et al., 2012).  
To further evaluate the activity of ClyX-1, a MIC test was performed against 
eight common serotypes of pneumococci including two penicillin-resistant strains and 
one capsule-free mutant (Table 3-1). Penicillin and levofloxacin were tested as 
standards to benchmark the antimicrobial activity. All of the strains were sensitive to 
levofloxacin (MIC<=2). Only the two penicillin-resistant strains indicated MICs 
larger than 2 µg/ml. The Cpl-1 MICs for all strains was between 16 µg/ml and 32 
µg/ml, comparable to MICs for this enzyme reported in the literature (Djurkovic et 
al., 2005). The MICs of ClyX-1 were lower than that of Cpl-1 and even levofloxacin, 
ranging from 0.13 µg/ml to 0.5 µg/ml. As expected, penicillin-resistance had no 
affect the MICs of ClyX-1.  
To validate the in vitro bactericidal activity of ClyX-1, we used a mouse 
systemic infection model to test the in vivo efficacy of the enzyme. Mice were 
challenged to lethal dose of 2.95×107 CFU, which proved lethal in 2 days for control 
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mice. One hour after infection, the mice were intraperitoneally injected with a single 
dose containing different amounts of either ClyX-1 or Cpl-1 ranging from 20 
μg/mouse to 80 μg/mouse. The antibiotic control was penicillin G at 100 μg/mouse, 
and the negative control was as PBS, pH 7.4 buffer. The mice were observed and 
survival data was recorded. All the mice treated with PBS buffer died within the first 
two days. ClyX-1 treatment resulted in rescuing 80%, 40% and 30% of the mice 
responding to the doses of 80 μg, 40 μg, and 20μg, respectively. The highest amount 
of Cpl-1, 80 μg, resulted in rescuing only 20% of the mice, and the mice treated with 
20 μg of Cpl-1 all died by day 5 (Figure 3-3 b).  These observations suggest that 





Figure 3-3. Comparisons of bactericidal activity of ClyX-1 and Cpl-1 in vitro and 
in vivo. (a) Different concentrations of ClyX-1 and Cpl-1 were mixed with 106 
overnight S. pneumoniae D39 culture for 5 min. The cells were then serial diluted and 
plated on the THY plates. Log killing was determined through comparison of PBS 
treatment and enzyme treatment. The experiments were repeated for three times, and 
the error bars represent standard deviation. (b)  Female BALB/c mice were injected 
intraperitoneally with pneumococcal strain Spn NS26 at a single lethal dose of 2.95 X 
107 CFU/mouse. One hour after the infections, different concentrations of endolysins, 
antibiotics, and PBS were injected to mice intraperitoneally. The mice were 
monitored for 10 days for survival and the data were represented as the percentage of 
survival. The data was plotted as Kaplan-Meier survival curves and analyzed via the 















































































































































































ixed in an am
ount ratio 1:1. 
107 
 
The High Activity of ClyX-1 is due to the Synergistic Effects of GyH and CHAP 
Domains 
The bactericidal assays suggest ClyX-1 is several hundred times more potent 
than Cpl-1 (compare 0.1 µg/ml ClyX-1 to 50 µg/ml Cpl-1 in Figure 3-3 a) and the 
MIC assay suggests ClyX-1 is 64-128 times more potent than Cpl-1 (compare MICs 
of 0.13 to 0.5 µg/ml for ClyX-1 to 16-32 µg/ml for Cpl-1 in Table 3-1), suggesting 
the EADs of ClyX-1 retain the synergy seen in PlyC. To confirm the synergy of GyH 
and CHAP domains in ClyX-1, we examined the activity of each domain separately. 
First, we made the constructs of GyH_Cpl-1 CBD (ClyX-11-356) and Cpl-1 
CBD_CHAP (ClyX-1205-512), each of which consists of the Cpl-1 CBD and a 
functional EAD from ClyX-1. Next, we analyzed the lytic activity via turbidity 
reduction assay and MIC assay for ClyX-1, GyH_Cpl-1 CBD (ClyX-11-356), Cpl-1 
CBD_CHAP (ClyX-1 205-512), and the combination of the GyH_Cpl-1 CBD and Cpl-1 
CBD_CHAP constructs. Neither GyH_Cpl-1 alone, Cpl-1_CHAP alone, or the 
combination of both in a 1:1 ratio attained 20% of the ClyX-1 lytic activity (Figure 3-
4). Consistent with these results, the MIC values showed all constructs performing 
similar to, or worse than, the parental Cpl-1 (Table 3-1). Thus, we suggest that the 
GyH and CHAP domains in ClyX-1 recapitulate the synergism due to positioning of 




Figure 3-4. GyH and CHAP domains in ClyX-1 show synergy. The constructs of 
GyH_Cpl-1 CBD (ClyX-11-356) and Cpl-1 CBD_CHAP (ClyX-1 205-512) were cloned 
and expressed for the synergy test. 5 µg/ml of each enzyme was used for the lytic 
activity via turbidity reduction assay against stationary phase S. pneumoniae R6 cells 
for 10 min. For the combination group, 2.5 µg/ml of GyH_Cpl-1 CBD (ClyX-11-356) 
and Cpl-1 CBD_CHAP (ClyX-1 205-512) were used. Values are presented as the 
percentage of lytic activity in relation to the highest activity observed. All 
experiments were done in triplicate, and the error bars represent the standard 
deviations.   
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Design and Engineer a Broad Host Range Chimera Containing PlyCA 
We next explored whether a different CBD can replace the Cpl-1 CBD in the 
ClyX-1 construct and likewise display synergistic activity, but on a new bacterial 
target. We, therefore, selected the PlySs2 CBD, which belongs to the SH3-5 domain 
family and is known to have a broad host range against most streptococci and 
enterococci. The new construct, termed ClyX-2 (Figure 3-1), was expressed as a 
soluble protein, purified, and its host spectrum was analyzed via the turbidity 
reduction assay. ClyX-2 was able to lyse every streptococcal species tested, including 
GAS, GBS, GCS, GES, S. uberis, and S. mutans, as well as Enterococcus faecalis, 
and select strains of Staphylococcus aureus (Figure 3-5 a). This host range overlaps 
the known host range of PlySs2, although S. mutans activity had not previously been 
associated with PlySs2. Next, the bactericidal efficacy of ClyX-2 and PlySs2 were 
compared via a log killing experiment (Figure 3-5 b). On all bacterial species tested, 
100 μg/ml of ClyX-2 caused a ~6 log reduction in CFUs while the same amount of 
PlySs2 only caused a ~4 log reduction. Decreasing the amount of ClyX-2 to 5 μg/ml 
resulted in a similar log reduction as that of PlySs2 at 100 μg/ml. It should be noted 
that due to the mass differences between ClyX-2 and PlySs2 (i.e. ClyX-2 is ~51 kDa 
and PlySs2 is ~ 26 kDa), the molarity of the PlySs2 is twice as that of ClyX-2, 
suggesting ClyX-2 possesses synergy between the EADs that equates to ~40 times the 
potency of parental PlySs2 (see Figure 3-5 b for a comparison of mass concentration 
and molar concentration). In a similar manner, the MICs of ClyX-2 were lower than 
that of PlySs2 (range 4x to 64x lower), especially for GAS (2 μg/ml vs. 128 μg/ml) 
and GCS (4 μg/ml vs. > 512 μg/ml) (Table 3-2). Notably, S. aureus was the only 
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strain that showed low MICs for PlySs2 than ClyX-2. However, despite PlySs2’s 
notable activity on staphylococcal strains, the PlySs2 CBD used in construction of 
ClyX-2, does not, in fact, bind the staphylococcal surface (Huang et al., 2015; Wei, 
2015) . The binding activity of PlySs2 for the staphylococcal surface is thought to be 
mediated by its EAD. These results provide a second example demonstrating the 
engineering platform that a CBD can be placed in the middle of the PlyCA GyH and 
CHAP domains, maintain the synergy between these catalytic domains, and redirect 





Figure 3-5. Lytic profile and bactericidal activity of ClyX-2. (a) Host range of 
ClyX-2. Different bacterial strains were used to test susceptibility via a turbidity 
reduction assay. The values were presented as the decrease OD600 in 10 min with 25 
µg/ml of ClyX-2. (b) Bactericidal activity of ClyX-2. PlySs2 and ClyX-2 were mixed 
with 106 CFUs for 1 h after which surviving colonies were plated. Log killing was 
determined through comparison of PBS treatment and ClyX-1 treatment. All 
experiments were done in triplicate, and the error bars represent the standard 
deviations.   
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Table 3-2. MICs of endolysins and antibiotics for other streptococci stains 
  
                                                                                  MIC (µg/ml) of: 
Species1 Strain1 PlySs2 ClyX-2 ClyX-4 
S. pyogenes (GAS) D471 128 2 32 
 MGAS315 128 2 32 
 A486 128 2 32 
S. agalactiae (GBS) A909 128 32 64 
 A349 256 32 128 
S. equi (GCS) 9528 >512 4 256 
GES K131 >512 64 256 
S. mutans 10449 >512 128 256 
 25175 >512 128 256 
S. uberis BAA-854 >512 64 256 
 700407 >512 64 256 
E. faecalis JH2-2 512 64 256 
 EF-17 512 64 256 
S. suis 730082 256 >512 64 
S. aureus NRS395 32 >512 >512 





Determine the Cleavage Specificity of PlyCA GyH and PlyCA CHAP  
In order to exploit the synergy between the PlyCA GyH and CHAP domains 
for bioengineering purposes, the bonds cleaved by these EADs must be present in the 
peptidoglycan being targeted. If one of the two EADs is “silent” because the bond it 
cleaves is not present in the peptidoglycan, synergy will be lost. Therefore, we need 
to ascertain exactly which peptidoglycan bonds are cleaved by GyH and CHAP.  
The PlyCA GyH domain was first characterized as a glycosyl hydrolyse due 
to its ability to generate reducing sugars during peptidoglycan digestion, however, it 
was never biochemically determined the glycosyl hydrolase activity was an N-
acetylmuramidase activity or an N-acetylglucosaminidase (McGowan et al., 2012). 
Recently, a DALI search identified that the closest homolog to the PlyCA GyH is an 
N-acetylglucosaminidase domain from the glycosyl hydrolase 73 family (GH73), but 
again, experimental evidence is lacking (Abdul Rahman et al., 2015). The PlyCA 
CHAP was first characterized as an “amidase” because digestion of peptidoglycan by 
CHAP yields a free N-terminus, and more specifically, an N-terminal alanine residue 
(Fischetti VA, 1972; McGowan et al., 2012). However, the streptococcal 
peptidoglycan often possesses a cross-bridge consisting of two alanine residues, so it 
is not clear whether the CHAP domain acts as an N-acetylmuramoyl-L-alanine 
amidase or as an endopeptidase acting on the cross-bridge.  
To further determine the specific cleavage sites, PlyC digested S. pyogens 
D471 peptidoglycan was analyzed via mass spectrometry (MS). Surprisingly, a 
muropeptide with an m/z value of 1079.5 corresponding to the size of O-acetylated N-
acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) with A4QK (Figure 3-
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6) was the most abundant species after digestion, suggesting that CHAP is not an 
amidase cleaving between NAM and L-alanine of the stem peptide. Moreover, these 
results confirmed that the PlyC GyH is a glucosaminidase due to the cleavage of the 
O-acetylated NAM, but left four possible cut sites for the CHAP domain (Figure 3-7). 
Through the comparison of the MS data and the host range of PlyC, ClyX-1, and 
ClyX-2, all the bacterial strains that were sensitive to these enzymes contain the D-ala 
and L-ala in the PG structure. Thus, we suggest that CHAP is an endopeptidase 
cutting the bonds between D-ala and L-ala which is only in streptococcal PG structure 































































































































































































































































Figure 3-7. Four structures for the muropeptide. These four scenarios correspond 
to the peak 1079.5, which is represented O-acetylated NAM and NAG with A4QK. 
The bacteria that are sensitive to ClyX-1 and ClyX-2 possess the D-Alanyl-L-Alanine 
bonds in the peptide stem. Supplementing with the host specificity information, 
CHAP domain in PlyC (PlyCA) suggests a function of D-Alanyl-L-Alanine 
endopeptidase, which is in figure (a).  
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Apply the Design Rationale to Add a C-terminal EAD 
We next asked whether the design rationale, i.e. two EADs at each side of the 
CBD, could be used to engineer non-PlyCA based endolysins for increased activity. 
Toward this end, we created the ClyX-3, the full-length Cpl-1 endolysin with an 
additional C-terminal PlyC CHAP domain, and ClyX-4, the full-length PlySs2 
endolysin, with an additional C-terminal Cpl-1 EAD (a GH25 family member) 
(Figure 3-1). These constructs were successfully expressed and purified as soluble 
proteins. We found that ClyX-3 was capable of reducing ~4 logs of the tested 
pneumococcal strains, whereas Cpl-1 only caused ~2 logs reduction (Figure 3-8 a). 
Similarly, the ClyX-4 was more active than PlySs2 against GAS, GBS, GCS, S. 
uberis, S. suis, and S. mutants (Figure 3-8 b). These results conclude that addition of 
the C-terminal EAD can augment the activity of the endolysin. Via further analysis of 
the MICs, we noticed that although the activity of ClyX-3 and ClyX-4 were better 
than parental endolysins (2-4X low MICs), they were still less active compared to 
ClyX-1 and ClyX-2 possessing the synergy activity (Table 3-1 and Table 3-2). These 
observations suggest that the effects of the two EADs in ClyX-3 and ClyX-4 may be 
more additive than synergistic, further underscoring the unique spatial arrangement of 





Figure 3-8. Bactericidal activity of ClyX-3 and ClyX-4. (a) Bactericidal effects of 
ClyX-3 against five strains of stationary phase S. pneumoniae. 5 µg/ml of enzymes 
were mixed with 106 CFUs for 5 min and survivors were serial diluted and plated. 
Log killing was determined through the comparison of PBS treatment and enzyme 
treatment. (b) Bactericidal effects of ClyX-4 against stationary phase streptococci. 50 
µg/ml of enzymes were mixed with 106 CFUs for 1 h and survivors were serial 
diluted and plated. Log killing was determined through the comparison of PBS 
treatment and enzyme treatment. The experiments were repeated for three times, and 




Although PlyC has a multimeric structure, it is not the only endolysin that 
harbors two catalytic domains. Several examples of dual catalytic domains include: 
Staphylococcus phage K endolysin, LysK, contains N-terminal CHAP and amidase 
domains (Becker et al., 2009); the GBS endolysin B30 (also known as PlyGBS) has 
both N-terminal N-acetylmuramidase and D-alanyl-L-alanyl endopeptidase domains 
(Pritchard et al., 2004); the streptococcal λsa2 phage endolysin consists of a centrally 
located CBD separating an N-terminal D-glutaminyl-L-lysine endopeptidase domain 
and a C-terminal N-acetylglucosaminidase domain (Pritchard et al., 2007). However, 
in virtually every example, the second catalytic domains in these endolysins were 
found to be silent in enzymatic  activity (Becker et al., 2009; Donovan & Foster-Frey, 
2008; Donovan et al., 2006). It is unknown why these enzymes possess silent 
catalytic domains. Toward this end, PlyC is the only known endolysin with two 
confirmed, enzymatically active domains that furthermore display synergy due to the 
spatial arrangement of the opposing GyH and CHAP catalytic domains [McGowan et 
al., 2012).  
Engineering endolysins to possess multiple EADs is not a new concept. 
Becker et al. has created a series of chimeric endolysins containing two, and even 
three, unique catalytic domains that cleave separate bonds in the peptidoglycan 
(Becker et al., 2016).  While these enzymes were more refractory to development of 
resistance, the addition of a second or third EAD did not yield an additive effect, 
much less a synergistic effect. It should be noted that all constructs contained EADs 
in a linear fashion, beginning at the N-terminus (i.e. the CBD was always at the C-
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terminal end), so it is unknown if any of these constructs may have performed better 
with a centrally located CBD as we have proposed for our engineering studies with 
PlyCA.  
We assume that taking advantage of known synergistic catalytic domains, the 
PlyC GyH and CHAP, was just a starting point for engineering highly active 
endolysins. Due to the success of the domain swapping methods, our initial approach 
was to add a CBD to the C-terminus of PlyCA. However, none of the constructs were 
expressed. Indeed, PlyCA itself is very difficult to express in the absence of co-
expression of PlyCB. Further examination of the PlyCA structure suggested the 
docking domain, linking GyH and CHAP with the octameric PlyCB, may not be 
required. We, therefore, decided to try adding a CBD, in the case of ClyX-1 it was the 
Cpl-1 CBD, to the middle position of the docking domain. Previous studies suggested 
the importance of the linker between EADs and CBDs (Schmelcher et al., 2011) and 
in the case of PlyCA, we expected the linkers would be exceptionally important to 
provide both spacing and flexibility to the EADs. However, to our surprise, the 
linkers turned out to be dispensible for activity (Figure 3-2 a), at least in the case of 
ClyX-1. Perhaps the Cpl-1 CBD, which contains six repeated choline binding 
modules, imparts greater flexibility than CBDs that lack such repeats. Nonetheless, 
the role of linkers for other engineered enzymes will need to be empirically 
determined for each system. Another unanticipated result was the ability of ClyX-1 to 
dimerize in the presence of choline (Figure 3-2 f). Although the CBDs of most 
pneumococcal endolysins form dimers in the presence of choline, it is not known if 
this process occurs on the bacterial surface or whether it is an absolute requirement 
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for lytic activity. Nonetheless, the ability of ClyX-1 to form dimers, given the central 
rather than terminal location of the Cpl-1 CBD, further suggests a degree of flexibility 
in this domain. In a similar manner, the SH3-5 domain (i.e. broad host spectrum CBD 
of PlySs2), was also able to properly fold and function as a binding domain despite 
the central location in ClyX-2 rather than the C-terminal location in the parental 
PlySs2.  
We propose this design idea for a broad application. Through the successful 
engineered examples, ClyX-1 and ClyX-2, we show that a central CBD could provide 
not only binding specificity but also required distance for the two EADs to reach their 
separate substrates. The two EADs, Cpl-1 EAD (GH25) and PlyC CHAP, did not 
show a synergistic or additive effect when mixed. However, being cloned in one 
endolysin, ClyX-3, they displayed increased enzymatic activity. ClyX-4 performed 
similarly in that cloning the two EADs, PlySs2 CHAP and Cpl-2 EAD (GH25) as into 
one protein, they displayed increased activity. Nonetheless, the activity of ClyX-3 and 
ClyX-4 were less than that of ClyX-1 and ClyX-2 since the GyH and CHAP together 
were known to show the most potent activity. To summarize, the achievement of 
these two chimeric endolysins suggests that the CBD in the middle of two EADs is a 
feasible method to engineer endolysins. 
The engineered endolysins, specifically ClyX-2, only worked on streptococci, 
but not on staphylococci or other species. One explanation is the binding specificity. 
The endolysins harboring SH3-5 binding domain were supposed to lysis the 
staphylococcal cells. However, research has proved that the CBD of PlySs2 could not 
bind to the staphylococci, while in the context of the full-length endolysin, the 
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dynamic of the protein leads to the binding and lysis of staphylococcal cells (Huang 
et al., 2015). The other explanation is cutting specificity. The GyH domain is a 
glucosaminidase cutting the β-(1,4) glycosidic bond between NAG and NAM. This 
bond is in all of the bacterial species, making the GyH domain a universal EAD. 
However, the CHAP domain is a D-alanyl-L-alanine endopeptidase. This is not the 
first EAD reported as the D-alanyl-L-alanine endopeptidase. Other endolysins 
possessing this enzymatic activity include include PlyB30/PlyGBS (Pritchard et al., 
2004), PlyPy (Lood et al., 2014), and the bacterium-produced bacteriocin, zoocin A 
(Gargis et al., 2009). This may explain why ClyX-2 is not active against 
Staphylococcus aureus and Streptococcus suis, which has peptidoglycan crossbridges 
that contains either give glycines or a direct cross-link to the ɛ-amino group of the 
lysine in the stem peptide, respectively (Schleifer & Kandler, 1972). Furthermore, it 
is not surprising that the host range of ClyX-2 is similar to the host ranges of PlyGBS 
and PlyPy. ClyX-2 has activity against other strains that contain D-Ala-L-Ala bonds, 
including S. mutans and E. faecalis, but not E. feacium. 
In conclusion, we proposed a novel design to harness the potent efficacy of 
PlyC towards streptococcal species insensitive to PlyC. We confirmed that ClyX-1 
and ClyX-2 displayed dramatically improved bacteriolytic and bactericidal activity 
compared to the parental CBD donors, due to the synergy effects of the GyH and 
CHAP domains. By applying the idea to design two EADs endolysins, we created 





Chapter 4:  




Bacteriophage endolysins, enzymes that degrade the bacterial peptidoglycan 
(PG), have gained increasing interest as alternative antimicrobial agents due to their 
ability to kill antibiotic resistant pathogens efficiently when applied externally as 
purified proteins. Classical endolysins consist of an N-terminal enzymatically-active 
domain (EAD) cleaving covalent bonds in PG, and a C-terminal cell-binding domain 
(CBD) that recognizes specific ligands on the surface of the PG. Although CBDs are 
essential for the EADs to access the peptidoglycan substrates, some EADs have 
activity in the absence of CBDs and a few display better activities profiles or an 
extended host spectrum. A current hypothesis suggests a net positive charge on the 
EAD enables it to reach the negatively charged bacterial surface via ionic interactions 
in the absence of a CBD. Here, we used the PlyC CHAP domain as a model EAD to 
further test the hypothesis. We mutated negatively charged surface amino acids of the 
CHAP domain that are not involved in structured regions to neutral or positively 
charged amino acids in order to increase the net charge from negative three to 
positive one through positive seven. The seven mutant candidates were successfully 
express and purified as soluble proteins. However, none of the mutants were as active 
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as WT CHAP. The analysis of electrostatic surface potential implied that the surface 
charge distribution may affect the activity of the positively charged EAD. Thus, we 
suggest that while charge should continue to be considered for future engineering 
efforts, it should not be the sole focus of such engineering efforts. 
4.2 Introduction 
 
Bacteriophage endolysins are peptidoglycan (PG) hydrolases produced by phage 
at the end of a lytic cycle (Fischetti, 2011). With the help of holins, pore-forming 
proteins, endolysins can pass the cytoplasmic membrane reaching and degrading the 
PG layer of the cell wall resulting in the lysis of the bacteria and the release of new 
progeny virions (Young, 1992). These enzymes are also capable of destroying the 
Gram-positive bacterial PG from outside the cell as recombinant proteins (Fischetti et 
al., 2006). Due to the protection of the outer membrane (OM), the exogenously added 
endolysins usually cannot access the PG of Gram-negative bacteria. However, 
engineered endolysins with cationic or membrane-disrupting peptides have been 
reported to successfully kill Gram-negative bacteria from without (Briers et al., 
2014). Consequently, endolysins are novel antimicrobial agents and can be used to 
treat antibiotic-resistant bacterial infections because their mode of action is not 
inhibited by traditional resistance mechanisms (Fischetti et al., 2006).  
Endolysins derived from phages that infect Gram-positive hosts have very similar 
modular structures with one or more N-terminal enzymatically-active domains (EADs) 
and a C-terminal cell wall binding domain (CBD) (Oliveira et al., 2013). The EADs 
that cleave covalent bonds in the PG are conserved into five mechanistic classes: 
muramidases, glucosaminidases, N-acetylmuramyl-L-alanine amidases, 
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endopeptidase, and lytic transglycosylases. In contrast, the CBDs possess no 
enzymatic activity but rather function to bind to the specific ligands on the cell wall, 
which are usually a carbohydrate or teichoic acid moiety. Thus, the endolysin host 
range is often dictated by the specificity of the CBD, which is either broad-spectrum, 
targeting molecules harbored by a bacterial genus or multiple genera, or narrow-
spectrum, targeting molecules shared by a single species or serovar (Broendum et al., 
2018a; Nelson et al., 2012). The CBDs have been shown to be essential for function 
of EADs in a number of modular endolysins, including PlyGRCS (Linden et al., 
2015), PlySs2 (Huang et al., 2015), PlyB (Porter et al., 2007), Cpl-1 (Sanz et al., 
1992), and PlyB30 (Donovan et al., 2006).  
Whereas many EADs require the presence of the CBD for binding and 
subsequent activity, some EADs can bind the bacterial surface independently of the 
CBD, and a few even have increased enzymatic activity compared to the full-length 
endolysin. One example is the staphylococcal phage endolysin, LysK. The LysK 
EAD, a cysteine-histidine amidohydrolase/endopeptidase (CHAP) domain, alone 
displays higher lytic activity against staphylococci than the full-length LysK (Horgan 
et al., 2009). Similarly, when the Group B streptococcal phage endolysin, PlyGBS, 
was truncated to the EAD, a ~20 fold increase in specific activities was noted 
compared to PlyGBS (Cheng & Fischetti, 2007). Moreover, without the constraining 
binding properties of the CBD, some EADs from the modular endolysins showed an 
extended host range compared with the full-length endolysins. Examples include the 
EAD of the Bacillus anthracis phage endolysin, PlyL (Low et al., 2011) and the EAD 
of the Clostridium difficile phage endolysin, CD27L (Mayer et al., 2011). 
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The reason why some EADs can target and lyse the PG in the absence of CBDs 
whereas the presence of CBDs is an absolute requirement for activity in other 
endolysins was unknown. Then, a ground-breaking study by Low et al. suggested that 
a net positive charge of an EAD enables it to function independently of its CBD, 
presumably through ionic interactions with the bacterial surface, which typically has a 
net negative charge due to surface carbohydrates (Low et al., 2011). This conceptual 
understanding was then applied by the authors to endolysin bioengineering studies for 
increasing activity of EADs and expansion of host range. For example, the EAD of a 
B. subtilis phage endolysin, XlyA, had a net charge (Z) of negative three at neutral pH. 
Site-directed mutagenesis of five non-cationic residues to lysine (K) produced a shift 
in net charge from Z=-3 to Z=+3, and the mutated XlyA EAD alone was able to lyse 
B. subtilis cells at a rate nearly identical to that of full-length XlyA. In a separate 
study, addition of a simple positively-charged peptide enhanced the lytic activity of 
the Sa2lys endolysin (Rodriguez-Rubio et al., 2016), suggesting the positive charges 
may increase the avidity of the enzyme for the bacterial surface.  
In the present work, we sought to validate the Low’s hypothesis. The model 
EAD for this study is the CHAP domain from the PlyC endolysin (McGowan et al., 
2012). This EAD possesses potent catalytic activity, is amenable to engineering (i.e., 
has been subjected to mutational analysis to improve thermostability (Heselpoth et al., 
2015)), and has been used as the EAD in chimeragenesis projects incorporating 
different CBDs (i.e., ClyR (Yang et al., 2015) and ClyJ (Yang et al., 2019)). The 
homolog of the PlyC CHAP domain via a DALI search is the LysK CHAP domain, 
which is known to harbor improved activity compared to full-length LysK. The net 
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charge of the LysK CHAP is Z=+1, whereas the net charge of the PlyC CHAP is Z=-
3. Therefore, the PlyC CHAP is a good candidate to test Low’s hypothesis that 
conversion of the net charge on an EAD will enable it to display lytic activity in the 
absence of a CBD.  
4.3 Material and Method 
Bacterial Strains and Culture Conditions  
Streptococcus pyogenes D471 was cultured from a -80°C frozen stock and 
grown in Todd Hewitt broth supplemented with 1% yeast extract (THY) without 
shaking at 37°C. E. coli strains DH5α and BL21 (DE3) were grown in Luria-Bertani 
(LB) broth. When needed, kanamycin (50 μg/ml) was added to the media. All 
bacterial cultures were grown at 37°C in a shaking incubator unless otherwise stated.  
In silico Modeling of PlyC CHAP Mutants  
The crystal structure of the PlyCA CHAP was obtained from the original 3.3-Å 
crystal structure of PlyC (Protein Data Bank ID 4F88). The XlyA and XlyA+5K 
structures were obtained from published data (Protein Data Bank ID 3RDR and ID 
3HMB, respectively). The strategy used to change the net surface charge (Z) of the 
CHAP domain was to substitute negatively charged amino acids, aspartic acid (D) 
and glutamic acid (E), that are surface exposed and not involved in structured regions 
(i.e. α-helix or β-sheet) to neutral (alanine (A)) or positively charged (lysine (K)) 
amino acids to increase the Z score from negative three to positive one through 
positive seven at pH 7.4. The net surface charges were calculated from the online 
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protein calculator (http://protcalc.sourceforge.net). PyMOL (The PyMOL Molecular 
Graphics System, Version 1.7.4 Schrödinger, LLC) was used to identify surface 
amino acids and a library of CHAP mutant candidates was established following the 
outlined strategy. Before further validation, the CHAP mutant candidates had their 
side-chain orientation optimized using the FoldX 3.0 Repair PBD command (Guerois 
et al., 2002). The resulting coordinates were then processed by FoldX 3.0 for 
calculating the free energy change of the mutants (ΔΔGFoldX). The desirable mutants 
possessed ΔΔGFoldX < 0 kcal/mol (ΔΔGFoldX = ΔGmut – ΔGWT) and the mutants with 
the largest negative ΔΔGFoldX were then picked for experimental study. The 
electrostatic surface potential was imaged using CCP4MG (McNicholas et al., 2011). 
Cloning and Site-directed Mutagenesis  
The primers used in this study are listed in Table 2. The WT gene of PlyCA 
CHAP domain was amplified from pBAD24::plyC (Nelson et al., 2006) and cloned 
via NdeI and BamHI sites into pET28a, as the template for the mutagenesis. The 
Change-ITTM Multiple Mutation Site-Directed Mutagenesis Kit from Affymetrix was 
used to generate all mutants. Each mutation was designed to be in the middle of a 30 
nucleotide phosphorylated forward primer and the mutagenesis followed instructions 
provided by the manufacturer of the kit. The resulting mutants were confirmed by 




Protein Expression and Purification  
The overnight cultures of E. coli BL21 (DE3) harboring the WT PlyCA CHAP 
domain or mutants were sub-cultured 1:100 into a 1.5 L LB supplemented with 
kanamycin in a 4 L baffled Erlenmeyer flask at 37°C in a shaking incubator. The 
culture was induced at mid-log phase (about 4 h) with 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) at incubated at 18°C overnight. The next morning, E. 
coli BL21 (DE3) bacterial cells were harvested at 5,000 rpm, resuspended in PBS, pH 
7.4, sonicated, and clarified via centrifugation at 12,000 rpm at 4°C. The soluble 
portion of the cell lysate was applied to a Ni-NTA resin column (Thermo Fisher). The 
6X His-tagged protein was washed and eluted using a gradient of imidazole from 20 
mM to 500 mM in PBS buffer, pH 7.4. The protein purity was assessed on a 7.5% 
SDS-PAGE gel before dialysis to remove the imidazole. The 6x His-tag was removed 
using the Thrombin Cleavage Capture Kit (EMD Millipore) according to the protocol 





Table 4-1. Primers information 
Plasmid Template Primer Sequence* 
CHAP D311K pET28a::chap XS3 
5’-ATGGGGTCTAAAAG 
AGTTGCAGCAAAC-3’ 
CHAP D355K pET28a::chap XS4 
5’-TCATACTCAACAGGTAAAC 
CAATGCTACCGTTA-3’ 
CHAP D363K pET28a::chap XS5 
5’-CTACCGTTAATTGGTAAAG 
GTATGAACGCTCAT-3’ 
CHAP D429K pET28a::chap XS6 
5’-ATTGAAAGCTGGTCAAAAA 
CTACCGTTACAGTC-3’ 
CHAP D429A pET28a::chap XS8 
5’-ATTGAAAGCTGGTCAGCGA 
CTACCGTTACAGTC-3’ 
CHAP D450K pET28a::chap XS7 
5’-ATACGCAGCACCTATAAAC 
TTAACACATTCCTA-3’ 




In Vitro Endolysin Activity 
The activities of the PlyC CHAP domain and its mutants were evaluated via a 
spectrophotometric-based turbidity reduction assay as described previously (Nelson et 
al., 2012). An overnight culture of S. pyogenes D471 was harvested at 4,500 rpm for 
10 min, washed twice and resuspended in PBS, pH 7.4 buffer to reach an OD600 = 2.0. 
In a flat-bottom 96-well plate (Fisher Science), bacterial cells were mixed 1:1 with 
equimolar amounts of the PlyC CHAP domain or its mutants and the OD600 was 
monitored every 15 sec for 1 hour at 37°C using a SpectraMax 190 
spectrophotometer (Molecular Devices). Each assay was conducted in triplicate. 
4.4 Results 
Library of PlyC CHAP Mutants 
The PlyC CHAP domain (C-terminal of PlyCA, amino acid 309-465) was 
isolated from the PlyC holoenzyme crystal structure and edited in PyMOL (atomic 
coordinates were only available for amino acid 310-464). Five surface and 
unstructured residues, Asp-311, Asp-355, Asp-363, Asp-429, and Asp-450, were 
selected for mutagenesis (Figure 4-1). Through different combinations of point 
mutations incorporating either a neutral charge (i.e. alanine) or a positive charge (i.e. 
lysine) in place of each aspartic acid residue, a library of 192 mutant candidates 






Figure 4-1. Mutation sites of PlyC CHAP. (a) 3.3 Å resolution of PlyC CHAP 
crystal structure. The magenta-colored amino acids represent the mutation site. (b) 
180° horizontal rotation of (a). The mutation sites are solvent exposed, not structured 








Prediction of the Properly Folded PlyC CHAP Mutants via ΔΔGFoldX  
FoldX is a computational biology tool developed for rapid evaluation of the 
effect of mutations on stability, folding, and dynamics of proteins (Schymkowitz, 
2005). FoldX was used to narrow down the mutants via the free energy change of 
proteins (ΔΔGFoldX = ΔGmut – ΔGWT). A negative ΔΔGFoldX (ΔΔGFoldX <0) suggests 
the mutation is more stable than the wild-type (WT) protein and should fold properly. 
However, 79% of the mutants were predicted to have positive ΔΔGFoldX, meaning the 
mutations had destabilizing effects (Figure 4-2). At each charge category (Z=+1 to 
Z=+7), only the mutants possessing the largest predicted negative ΔΔGFoldX were 
chosen to be made (Table 4-2). Notably, the selected +6 charged and +7 charged 
CHAP mutants contained either neutral or positive ΔΔGFoldx, probably due to the high 
number of required mutations (Table 4-2). 
Protein Solubility and Purity 
All the chosen mutants were expressed and purified by nickel affinity 
chromatography. The 6x His-tag at the N-terminus of each protein, which might 
affect the net surface charge in solution, was cleaved by thrombin before further 
purification. The SDS-PAGE gel after His-tag removal suggested that the PlyC 




Figure 4-2. Distribution of the predicted change in folding free energy (∆∆GfoldX) 
for all 192 possible CHAP mutants calculated with FoldX3.0. Mutations with 














CHAP WT 6.11 -3 NA 0 
CHAP +1 7.89 +1 D311K:D355K -5.32 































Figure 4-3. The SDS-PAGE analysis of the PlyC CHAP WT and mutants. The 
solubility and purity of each enzyme after the His-tag cleavage were accessed via on a 
7.5% SDS-PAGE gel. The lanes correlate to: (M) biorad molecular protein marker, 
(1) PlyC CHAP WT, (2) PlyC CHAP +1, (3) PlyC CHAP +2, (4) PlyC CHAP +3, (5) 
PlyC CHAP +4, (6) PlyC CHAP +5, (7) PlyC CHAP +6 and, (8) PlyC CHAP +7.  
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In Vitro PlyC CHAP Mutants’ Activity 
PlyC is one of the most potent endolysins studied to date (Nelson et al., 2001) 
and the PlyC CHAP domain requires the CBD for full activity. However, despite the 
Z=-1 charge, the PlyC CHAP domain does retain a very small (<1% of PlyC), but 
measurable and reproducible lytic activity against sensitive streptococcal species 
(McGowan et al., 2012). A turbidity reduction assay was used to benchmark the lytic 
activity of the PlyC CHAP mutants to WT PlyC CHAP. However, none of the CHAP 
mutants displayed increased lytic activity compared with WT using Streptococcus 
pyogenes D471 as host over a broad concentration range (Figure 4-4). Nonetheless, 
the data has several interesting aspects. First, the CHAP mutants with a net positive 
one and positive two surface charges (CHAP+1 and CHAP+2) showed the same lytic 
activity as WT, which suggested that the positive charge alone does not affect lytic 
activity. Second, in the low concentration range (< 16 μg/ml), the CHAP mutants 
with positive three to seven surface charges (CHAP+3 to CHAP+7) were virtually 
devoid of lytic activity, but as the concentration increased, they had similar lytic 
activity as WT and CHAP+1 and CHAP+2. The activity noted for CHAP WT 
compared to the full PlyC holoenzyme is consistent with previous data (McGowan et 
al., 2012), and presumably represents activity resulting from random collisions of 





Figure 4-4. In vitro lytic activity against S. pyogenes D471. The different 
concentrations of enzymes were added to the overnight washed bacterial culture. The 
OD600 was recorded every 15 sec for 1 hour. The OD600 decrease was represented as 
the enzymes activity. The experiment was conducted on triplicates, and the error bars 




Analysis of PlyC CHAP Electrostatic Surface Potential 
The surface charge distributions were then examined through CCP4MG 
software (McNicholas et al., 2011). The active site residues (C333 and H420) of PlyC 
CHAP are in a neutral groove, which remains unchanged in CHAP mutants. Although 
the increased positive charge indicates increased positive electrostatic potential in the 
CHAP mutants, the regions accumulating the positive surface potential is evenly 
distributed on the PlyC CHAP surface (Figure 4-5A). Low et. al did not imply the 
relationship between the relative position of the active site and the positive charge 
distribution (Low et al., 2011). However, when we examined the surface potential of 
their mutants, XlyA vs. XlyA+5K, we did notice the mutations resulted in an 
accumulation of positive surface potential near the active site (negative groove in 
Figure 4-5B). Thus, simple conversion of the charge on the EAD may not adequate to 















Figure 5. CCP4MG generated electrostatic surface potential maps of 
PlyC CHAP and XlyA and their mutants. Surfaces are color-coded 
according to electrostatic potential (calculated by the Poisson-Boltzmann 
solver within CCP4MG). The color of the surface represents the electrostatic 
potential at the protein surface, going from blue (potential of +10kT/e) to red 
(potential of -10kT/e). (A) Electrostatic surface potential of PlyC CHAP WT 
(PDB: 4F88), CHAP +1, and CHAP +7 in different orientations. The active 
site of PlyC CHAP is in a neutral groove. (B) Electrostatic surface potential 
of XlyA and XlyA+5K in different orientations. The active site of XlyA is in 




Bacteriophage endolysins have been studied for over 50 years and used as tools 
in the laboratory to lyse Gram-positive bacterial cells. Their function of lysis from 
without was not appreciated as an alternative to antibiotics until the widespread 
emergence of antibiotic resistance. Fischetti’s group was the first to report the use of 
a purified endolysin in vivo to control a Gram-positive bacterial infection (Nelson et 
al., 2001). In this study, an endolysin derived from the streptococci C1 phage, PlyC, 
protected mice from oral colonization S. pyogenes as well as eliminated the bacteria 
in pre-colonized mice within 2 hours. This was the first evidence that endolysins had 
the therapeutic potential as antimicrobials. Later, more endolysins were characterized 
in vitro and studied in vivo via various animal models. An S. pneumoniae phage 
endolysin, Cpl-1, was validated to effectively kill bacteria and protect mice in both a 
nasal model (Loeffler et al., 2001) and pneumococcal bacteremia models (Jado et al., 
2003; Loeffler et al., 2003). In addition to the mouse models, Cpl-1 showed efficacy 
in an S. pneumoniae-induced endocarditis rat model (Entenza et al., 2005) and in an 
infant rat model of pneumococcal meningitis (Grandgirard et al., 2008). Endolysins 
have also been validated against other bacterial species. The first in vivo anti-
staphylococcal investigation was the use of the MV-L endolysin that successfully 
reduced 3 logs of methicillin-resistant Staphylococcus aureus (MRSA) in a nasal 
colonization model and protect all the mice in an intraperitoneal model (Rashel et al., 
2007). Other anti-staphylococcal endolysins, LysGH15, CHAPK, and an engineered 
endolysin ClyS, all displayed potent bacteriolytic properties against MRSA in animal 
studies (Cheng, M. et al., 2018; Daniel et al., 2010; Fenton et al., 2010; Gu et al., 
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2011). In other animal models, the PlyGBS endolysin reduced Group B streptococci 
by 3 logs in a murine vaginal model (Cheng et al., 2005) and the PlyG endolysin 
provided protection for 13 out of 19 mice in a B. anthracis-induced intraperitoneal 
mouse model (Schuch et al., 2002). Most recently, the Ply6A3 endolysin derived 
from an Acinetobacter baumannii phage, demonstrated a 70% rescue rate of the mice 
in a lethal A. baumannii sepsis model (Wu et al., 2018). These in vivo studies have led 
to several endolysin in human clinical trials. SAL200 is a pharmaceutical composition 
consisting of the SAL-1 endolysin that is bacteriolytic to S. aureus. It has successfully 
passed Phase I clinical trials with no serious safety concerns and entered Phase II 
clinical trials (Jun et al., 2016). Another pharmaceutical product, CF-301 contains the 
PlySs2 endolysin, which also targets staphylococci and has likewise passed Phase I 
trials for the safety and tolerability (Abdelkader et al., 2019). Another endolysin 
product, known as Gladskin, contains the Staphefekt SA.100 endolysin and is 
currently commercialized as a skin care product for atopic dermatitis (Totte et al., 
2017). 
Bacteriophage have optimized endolysins for lytic activity through coevolution 
with bacterial hosts to ensure their survival. When applied as recombinant proteins 
exogenously, endolysins are not being used for their intended purpose and lose this 
evolutionary pressure. Therefore, these enzymes have the engineering potential to be 
further modified to increase activity, alter host range, or overcome complex 
extracellular environments (Schmelcher et al., 2012). As a growing amount of 
research focuses on the modular design and crystal structures of endolysins, structure-
based rational engineering approaches, such as structure-guided site-directed 
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mutagenesis and chimeragenesis, have produced engineered endolysins with desirable 
properties for specific applications. The site-directed mutagenesis of PlyC CHAP 
Thr406 to arginine was shown to stabilize PlyC with a 16 fold increase of half-life at 
45°C (Heselpoth et al., 2015). In another study, site-directed mutagenesis was applied 
to convert the negatively charged CBD of Cpl-7 from -14.93 to +3.0 at the neutral pH, 
resulting in the improvement of the lytic activity in vitro and in vivo compared to the 
native Cpl-7 endolysin (Diez-Martinez et al., 2013). Chimeragenesis is a method to 
exchange the endolysin’s functional modules for better activities and expanded host 
range. This engineering approach has been exploited by nature itself, such as the 
pneumococcal endolysin Pal whose two domains indicate homology to different 
phage species (Sheehan et al., 1997). Some well-studied chimeolysins that harbor 
extended host ranges include λSA2-E-Lyso-SH3b (Becker et al., 2009), λSA2-E-
LysK-SH3b (Schmelcher et al., 2012), ClyR (Yang et al., 2016; Yang et al., 2015), 
and, ClyS (Daniel et al., 2010). Others possessing superior activity than their parental 
enzymes include Cpl-711 (Diez-Martinez et al., 2015), Csl2 (Vazquez et al., 2017), 
and PL3 (Blazquez et al., 2016). 
The ultimate goal of this study is to create an engineered endolysin that is simple 
(i.e., one catalytic domain) and works on a very broad host range (i.e., does not 
require a CBD, meaning the EAD alone defines host range). Toward this end, we 
sought to engineer the PlyC CHAP domain to be such an enzyme using engineering 
principles guided by the findings of Low et al. Toward this, we successfully made a 
range of positively charged CHAP mutants. The crystal structure of PlyC provided a 
model for selecting the potential point mutations. The computational tool, FoldX, 
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helped narrow down the candidates from a total of 192 to 40. The ones that are most 
stable among the 40 candidates were used for cloning, protein expression, and 
purification. The achievement of this experimental design suggests that computational 
tools, like FoldX, can be used in the upstream evaluation providing a rationale for the 
random mutations. Our results indicated that none of the positively charged CHAP 
mutants displayed similar or higher lytic activity than WT CHAP. Thus, at least for 
the PlyC CHAP, the hypothesis developed by Low et al. is not supported. 
In summary, our research tested a novel method to fine-turn the lytic activity 
and the host range. Although the computational model led us to engineer the PlyCA 
CHAP with positive charge successfully, the engineered enzymes did not display 
improved activity. We suggest that while the positive charge should continue to be 
acknowledged for future engineering efforts, it should not be the sole focus and other 
characteristics related to positive charge (i.e., charge distribution/electrostatics 
surface potential) should be taken into consideration.  
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Chapter 5:  
Discussion and Future Directions 
 
5.1 Summary of the dissertation 
The Streptococcus is a genus of bacteria causing several diseases from mild 
superficial infections to life-threatening conditions in both humans and animals. 
Although it is one of the few bacterial genera that is still sensitive to antibiotics, the 
emergence of resistant species has been noticed recent years, such as drug-resistant 
Streptococcus pneumoniae, erythromycin-resistant Group A streptococcus, and 
clindamycin-resistant Group B streptococcus. In addition, streptococci show a 
propensity to colonize as intracellular pathogens or to form biofilms, which result in 
antibiotic evasion.  
Endolysins are the PG hydrolases produced at the end of the phage replication 
cycle. They can lyse the Gram-positive bacterial PG from outside leading to the 
osmotic lysis of bacteria. The antimicrobial efficacy of these enzymes has been 
addressed in vitro and in vivo against varieties of Gram-positive pathogens, especially 
the antibiotic-resistant species. The data suggest a broad use of these enzymes in 
medication, food safety, and disinfection. Compared to antibiotics, the resistance to 
endolysins is unlikely to develop based on several studies and the killing of 
endolysins is much more specific to their target species due to the cell binding 
domain (CBD). Furthermore, endolysins have been reported to clear intracellular 
bacteria (Shen et al., 2016) as well as to disrupt biofilms (Donlan, 2008; O'Flaherty et 
al., 2005; Sass & Bierbaum, 2007; Shen et al., 2013; Son et al., 2010).  
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PlyC, an endolysin from streptococcal C1 phage, is the most potent endolysin to 
date targeting GAS, GCS, GES, and S. uberis. Such high bactericidal activity is 
related to its unique structure. Unlike typical modular endolysins that contain two 
domains on one polypeptide, PlyC is a holoenzyme composed of eight cell binding 
domain subunits (PlyCB) and one enzymatically-active domain (PlyCA) interacting 
via protein-protein interactions to create a holoenzyme. The eight PlyCB subunits 
form an octamer and provide the binding specificity, and the PlyCA consists of two 
catalytic domains, a glycosyl hydrolase domain (GyH) and a cysteine, histidine-
dependent amidohydrolase/peptidase (CHAP) domain. As much as the structural and 
biological data indicate the unique properties of PlyC, many questions remain. When 
it comes to application, PlyC is limited to some species of streptococci due to the host 
specificity of PlyCB. It is hard to change this specificity since it is not clear how 
PlyCB binds its substrate. Alternatively, if different CBDs can substitute PlyCB to 
allow PlyCA to retain activity, then the host range may be dramatically expanded. 
Rationale-based engineer techniques, such as chimeragenesis (Blazquez et al., 2016; 
Diez-Martinez et al., 2015; Pastagia et al., 2011; Yang et al., 2015) and site-directed 
mutagenesis (Diez-Martinez et al., 2013; Low et al., 2011), have been shown to 
effectively arm the endolysins with enhanced activity and expanded host spectrum.  
In this dissertation, tailored engineering methods have been applied either to 
study the binding mechanism of PlyCB (Chapter 2) or to expand the host range of 
PlyCA (Chapter 3 and 4). The thesis aimed to overcome the host limitation of PlyC 
that could eventually be applied to more species as a new antimicrobial agent. First, 
the binding mechanism of PlyCB was addressed: whether all eight PlyCB monomers 
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participate in binding or whether the presence of all eight merely increased the avidity 
of the interactions. The site-directed mutagenesis was used to dissociate PlyCB 
octamer, and the binding affinity was assessed to learn the binding mechanism 
(Chapter 2). Second, a variety of CBDs were added to PlyCA in different forms to 
create specific/expanded host ranges different than observed for PlyC (Chapter 3). 
Third, a hypothesis that the positive protein net charge could expand the host 
spectrum was tested by converting the net charge of the CHAP domain from a 
negative charge to positive charge (Chapter 4). 
The crystal structure reveals that the oligomerization of PlyCB is mediated 
through strand/helix hydrogen bonding interactions at each interface. Ccomputational 
analysis determined the important residues, Lys40, Asp41, and Glu43, are involved in 
monomer/monomer interactions. Site-directed mutagenesis of Lys40 and Glu43 to 
alanine decreases the number of monomer/monomer hydrogen bonds from 12 to only 
2, which creates the PlyCB monomer (PlyCBm). Then, the PlyCBm was validated via 
analytical gel filtration and cross-linking. As expected, the PlyCBm retains the 
binding specificity of the PlyCB octamer to GAS, GCG, GES, and S. uberis. 
However, the binding affinity of the octamer is much higher than the monomer, 
which suggests that the octamer binds on the bacterial surface concurrently. Next, the 
relation of lytic activity and the binding affinity was assessed via chimeric endolysins 
containing PlyCBm and PlyCB2m. The results indicate that both the affinity, and 
subsequently the lytic activity, can be tuned to an idealized optimal through 
engineering efforts and modulation of the number of PlyCB monomers.  
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Direct substitution of PlyCB with other CBDs was applied to change the host 
range of PlyC aiming to exploit the synergistic bactericidal effect of PlyCA towards 
other bacteria. The synergy does not remain in the traditional domain swapping by the 
addition of a CBD at the C-terminus of PlyCA. Thus, a novel design that replaces the 
docking domain of PlyCA with a CBD created ClyX-1. The host range of ClyX-1 and 
ClyX-2 depends on the nature of their CBD, and their activities are 20-100 fold 
increased over the CBD donor parental enzymes. Moreover, this design can be 
applied to engineer two functional EADs in one endolysin. ClyX-3 and ClyX-4 are 
the engineered endolysins with an additional EAD targeting different bonds in PG at 
the C-terminus. The activity evaluations of ClyX-3 and ClyX-4 suggest that the two 
EADs separated by the CBD function normally to improve the lytic activity. This 
design can be further applied to create two EAD endolysins targeting other bacterial 
species. 
Site-directed mutagenesis of CHAP to convert the net charge is a method 
adapted from Low’s research (Low et al., 2011). Theoretically, a positively charged 
EAD displays the bactericidal activity in a CBD-independent manner due to the 
physical attraction of the positive charge and the negative charge on the bacterial 
surface. Five surface unstructured amino acids of CHAP, D311, D355, D363, D429, 
and D450, were mutated to alanine or lysine in different combinations to convert the 
charge of CHAP from negative three to positive one through positive seven. 
Computational screening of the mutants using the FoldX algorithm can effectively 
identify the ones with correct folding. Even though the CHAP mutants with the net 
charge from positive one through positive seven were expressed and purified 
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successfully, their activity did not show a CBD-independent manner suggesting other 
factors, such as the surface electrostatic potential of the EAD, may be involved in this 
method for refining the host range.  
 
5.2 Discussion 
Before the studies mentioned in Chapter 2 to Chapter 4, there is no published 
research involving host range modification of PlyC. Although it is the most potent 
endolysin to date, the complex holoenzyme structure is a hurdle to further 
engineering. One reason for that is PlyC is encoded by two separate genes. The 
addition of different genes to either the end of plyCA or plyCB leads to expression 
and/or folding issues. The other reason is that the PlyCB subunits form an octamer as 
the cell binding domain and interact with PlyCA via protein-protein interaction. The 
widely applied method to change/expand the host range of an endolysin is via domain 
swapping. This method is more suitable for a traditional structured endolysin encoded 
by one gene with the monomeric architecture of an N-terminal EAD linked to a C-
terminal CBD. The specificity of monomeric CBDs is dependent on the different 
substrates, usually carbohydrates, on the surface of the bacterial PG. It is unknown 
how the PlyCB octamer binds to the surface of the bacteria. Is the specificity due to 
the oligomerization or the different substrates on the bacterial surface? Thus, the first 
aim of this thesis is to understand the binding mechanism of PlyCB.  
The PlyCBm obtained from mutagenesis retained the same host range as that of 
the PlyCB octamer. Based on the fluorescence protein bacterial cell binding assay, 
both fluorescently-labeled PlyCBm and the PlyCB octamer similarly decorated the 
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cell wall, suggesting that they recognized the same ligand on the bacterial surface. 
Thus, the specificity of PlyCB to GAS, GCS, GES, and S. uberis is not due to the 
oligomerization of the CBD but to the specific ligand binding. The binding affinity is 
important to understand the binding mechanism of the PlyCB octamer. A concurrent 
binding indicates a higher affinity of the octamer, while the consecutive interaction 
indicates the similar affinity of monomer and octamer. Two label-free technologies, 
surface plasmon resonance (SPR) and bio-layer interferometry (BLI), are commonly 
used to measure the biomolecular interactions (Douzi, 2017; Shah & Duncan, 2014). 
However, both systems measure the wavelength before and after the proteins binding 
to the immobilized ligands, and the wavelength shifts represent the amount of 
binding. The size of the bacteria is about 102 times larger than the size of the CBDs. 
The wavelength shift is hard to detect when CBDs bind to the bacteria immobilized 
on the surface. Therefore, the fluorescence labeling binding assay was adopted for 
quantitative measurement. Although the results from this assay were preliminary and 
not precise for the affinity, they implied that the binding of PlyCB is concurrent. 
The PlyCBm is a good tool to study the relation of binding affinity and 
bactericidal activity. The previous study indicated that the increased binding affinity 
decreases the lytic activity under physiological condition but increases the lytic 
activity under high salt concentration (Schmelcher et al., 2011). The chimeric 
endolysin containing the PlyCA CHAP and PlyCBm (CHAP_CBm) was created to 
compare the activity with PlyCΔGyH (PlyCA CHAP and PlyCB octamer). 
PlyCΔGyH displayed higher lytic activity compared that of CHAP_CBm, indicating 
that in our case, the higher binding affinity results in higher lytic activity. This is 
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supported by the chimeric endolysin containing the PlyCA CHAP and PlyCB2m, 
which displayed better activity than that of CHAP_PlyCBm, indicating that PlyCA 
CHAP favors a tighter binding. Interestingly, changing the EAD from PlyC CHAP to 
the LysK CHAP with PlyCBm and PlyCB2m enhanced the lytic activity even further, 
implying that the different EADs prefer the CBD with different binding affinity.  
Even though PlyCBm provides limited use in the chimeragenesis application, 
since it keeps the same host range and contains low binding affinity, PlyCBm is 
nonetheless suitable for other applications due to its simple structure. The PlyCB 
octamer and PlyCBm have a moonlight function, which is to enter the mammalian 
cell via endocytosis by the interaction of PlyCB and phosphatidylserine (Shen et al., 
2016). Thus, the PlyCBm can be an intracellular peptide fused with endolysins 
targeting intracellular bacterial pathogens. The other application of PlyCBm is to use 
as a tool to diagnose GAS, GCS, GES, and S. uberis. Although the binding affinity of 
PlyCBm and bacteria is low, the effective concentration of 50% PlyCBm is in a 
nanomolar range which is similar or even better than the binding affinity of 
antibodies (Fischetti, 2010).  
Changing/expanding the host range from the perspective of PlyCB is not feasible 
since the PlyCB octamer and PlyCB bind to the specific epitope on the surface of 
GAS, GCS, GES, and S. uberis. Thus, the fusion of a different CBD to PlyCA is the 
second aim. Direct addition of a CBD to the N-terminal or C-terminal PlyCA resulted 
in an unexpressed protein. The results are similar to the overexpression of PlyCA 
only. The PlyCA in a previous study was overexpressed with the PlyCB mutant that 
cannot form the holoenzyme, and only then was it able to be purified using 
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ammonium sulfate precipitation. One explanation is the gene composition of PlyC. 
PlyC is encoded by an operon. The first ORF is plyCB; the second ORF is a putative 
endonuclease gene called lil for lysin intergenic locus; the third ORF is plyCA. The lil 
is not translated in the expression of PlyC, but Δlil construct ablates enzyme activity 
(Nelson et al., 2006). Thus, the function of lil remains unknown but may relate to the 
eight PlyCB monomers to one PlyCA ratio. Surprisingly, when the docking domain in 
PlyCA was replaced with a CBD, the expression issues were solved, and the protein 
was easily overexpressed. This result may indicate that the lil responds to the region 
of the plyCA docking gene resulting in the production of eight PlyCB for one PlyCA.  
The central CBD provides both length and flexibility for the GyH and CHAP 
domains to perform synergistically. The goal is to translate the endolysin as an 
antimicrobial agent. The mouse pneumococcal infection model showed that a low 
dose of ClyX-1 protected 80% mice. Although 20 μg of ClyX-1 only protected 30% 
mice, the same amount of Cpl-1 treated mice died in the first five days. So far, the 
doses of ClyX-1 in this study were the lowest amount compared to the amount of 
endolysin used in other pneumococcal mouse infection models. Furthermore, the 
MICs indicated that ClyX-1 was efficient for the penicillin-resistant strains. Thus, 
these data suggest that ClyX-1 is a novel candidate for resistant pneumococcal 
infections.  
At present, the engineered endolysins do not work on any bacterial species other 
than streptococci. One explanation is the CBDs we used do not bind to other bacterial 
species. The other explanation is that the GyH and CHAP domains only cut the bonds 
involved in the streptococcal PG. To test the second hypothesis, we ran the mass 
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spectrophotometry for the digested PG. The results reveal that GyH is 
glycosaminidase that cuts the sugar backbone, while the CHAP is an endopeptidase 
cutting D-Ala-L-Ala bonds in the cross-bridge only in the streptococcal PG and 
several enterococcal PG. Thus, the synergy of GyH and CHAP cannot be applied to 
any other species due to the specificity of the CHAP.  
The failure of creating the CBD-independent CHAP does not indicate the 
method on conversion of EADs surface net charge will not work. Using the CHAP 
domain for this study was far from ideal. With GyH domain in PlyCA, they display a 
synergic effect. However, any one of the domains possesses very low enzymatic 
activity (McGowan et al., 2012). One reason to use the PlyCA CHAP domain is the 
easy accessibility of the clone for expressing. The other reason to use is that the 
homolog of CHAP from LysK shows activity in a CBD-independent manner. 
Moreover, the surface net charge of the PlyCA CHAP is negative three while that of 
the LysK CHAP is positive one. Thus, we believed changing the net negative charge 
to positive will arm the PlyCA CHAP as a CBD-independent enzyme. The deficiency 
of the study is that we neglected the importance of surface charge distribution. 
Therefore, in the future application, we will add more criteria for selecting the point-
mutations. 
 




Further Application: analysis of ClyX-1 and ClyX-2 
Although we assessed the bactericidal activity of ClyX-1 and ClyX-2 in Chapter 
2, these two chimeric endolysins can be applied to many fields. S. pneumoniae forms 
a biofilm during different infection states, such as otitis media, chronic rhinosinusitis, 
and pneumonia (Hall-Stoodley et al., 2006; Hoa et al., 2009; Sanderson et al., 2006). 
Several studies have proved that endolysins are effective to disperse biofilms and kill 
the bacteria involved in biofilm formation (Shen, J. et al., 2013; Son et al., 2010). Due 
to the high activity of ClyX-1 on pneumococci in vitro and in vivo, ClyX-1 is a 
potential new source of antibiofilm therapy. ClyX-2 is the chimeric endolysin with a 
broad spectrum. Besides the anti-biofilm application, it may be used as an 
antimicrobial agent in the infections involved different bacteria. One example is 
bovine mastitis, which is a mammary gland infection in dairy cows causing the loss in 
milk production and quality. The mastitis pathogens, such as the GBS in the milk can 
lead to the infections in newborn babies (Ismail et al., 2011) and S. uberis causes 95% 
intramammary infections (Pedersen et al., 2003). ClyX-2 harboring the bactericidal 
activity against these two bacteria species and can be applied as the treatment of 
bovine mastitis as well as the biological disinfectant. 
 
Adopting the Novel Design Method to Create Engineered Two-EAD Endolysins on 
Other Bacterial Species 
The novel design to harness the synergy of two catalytic domains can be applied 
for chimeric endolysins on other bacterial species by changing the EADs for specific 
bonds. For example, the CHAP domain from LysK specifically cleaves the D-ala-gly 
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bonds in the staphylococcal PG, and the EAD from lysostaphin specifically cleavages 
a glycyl-glycine bond in staphylococci PG. Previously studies created a chimeric 
endolysin using these two EADs in a structure where both EADs are side by side at 
the N-terminus and the CBD is at the C-terminus (Becker et al., 2016). Although the 
chimeric endolysins displayed an advantage in not inducing resistance, the activity 
compared to parental endolysins did not improve. One explanation is that the 
tandemly linked EADs lose the flexibility to reach both substrates.  
To further apply the novel design, we can generate a library of EADs with 
known cleavage specificities and CBDs with known host ranges. Then, randomly 
shuffle the EADs and CBDs based on the design that forces the CBD to be in the 
middle of two EADs. By doing so, we may generate the endolysins harboring high 





















































Protein Sequence (Holoenzyme is 1032 aa, 113.11 kDa) 
 







































































































































































































GyH (PlyCA1-205), Cpl-1 CBD(191-339) and CHAP (PlyCA309-465), fused via 2 round of 












































































GyH with linker (PlyCA1-227), Cpl-1 CBD(191-339) and CHAP with linker (PlyCA287-












































































GyH (PlyCA1-205), PlySs2 CBD(148-245) and CHAP (PlyCA309-465), fused via 2 round of 















































GyH (PlyCA1-205) and Cpl-1 CBD(191-339) , amplified using pET28a(+)::clyX-1 as 










































Cpl-1 CBD(191-339) and CHAP (PlyCA309-465), amplified using pET28a(+)::clyX-1 as 



































































Cpl-1 full length and CHAP (PlyCA309-465), fused via 2 round of SOE PCR cloned 








































































PlySs2 full length and Cpl-1 EAD (Cpl-11-190), fused via 1 round of SOE PCR cloned 









































Template Primer Sequence (5’>3’) 




Site-direct mutagenesis of the 41st amino acid from aspartic acid to alanine; N-

















Template Primer Sequence (5’>3’) 
pBAD24::plyCB XS35 [Phos]-GGTATTAAAGACATTGCGACCGTACAAGGATTT 
 
Notes 
Site-direct mutagenesis of the 43rd amino acid from glutamic acid to alanine; N-
























Site-direct mutagenesis of the 40th amino acid lysine and the 41st amino acid aspartic 




pBAD24::plyCB K40A E43A (pBAD24::plyCBm) 

























Site-direct mutagenesis of the 40th amino acid lysine and the 43rd amino acid glutamic 

























Site-direct mutagenesis of the 41st amino acid aspartic acid and 43rd amino acid 




pBAD24::plyCBK40A D41A E43A 


















Site-direct mutagenesis of 40th amino acid lysine, the 41st amino acid aspartic acid 




































An additional plyCBm gene cloned into XbaI/SalI sites of pBAD24::plyCBm-N’6His; 











































An additional PlyCB2m gene cloned into SalI/PstI sites of pBAD24::PlyCB2m-














































AmidasePal with its linker (Pal1-149) and PlyCBm fragments, fused via SOE PCR 















































AmidasePlyG with its linker (PlyG1-172) and PlyCBm fragments, fused via SOE PCR 











































CHAP (PlyCA309-465) and PlyCBm fragments, fused via SOE PCR cloned into 



















































GyH (PlyCA1-205) and PlyCBm fragments, fused via SOE PCR cloned into 


















































CHAPK with its linker (LysK1-197) and PlyCBm fragments, fused via SOE PCR 















































CHAPS with its linker (PlySs21-166) and PlyCBm fragments, fused via SOE PCR 





























































































































CHAP (PlyCA309-465) and PlyCB2m fragments, fused via SOE PCR cloned into 
NdeI/EcoRI sites of pET28a(+). 
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pET28a:: plyC CHAP 






























pET28a:: plyC CHAPD311K D355K (CHAP+1) 






























pET28a:: plyC CHAPD311K D355K D429A (CHAP+2) 



























Site-directed mutagenesis of 311th and the 355th aspartic acid of PlyCA to lysine. Site-








pET28a:: plyC CHAPD311K D355K D363K (CHAP+3) 








































pET28a:: plyC CHAPD311K D355K D363K D429A (CHAP+4) 




























Site-directed mutagenesis of 311th, 355th and 363rd aspartic acid of PlyCA to lysine. 








pET28a:: plyC CHAPD311K D355K D363K D429K (CHAP+5) 







































pET28a:: plyC CHAPD311K D355K D363K D429A D450K (CHAP+6) 




























Site-directed mutagenesis of 311th, 355th, 363rd , and 450th aspartic acid of PlyCA to 












pET28a:: plyC CHAPD311K D355K D363K D429K D450K (CHAP+7) 




























Site-directed mutagenesis of 311th, 355th, 363rd, 429th, and 450th aspartic acid of 
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Organism Serotype Strain ATCC Source* Notes 
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Enterococcus faecalis  JH2-2  5  
Enterococcus faecalis  EF-1  5 VanR 
Enterococcus faecalis  EF-17  5 VanR 
Enterococcus faecalis  EF-24  5  
Enterococcus faecalis  EF-25  5  
Enterococcus faecium  EFSK2  5 VanR 
Enterococcus faecium  EFSK16  5 VanR 
Enterococcus faecium  EFSK33  5 VanR 
Group E streptococci 2 K131 123191 1 Group E 
streptococcus 
Staphylococcus aureus  NRS385  6 MRSA, 
MDR, 
USA500 
Staphylococcus aureus  NRS14  6 VISA 
Streptococcus agalactiae Type III A909  1 Group B 
streptococcus 
Streptococcus agalactiae Type IA A349  1 Group B 
streptococcus 




  21597 2 Group C 
streptococcus 




  700400 2 Group C 
streptococcus 
Streptococcus mutans Type c 10449  2  
Streptococcus mutans Type c  25175 2  
Streptococcus mutans Type e LM7  2  
Streptococcus pneumoniae 11 DCC1811  5  
Streptococcus pneumoniae 15 DCC1476  5  
Streptococcus pneumoniae 23F (Sp23-1) DCC1420  5  
Streptococcus pneumoniae 19 DCC1355  5  
Streptococcus pneumoniae 14 (Sp14-3) DCC1494  5  
Streptococcus pneumoniae 6 DCC1850  5  
Streptococcus pneumoniae 14 DCC1490  5  
Streptococcus pneumoniae 3 DCC1714  5  
Streptococcus pneumoniae 9V (Sp9-3) DCC1335  5  
Streptococcus pneumoniae Derived from 
D39  
R36A  5 Capsule free 
strain. 
Streptococcus pneumoniae Derived from 
R36A  
R6  5 Capsule free 
strain. 
Streptococcus pneumoniae  765  5  
Streptococcus pneumoniae  #8  5  
Streptococcus pneumoniae  763  5  
Streptococcus pneumoniae 2 D39  5  
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Streptococcus pneumoniae 4 TIGR 4  5  
Streptococcus pneumoniae 18 GB2017  5  
Streptococcus pneumoniae 1 AR620  5  
Streptococcus pneumoniae 10 GB2163  5  
Streptococcus pneumoniae 4 GB2092  5  
Streptococcus pneumoniae 5 AR314  5  
Streptococcus pneumoniae Derived from 
R6 
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Streptococcus pyogenes  MGAS315  1 Group A 
streptococcus 
Streptococcus pyogenes M6 D471  1 Group A 
streptococcus 
Streptococcus pyogenes A-variant 
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Streptococcus suis  7-3008-2  7  
Streptococcus uberis   BAA-
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Streptococcus uberis   700407 2  
Streptococcus uberis   27958 2  
Streptococus sobrinus  6715  4  
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